a:4:{s:5:"child";a:1:{s:0:"";a:1:{s:3:"rss";a:1:{i:0;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:1:{s:0:"";a:1:{s:7:"version";s:3:"2.0";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:1:{s:0:"";a:1:{s:7:"channel";a:1:{i:0;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:27:"http://www.w3.org/2005/Atom";a:1:{s:2:"id";a:1:{i:0;a:5:{s:4:"data";s:34:"tag:blogger.com,1999:blog-36762711";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:0:"";a:8:{s:13:"lastBuildDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Fri, 11 Apr 2014 19:17:32 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:259:{i:0;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:12:"Class Action";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:8:"Pleading";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:14:"Medical Device";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:4;a:5:{s:4:"data";s:18:"Implied Preemption";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:5;a:5:{s:4:"data";s:20:"Learned Intermediary";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:6;a:5:{s:4:"data";s:18:"Express Preemption";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:7;a:5:{s:4:"data";s:13:"Generic Drugs";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:8;a:5:{s:4:"data";s:13:"Off-Label Use";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:9;a:5:{s:4:"data";s:3:"MDL";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:10;a:5:{s:4:"data";s:3:"FDA";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:11;a:5:{s:4:"data";s:9:"Causation";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:12;a:5:{s:4:"data";s:16:"Expert Witnesses";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:13;a:5:{s:4:"data";s:14:"Consumer Fraud";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:14;a:5:{s:4:"data";s:12:"Pennsylvania";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:15;a:5:{s:4:"data";s:7:"Removal";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:16;a:5:{s:4:"data";s:8:"Warnings";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:17;a:5:{s:4:"data";s:7:"Daubert";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:18;a:5:{s:4:"data";s:13:"Supreme Court";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:19;a:5:{s:4:"data";s:6:"Levine";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:20;a:5:{s:4:"data";s:8:"Blogging";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:21;a:5:{s:4:"data";s:9:"Discovery";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:22;a:5:{s:4:"data";s:19:"Law Review Articles";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:23;a:5:{s:4:"data";s:10:"New Jersey";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:24;a:5:{s:4:"data";s:25:"Parallel Violation Claims";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:25;a:5:{s:4:"data";s:10:"California";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:26;a:5:{s:4:"data";s:13:"Jurisprudence";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:27;a:5:{s:4:"data";s:13:"Design Defect";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:28;a:5:{s:4:"data";s:16:"Punitive Damages";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:29;a:5:{s:4:"data";s:5:"Conte";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:30;a:5:{s:4:"data";s:15:"First Amendment";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:31;a:5:{s:4:"data";s:13:"Aredia/Zometa";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:32;a:5:{s:4:"data";s:13:"Choice Of Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:33;a:5:{s:4:"data";s:5:"Iqbal";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:34;a:5:{s:4:"data";s:10:"Mass Torts";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:35;a:5:{s:4:"data";s:16:"Warning Adequacy";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:36;a:5:{s:4:"data";s:11:"Legislation";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:37;a:5:{s:4:"data";s:8:"Evidence";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:38;a:5:{s:4:"data";s:16:"Fraud On The FDA";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:39;a:5:{s:4:"data";s:6:"Riegel";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:40;a:5:{s:4:"data";s:5:"Texas";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:41;a:5:{s:4:"data";s:4:"Food";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:42;a:5:{s:4:"data";s:9:"Pain Pump";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:43;a:5:{s:4:"data";s:23:"Private Right Of Action";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:44;a:5:{s:4:"data";s:9:"Colacicco";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:45;a:5:{s:4:"data";s:22:"Statute Of Limitations";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:46;a:5:{s:4:"data";s:7:"Zyprexa";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:47;a:5:{s:4:"data";s:17:"Negligence Per Se";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:48;a:5:{s:4:"data";s:5:"Vioxx";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:49;a:5:{s:4:"data";s:5:"SSRIs";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:50;a:5:{s:4:"data";s:13:"FDA Deference";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:51;a:5:{s:4:"data";s:11:"E-Discovery";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:52;a:5:{s:4:"data";s:12:"FDA Evidence";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:53;a:5:{s:4:"data";s:16:"False Claims Act";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:54;a:5:{s:4:"data";s:18:"Medical Monitoring";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:55;a:5:{s:4:"data";s:17:"Third-Party Payer";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:56;a:5:{s:4:"data";s:8:"Bartlett";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:57;a:5:{s:4:"data";s:4:"CAFA";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:58;a:5:{s:4:"data";s:17:"FDA On Preemption";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:59;a:5:{s:4:"data";s:18:"Fraudulent Joinder";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:60;a:5:{s:4:"data";s:5:"Fraud";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:61;a:5:{s:4:"data";s:7:"Florida";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:62;a:5:{s:4:"data";s:8:"Illinois";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:63;a:5:{s:4:"data";s:5:"Lists";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:64;a:5:{s:4:"data";s:9:"Comment K";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:65;a:5:{s:4:"data";s:13:"Erie Doctrine";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:66;a:5:{s:4:"data";s:8:"New York";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:67;a:5:{s:4:"data";s:22:"Product Identification";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:68;a:5:{s:4:"data";s:15:"Confidentiality";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:69;a:5:{s:4:"data";s:15:"Practice Of Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:70;a:5:{s:4:"data";s:11:"Vaccine Act";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:71;a:5:{s:4:"data";s:8:"standing";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:72;a:5:{s:4:"data";s:12:"Duty To Test";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:73;a:5:{s:4:"data";s:20:"Forum Non Conveniens";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:74;a:5:{s:4:"data";s:32:"Interviewing Treating Physicians";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:75;a:5:{s:4:"data";s:4:"Kent";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:76;a:5:{s:4:"data";s:13:"international";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:77;a:5:{s:4:"data";s:8:"Accutane";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:78;a:5:{s:4:"data";s:23:"Adverse Event Reporting";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:79;a:5:{s:4:"data";s:15:"Clinical Trials";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:80;a:5:{s:4:"data";s:19:"Collateral Estoppel";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:81;a:5:{s:4:"data";s:19:"Heeding Presumption";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:82;a:5:{s:4:"data";s:9:"Minnesota";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:83;a:5:{s:4:"data";s:30:"Presumption Against Preemption";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:84;a:5:{s:4:"data";s:4:"RICO";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:85;a:5:{s:4:"data";s:10:"Settlement";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:86;a:5:{s:4:"data";s:7:"Tolling";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:87;a:5:{s:4:"data";s:13:"West Virginia";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:88;a:5:{s:4:"data";s:13:"Amicus Curiae";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:89;a:5:{s:4:"data";s:9:"Louisiana";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:90;a:5:{s:4:"data";s:11:"Mississippi";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:91;a:5:{s:4:"data";s:25:"Attorney-Client Privilege";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:92;a:5:{s:4:"data";s:16:"Express Warranty";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:93;a:5:{s:4:"data";s:7:"Fosamax";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:94;a:5:{s:4:"data";s:16:"Informed Consent";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:95;a:5:{s:4:"data";s:20:"Manufacturing Defect";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:96;a:5:{s:4:"data";s:8:"Missouri";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:97;a:5:{s:4:"data";s:4:"Ohio";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:98;a:5:{s:4:"data";s:8:"Seroquel";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:99;a:5:{s:4:"data";s:14:"CBE Regulation";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:100;a:5:{s:4:"data";s:18:"Compensable Injury";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:101;a:5:{s:4:"data";s:18:"Constitutional Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:102;a:5:{s:4:"data";s:29:"Expert Witness Opinion On Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:103;a:5:{s:4:"data";s:3:"HRT";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:104;a:5:{s:4:"data";s:6:"Infuse";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:105;a:5:{s:4:"data";s:8:"Oklahoma";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:106;a:5:{s:4:"data";s:16:"State Of The Art";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:107;a:5:{s:4:"data";s:8:"Vaccines";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:108;a:5:{s:4:"data";s:3:"ALI";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:109;a:5:{s:4:"data";s:16:"Implied Warranty";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:110;a:5:{s:4:"data";s:8:"Nuisance";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:111;a:5:{s:4:"data";s:21:"Personal Jurisdiction";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:112;a:5:{s:4:"data";s:7:"Science";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:113;a:5:{s:4:"data";s:9:"Tennessee";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:114;a:5:{s:4:"data";s:11:"Tort Reform";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:115;a:5:{s:4:"data";s:7:"alabama";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:116;a:5:{s:4:"data";s:10:"Bruesewitz";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:117;a:5:{s:4:"data";s:30:"Manufacturer's Representatives";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:118;a:5:{s:4:"data";s:8:"Medicare";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:119;a:5:{s:4:"data";s:18:"Pharmacy Liability";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:120;a:5:{s:4:"data";s:6:"Recall";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:121;a:5:{s:4:"data";s:17:"Res Ipsa Loquitur";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:122;a:5:{s:4:"data";s:28:"Subsequent Remedial Measures";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:123;a:5:{s:4:"data";s:8:"Arkansas";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:124;a:5:{s:4:"data";s:11:"Cheat Sheet";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:125;a:5:{s:4:"data";s:12:"Epidemiology";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:126;a:5:{s:4:"data";s:8:"Nuvaring";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:127;a:5:{s:4:"data";s:34:"Principles Of Aggregate Litigation";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:128;a:5:{s:4:"data";s:11:"Safe Harbor";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:129;a:5:{s:4:"data";s:9:"Sanctions";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:130;a:5:{s:4:"data";s:8:"Warranty";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:131;a:5:{s:4:"data";s:6:"Canada";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:132;a:5:{s:4:"data";s:18:"Compliance Defense";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:133;a:5:{s:4:"data";s:35:"Government Contingent Fee Contracts";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:134;a:5:{s:4:"data";s:20:"Investigational Drug";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:135;a:5:{s:4:"data";s:15:"Judicial Notice";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:136;a:5:{s:4:"data";s:9:"Marketing";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:137;a:5:{s:4:"data";s:17:"Restatement Third";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:138;a:5:{s:4:"data";s:10:"Scorecards";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:139;a:5:{s:4:"data";s:16:"Strict Liability";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:140;a:5:{s:4:"data";s:17:"Unjust Enrichment";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:141;a:5:{s:4:"data";s:9:"Wisconsin";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:142;a:5:{s:4:"data";s:17:"Black Box Warning";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:143;a:5:{s:4:"data";s:7:"Damages";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:144;a:5:{s:4:"data";s:8:"Delaware";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:145;a:5:{s:4:"data";s:13:"Economic Loss";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:146;a:5:{s:4:"data";s:19:"Foreign Regulations";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:147;a:5:{s:4:"data";s:9:"Gunvalson";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:148;a:5:{s:4:"data";s:8:"Kentucky";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:149;a:5:{s:4:"data";s:20:"Accounting Standards";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:150;a:5:{s:4:"data";s:30:"Direct To Consumer Advertising";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:151;a:5:{s:4:"data";s:5:"HIPAA";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:152;a:5:{s:4:"data";s:7:"Indiana";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:153;a:5:{s:4:"data";s:22:"Investigational Device";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:154;a:5:{s:4:"data";s:16:"Motion In Limine";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:155;a:5:{s:4:"data";s:9:"Neurontin";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:156;a:5:{s:4:"data";s:8:"Reliance";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:157;a:5:{s:4:"data";s:8:"Virginia";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:158;a:5:{s:4:"data";s:13:"Consolidation";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:159;a:5:{s:4:"data";s:21:"Fraudulent Misjoinder";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:160;a:5:{s:4:"data";s:7:"Georgia";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:161;a:5:{s:4:"data";s:15:"Lone Pine Order";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:162;a:5:{s:4:"data";s:13:"Massachusetts";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:163;a:5:{s:4:"data";s:22:"Over The Counter Drugs";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:164;a:5:{s:4:"data";s:20:"Primary Jurisdiction";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:165;a:5:{s:4:"data";s:19:"Publisher liability";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:166;a:5:{s:4:"data";s:17:"Statute Of Repose";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:167;a:5:{s:4:"data";s:16:"Abigail Alliance";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:168;a:5:{s:4:"data";s:9:"Antitrust";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:169;a:5:{s:4:"data";s:15:"Component Parts";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:170;a:5:{s:4:"data";s:14:"Discovery Rule";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:171;a:5:{s:4:"data";s:19:"Extraterritoriality";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:172;a:5:{s:4:"data";s:8:"Fen-Phen";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:173;a:5:{s:4:"data";s:13:"Legal Writing";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:174;a:5:{s:4:"data";s:10:"Misjoinder";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:175;a:5:{s:4:"data";s:7:"Montana";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:176;a:5:{s:4:"data";s:6:"Nevada";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:177;a:5:{s:4:"data";s:13:"New Hampshire";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:178;a:5:{s:4:"data";s:14:"North Carolina";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:179;a:5:{s:4:"data";s:12:"Rhode Island";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:180;a:5:{s:4:"data";s:14:"Securities Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:181;a:5:{s:4:"data";s:27:"Subject Matter Jurisdiction";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:182;a:5:{s:4:"data";s:8:"Taxation";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:183;a:5:{s:4:"data";s:10:"Bankruptcy";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:184;a:5:{s:4:"data";s:12:"Biomaterials";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:185;a:5:{s:4:"data";s:8:"Colorado";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:186;a:5:{s:4:"data";s:20:"Comparative Warnings";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:187;a:5:{s:4:"data";s:11:"Connecticut";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:188;a:5:{s:4:"data";s:7:"Cy Pres";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:189;a:5:{s:4:"data";s:19:"Document Production";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:190;a:5:{s:4:"data";s:13:"Duty To Train";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:191;a:5:{s:4:"data";s:16:"Field Preemption";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:192;a:5:{s:4:"data";s:14:"Foreseeability";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:193;a:5:{s:4:"data";s:18:"Hospital Liability";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:194;a:5:{s:4:"data";s:4:"Iowa";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:195;a:5:{s:4:"data";s:8:"Maryland";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:196;a:5:{s:4:"data";s:8:"Michigan";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:197;a:5:{s:4:"data";s:6:"Misuse";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:198;a:5:{s:4:"data";s:10:"New Mexico";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:199;a:5:{s:4:"data";s:6:"Oregon";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:200;a:5:{s:4:"data";s:14:"South Carolina";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:201;a:5:{s:4:"data";s:26:"Unavoidably Unsafe Product";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:202;a:5:{s:4:"data";s:9:"Voir Dire";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:203;a:5:{s:4:"data";s:7:"Vytorin";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:204;a:5:{s:4:"data";s:30:"Alternative Dispute Resolution";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:205;a:5:{s:4:"data";s:13:"Bulk Supplier";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:206;a:5:{s:4:"data";s:8:"Celebrex";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:207;a:5:{s:4:"data";s:12:"Criminal law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:208;a:5:{s:4:"data";s:19:"Dear Doctor Letters";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:209;a:5:{s:4:"data";s:11:"Due Process";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:210;a:5:{s:4:"data";s:4:"Erie";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:211;a:5:{s:4:"data";s:6:"Ethics";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:212;a:5:{s:4:"data";s:10:"Gadolinium";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:213;a:5:{s:4:"data";s:8:"Genetics";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:214;a:5:{s:4:"data";s:24:"Government Cost Recovery";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:215;a:5:{s:4:"data";s:16:"In-House Counsel";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:216;a:5:{s:4:"data";s:17:"Judicial Estoppel";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:217;a:5:{s:4:"data";s:9:"Labor Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:218;a:5:{s:4:"data";s:22:"Market Share Liability";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:219;a:5:{s:4:"data";s:13:"Overpromotion";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:220;a:5:{s:4:"data";s:11:"Overwarning";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:221;a:5:{s:4:"data";s:7:"Qui Tam";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:222;a:5:{s:4:"data";s:9:"Risperdal";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:223;a:5:{s:4:"data";s:12:"South Dakota";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:224;a:5:{s:4:"data";s:10:"spoliation";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:225;a:5:{s:4:"data";s:5:"Actos";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:226;a:5:{s:4:"data";s:6:"Alaska";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:227;a:5:{s:4:"data";s:15:"Bisphosphonates";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:228;a:5:{s:4:"data";s:9:"Bystander";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:229;a:5:{s:4:"data";s:19:"Combination Product";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:230;a:5:{s:4:"data";s:6:"Comity";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:231;a:5:{s:4:"data";s:8:"Contract";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:232;a:5:{s:4:"data";s:11:"Copromotion";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:233;a:5:{s:4:"data";s:17:"Country of Origin";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:234;a:5:{s:4:"data";s:17:"Cross-Examination";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:235;a:5:{s:4:"data";s:9:"Debarment";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:236;a:5:{s:4:"data";s:12:"Distributors";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:237;a:5:{s:4:"data";s:18:"Emotional Distress";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:238;a:5:{s:4:"data";s:24:"Good Samaritan liability";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:239;a:5:{s:4:"data";s:6:"Hawaii";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:240;a:5:{s:4:"data";s:5:"Idaho";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:241;a:5:{s:4:"data";s:6:"Kansas";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:242;a:5:{s:4:"data";s:26:"Lost Chance/Increased Risk";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:243;a:5:{s:4:"data";s:11:"Malpractice";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:244;a:5:{s:4:"data";s:17:"Medication Guides";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:245;a:5:{s:4:"data";s:7:"Mirapex";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:246;a:5:{s:4:"data";s:17:"Necessary Parties";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:247;a:5:{s:4:"data";s:7:"Privacy";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:248;a:5:{s:4:"data";s:11:"Puerto Rico";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:249;a:5:{s:4:"data";s:12:"Reprocessing";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:250;a:5:{s:4:"data";s:9:"Resources";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:251;a:5:{s:4:"data";s:9:"Severance";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:252;a:5:{s:4:"data";s:17:"Translation Costs";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:253;a:5:{s:4:"data";s:4:"Utah";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:254;a:5:{s:4:"data";s:6:"Viagra";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:255;a:5:{s:4:"data";s:10:"Washington";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:256;a:5:{s:4:"data";s:7:"Wyoming";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:257;a:5:{s:4:"data";s:4:"plea";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:258;a:5:{s:4:"data";s:8:"replevin";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:19:"Drug and Device Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:37:"http://druganddevicelaw.blogspot.com/";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:14:"managingEditor";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Michelle Yeary)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:9:"generator";a:1:{i:0;a:5:{s:4:"data";s:7:"Blogger";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"item";a:25:{i:0;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-6027403342928451911";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Fri, 11 Apr 2014 19:15:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:2:{i:0;a:5:{s:4:"data";s:9:"Discovery";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:11:"E-Discovery";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:57:"Breaking News:  Proposal to Amend Federal Rules Finalized";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:5379:"The so-called “Duke Subcommittee” today finalized and voted on its version of proposed amendments to the Federal Rules of Civil Procedure.<span style="mso-spacerun: yes;">&nbsp; </span>These amendments include those we’ve <a href="http://druganddevicelaw.blogspot.com/2013/09/everybody-bitches-about-ediscovery-but.html">blogged about before</a>, making alterations to the scope of discovery, the proportionality requirement, and with respect to ediscovery the availability of sanctions.<span style="mso-spacerun: yes;">&nbsp; </span>Except for the sanctions amendments (Rule 37(e)), the other rules changes are substantively the same as those released by the Subcommittee last month in its “Agenda Book.”<span style="mso-spacerun: yes;">&nbsp; </span>You can review those changes <a href="http://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;frm=1&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0CCwQFjAA&amp;url=http%3A%2F%2Fwww.aceds.org%2Fwp-content%2Fuploads%2F2014%2F03%2F2014-Comments-on-Rule-Package-Portland-Memo-Thomas-Allman.pdf&amp;ei=qzVIU4v7IsnY2QXqtIGYCg&amp;usg=AFQjCNF5lA9VtWTCAcxqeJaZc34H1E37UA&amp;sig2=dvRZcNh-tQRa2ri3sIJchw">here</a>.<span style="mso-spacerun: yes;">&nbsp; </span>Most importantly, from our perspective, the final proposed amendments excise the much abused “reasonably calculated to lead to the discovery of admissible evidence” language from Rule 26(b)(1) and replace it with proportionality considerations.<span style="mso-spacerun: yes;">&nbsp; </span>As amended, scope of discovery would become:<o:p></o:p><br /><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Parties may obtain discovery regarding any nonprivileged matter that is relevant to any party’s claim or defense and proportional to the needs of the case, considering the importance of the issues at stake in the action, the amount in controversy, the parties relative access to relevant information, the parties’ resources, the importance of the discovery in resolving the issues, and whether the burden or expense of the proposed discovery outweighs its likely benefit.<span style="mso-spacerun: yes;">&nbsp; </span>Information within this scope of discovery need not be admissible in evidence to be discoverable.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The only substantive changes that the Duke Subcommittee has made from its March, 2014 proposal concern the sanctions available under Fed. R. Civ. P. 37(e) for loss of electronic information.<span style="mso-spacerun: yes;">&nbsp; </span>As of today, amended Rule 37(e) now reads:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">(e) FAILURE TO PRESERVE ELECTRONICALLY STORED INFORMATION.<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">If electronically stored information that should have been preserved in the anticipation or conduct of litigation is lost because a party failed to take reasonable steps to preserve the information, and the information cannot be restored or replaced through additional discovery, the court may:<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></div><br /><div class="MsoBlockText" style="margin: 0in 1in 12pt;">(1) Upon a finding of prejudice to another party from loss of the information, order measures no greater than necessary to cure the prejudice;<o:p></o:p></div><br /><div class="MsoBlockText" style="margin: 0in 1in 12pt;">(2) Only upon a finding that the party acted with the intent to deprive another party of the information's use in the litigation,<o:p></o:p></div><br /><div class="MsoBlockText" style="margin: 0in 1in 12pt 1.5in;">(A) presume that the lost information was unfavorable to the party;<o:p></o:p></div><br /><div class="MsoBlockText" style="margin: 0in 1in 12pt 1.5in;">(B) instruct the jury that it may or must presume the information was unfavorable to the party; or <o:p></o:p></div><br /><div class="MsoBlockText" style="margin: 0in 1in 12pt 1.5in;">(C) dismiss the action or enter a default judgment.<o:p></o:p></div><br /><div class="BodyTextContinued" style="margin: 0in 0in 0pt;">We understand that the Committee voted unanimously:<span style="mso-spacerun: yes;">&nbsp; </span>(1) to adopt the amendments, and (2) that the latest revisions do not require republication of the amendments and/or a new comment period.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">While hardly perfect, these changes to Rule 37(a) are a welcome step in the right direction.<span style="mso-spacerun: yes;">&nbsp; </span>They would appear to preclude, for example, substantive sanctions (presumptions; adverse inference instructions) in a situation similar to <i style="mso-bidi-font-style: normal;">ex post facto</i> sanctions in the <u>Actos</u> litigation we described <a href="http://druganddevicelaw.blogspot.com/2014/04/litigation-holds-matter.html%20">last week</a>, where a litigation hold remained from prior litigation, but “the litigation” (as provided in proposed Rule 27(e)(2) had not yet been filed.<span style="mso-spacerun: yes;">&nbsp; </span>Logically, it seems impossible for a party to have “intent to deprive” anybody of anything for “use” in litigation that does not exist.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:89:"http://druganddevicelaw.blogspot.com/2014/04/breaking-news-proposal-to-amend-federal.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-11T15:17:32.357-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:1;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-8757388860833381534";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Fri, 11 Apr 2014 12:00:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:4:{i:0;a:5:{s:4:"data";s:13:"Design Defect";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:18:"Express Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:20:"Manufacturing Defect";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:8:"Warnings";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:41:"Hip Order on Preemption Plays a Sour Note";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:12858:"  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;">The district court’s express preemption ruling in <i style="mso-bidi-font-style: normal;">Simoneau v. Stryker, Corp.</i>, No. 3:13-CV-1200, 2014 U.S. Dist. LEXIS 43137 (D. Conn. Mar. 31, 2014), reminds us of the piano we learned to play on as a child.<span style="mso-spacerun: yes;">&nbsp; </span>It was a nice old piano, maybe even an antique, and it remains to this day in the Drug and Device Law Family.<span style="mso-spacerun: yes;">&nbsp; </span>The problem was that there were a few keys that just would not stay in tune.<span style="mso-spacerun: yes;">&nbsp; </span>Just a few.<span style="mso-spacerun: yes;">&nbsp; </span>There we were, tearing off a killer Minuet in G, and then “clunk,” we hit the offending keys.<span style="mso-spacerun: yes;">&nbsp; </span>Or maybe it was “clank.”<span style="mso-spacerun: yes;">&nbsp; </span>Either way, it was just one or two notes, but it was enough to dampen our spirit over an entire song.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="RSBodyText" style="margin: 0in 0in 12pt;">And so is the small but significant part of <i style="mso-bidi-font-style: normal;">Simoneau</i> that permitted manufacturing defect claims to go forward in a case involving PMA-approved hip replacement devices.<span style="mso-spacerun: yes;">&nbsp; </span>We harken to the piano analogy because the rest of the <i style="mso-bidi-font-style: normal;">Simoneau</i>order is music to our ears, so let’s start with the good parts:<span style="mso-spacerun: yes;">&nbsp; </span>In <i style="mso-bidi-font-style: normal;">Simoneau</i>, the plaintiff was treated with a PMA-approved hip implant device in 2003 and had to undergo revision surgery in 2012.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at **3-4.<span style="mso-spacerun: yes;">&nbsp; </span>In the meantime, the FDA issued two warning letters in 2007 relating to the defendant’s manufacturing facilities, and two recalls followed in 2009—one recall of a hip replacement component and another of a bone screw.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at **8-9, 17.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="RSBodyText" style="margin: 0in 0in 12pt;">The plaintiff sued the manufacturer and alleged several product liability theories under the Connecticut Product Liability Act, including design defect, manufacturing defect, and failure to warn.<span style="mso-spacerun: yes;">&nbsp; </span>We note first that the court’s order is one of the most carefully crafted orders we’ve seen in a long time, including a long description of the regulatory framework for medical devices and an accurate recitation of the general rules governing express preemption:<span style="mso-spacerun: yes;">&nbsp; </span>“First the court must find that the federal government has imposed requirements on the medical device at issue.<span style="mso-spacerun: yes;">&nbsp; </span>If so then the court must determine whether plaintiff’s claims are based on state requirements that are ‘”different from or in additional to” the federal ones, and that related to safety and effectiveness.’”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at **13-14 (citing <i style="mso-bidi-font-style: normal;">Riegel</i>).<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="RSBodyText" style="margin: 0in 0in 12pt;">Applying this rule, the court concluded correctly that federal law preempted the plaintiff’s design claims and warnings claims, which sounded both in strict liability and negligence.<span style="mso-spacerun: yes;">&nbsp; </span>On design, the court played a short and sweet tune:<o:p></o:p></div><br /><div class="RSQuote" style="margin: 0in 0.5in 12pt;">With respect to a Class III medical device, which is subject to the rigorous PMA process, state law claims for defective design cast doubt on the FDA’s findings concerning the safety of that device’s design and, thus, are categorically preempted by the MDA.<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></div><br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><i style="mso-bidi-font-style: normal;">Id.</i> at *27.<span style="mso-spacerun: yes;">&nbsp; </span>We’ve written a lot about express preemption over design related claims, and we don’t see how a court could come to any different result.<span style="mso-spacerun: yes;">&nbsp; </span>Fortunately this court saw it the same way.</div><div class="RSBodyText" style="margin: 0in 0in 12pt;">On the warnings-related claims, the court took somewhat longer, but reached the same result.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff argued that her state-law warnings claims were based on violations of FDA regulations and thus were “parallel” claims.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at **28-30.<span style="mso-spacerun: yes;">&nbsp; </span>But the court rejected that argument because the plaintiff had not linked her alleged injuries to any such violation.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at **30-31.<span style="mso-spacerun: yes;">&nbsp; </span>Nor could the plaintiff claim that her state law claims were based on the “misbranding” of the devices because misbranding claims “necessarily impose requirements different from or additional to the FDA’s requirements.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *31.<span style="mso-spacerun: yes;">&nbsp; </span>This last point should be obvious because FDA-approved warnings cannot be “misbranded” unless you hold that the labeling should have been different, which is the definition of express preemption.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="RSBodyText" style="margin: 0in 0in 12pt;">Finally, the plaintiff argued that the defendant failed to advise her of the recalls or to report adverse events to the FDA.<span style="mso-spacerun: yes;">&nbsp; </span>The latter argument regrettably gained traction in one of the <a href="http://druganddevicelaw.blogspot.com/2013/12/the-bad-and-ugly-worst-prescription_23.html">worst opinions of 2013</a>—<i style="mso-bidi-font-style: normal;">Stengel v. Medtronic, Inc.</i>, 704 F.3d 1224 (9th Cir. 2013).<span style="mso-spacerun: yes;">&nbsp; </span>This court, however, rejected these arguments on the concise and reasoned bases that there is no state-law duty to warn patients about recalls of prescription products and also no state-law duty to warn the FDA.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at **32-33.<span style="mso-spacerun: yes;">&nbsp; </span>(If only the <a href="http://druganddevicelaw.blogspot.com/2013/01/stengel-revisited-we-simply-dont-like-it.html">Ninth Circuit</a> had seen it so clearly).<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="RSBodyText" style="margin: 0in 0in 12pt;">Finely tuned on design, and finely tuned on warnings.<span style="mso-spacerun: yes;">&nbsp; </span>Which leads to the “clunk”—manufacturing defect.<span style="mso-spacerun: yes;">&nbsp; </span>On this theory, the court regrettably took its cue from one of the worst decisions of 2010 (although we <a href="http://druganddevicelaw.blogspot.com/2011/12/dregs-ten-worst-drugmedical-device.html">reported it in 2011</a>  because it was published so late in the year)—<i style="mso-bidi-font-style: normal;"><a href="http://druganddevicelaw.blogspot.com/2011/01/bashing-bausch.html">Bausch v. Stryker</a> Corp</i>., 630 F.3d 546 (7th Cir. 2010).<span style="mso-spacerun: yes;">&nbsp; </span>Because the plaintiff alleged that the recall-related manufacturing issues were directly related to the manufacture of the products she received in 2003, the court basically held that she had alleged violations of federal regulations that were also breaches of state-law duties, <i style="mso-bidi-font-style: normal;">i.e.</i>, “parallel” claims.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at **17-24.<span style="mso-spacerun: yes;">&nbsp; </span>When stated this way (which is generous to the court’s reasoning), it does not sound so bad.<span style="mso-spacerun: yes;">&nbsp; </span>We have always acknowledged the possibility that if a violation of FDA manufacturing regulations actually results in a product that does not meet manufacturing standards, there could be a parallel claim if that nonconforming aspect of the product causes an injury.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="RSBodyText" style="margin: 0in 0in 12pt;">What then is the problem?<span style="mso-spacerun: yes;">&nbsp; </span>The district court (like the Seventh Circuit in <i style="mso-bidi-font-style: normal;">Bausch</i>) gave the plaintiff a pass on <i style="mso-bidi-font-style: normal;">TwIqbal</i> pleading standards.<span style="mso-spacerun: yes;">&nbsp; </span>Sure, the plaintiff alleged that the <span style="mso-spacerun: yes;">&nbsp;</span>2009 recalls “directly relate to the manufacture of the [hip implant] she received in 2003,” but she needed to allege facts showing a plausible basis for that alleged relationship, plus more.<span style="mso-spacerun: yes;">&nbsp; </span>How exactly did her product deviate from what the manufacturer intended and how was it in a defective condition unreasonably dangerous as a result?<span style="mso-spacerun: yes;">&nbsp; </span>If she did not plead a plausible state-law manufacturing defect claim, she should not get even to square one.<span style="mso-spacerun: yes;">&nbsp; </span>On express preemption, how exactly did a 2009 recall impact manufacturing in 2003?<span style="mso-spacerun: yes;">&nbsp; </span>Did manufacturing issues actually result in a product that did not meet the manufacturer’s specifications?<span style="mso-spacerun: yes;">&nbsp; </span>Did that nonconforming aspect of the product result in plaintiff’s injury?<span style="mso-spacerun: yes;">&nbsp; </span>The court brushed off <i style="mso-bidi-font-style: normal;">TwIqbal</i> in a footnote and excused plaintiff from pleading plausible claims.<span style="mso-spacerun: yes;">&nbsp; </span>Why?<span style="mso-spacerun: yes;">&nbsp; </span>Because “’much of the critical information . . . is kept confidential as a matter of federal law’ and will, therefore, be unavailable to a plaintiff without discovery.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *19.<span style="mso-spacerun: yes;">&nbsp; </span>So discovery solves all woes.<span style="mso-spacerun: yes;">&nbsp; </span>Clank.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="RSBodyText" style="margin: 0in 0in 12pt;">The district court also accepted that a parallel claim can be based on violations of generally applicable cGMPs, rather than device-specific requirements.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at **20-22.<span style="mso-spacerun: yes;">&nbsp; </span>As in <i style="mso-bidi-font-style: normal;">Bausch</i>, the court seemed disinclined to examine too closely the actual basis for the plaintiff’s “parallel” claim, again because “policing that limitation at the pleadings stage would work especial hardship for plaintiffs in this context.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *22.</div><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-theme-font: minor-bidi; mso-fareast-font-family: &quot;Times New Roman&quot;; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;">We don’t want to work especial hardship on anyone, but we do know that hardship is not an element of the express preemption analysis.<span style="mso-spacerun: yes;">&nbsp; </span>Preemption is powerful because it eliminates entire complaint in deference to federal regulation.<span style="mso-spacerun: yes;">&nbsp; </span>It embodies the <a href="http://druganddevicelaw.blogspot.com/2008/02/much-is-given-much-is-expected.html">high regulation, low litigation</a>  model that we favor, and while <i style="mso-bidi-font-style: normal;">Simoneau</i>plays a sweet melody on many issues, its tune on manufacturing defect is decidedly off key.<span style="mso-spacerun: yes;">&nbsp; </span></span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:89:"http://druganddevicelaw.blogspot.com/2014/04/hip-order-on-preemption-plays-sour-note.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:37:"noreply@blogger.com (Steven Boranian)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-11T08:00:01.023-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:2;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-5402034355837017745";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Thu, 10 Apr 2014 18:58:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:4:{i:0;a:5:{s:4:"data";s:19:"Dear Doctor Letters";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:29:"Expert Witness Opinion On Law";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:18:"Implied Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:12:"Pennsylvania";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:49:"The Perils of Letting Regulatory Experts Run Wild";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:24645:"  Although <u>Czimmer v. Janssen Pharmaceuticals, Inc.</u>, 2014 WL 1335511 (Pa. C.P. Philadelphia Co. Jan. 2, 2014), was decided several months ago, we only became aware of it (because of our ongoing automatic searches) the other day.<span style="mso-spacerun: yes;">&nbsp; </span>While there are a number of grounds for feeling uneasy about what went on in <u>Czimmer</u>, we’re focusing on only a couple.<span style="mso-spacerun: yes;">&nbsp; </span>To us, <u>Czimmer</u> is a poster child for what can go wrong when FDA regulatory “experts” spouting legal conclusions are allowed to run wild in a courtroom.&nbsp; It’s also a preemption case, or should have been.<o:p></o:p><br />  <br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">In Pennsylvania, as elsewhere, it is “well-settled that an expert is not permitted to give an opinion on a question of law.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Waters v. State Employees’ Retirement Board</u>, 955 A.2d 466, 471 n.7 (Pa. Commw. 2008).<span style="mso-spacerun: yes;">&nbsp; </span>“Just because a hired expert makes a legal conclusion does not mean that a trial judge has to adopt it.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Gregg v. V-J Auto Parts</u>, 943 A.2d 216, 223 (Pa. 2007) (barring testimony on what constituted a “substantial factor”).<span style="mso-spacerun: yes;">&nbsp; </span>“[E]xpert opinions relating to the meaning of laws are not relevant evi­dence.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Newtown Square East, L.P. v. National Realty Corp.</u>, 38 A.3d 1018, 1026 n.10 (Pa. Commw. 2011).<span style="mso-spacerun: yes;">&nbsp; </span>Therefore, an “expert opinion on a question of law is inadmissible,” <u>41 Valley Associates v. Board of Supervisors</u>, 882 A.2d 5, 14 n.12 (Pa. Commw. 2005); <u>see</u> <u>Browne v. Pennsylvania DOT</u>, 843 A.2d 429, 433 (Pa. Commw. 2004) (“[l]egal opinion testimony is not admissible”), and “admission of incompetent opinion evidence which goes to the legal conclusions to be drawn by the factfinder constitutes reversible error.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Taylor v. Fardink</u>, 331 A.2d 797, 799 (Pa. Super. 1975).<span style="mso-spacerun: yes;">&nbsp; </span>Expert opinions have “no effect” on questions of law.<span style="mso-spacerun: yes;">&nbsp; </span><u>Novak v. Jeannette District Memorial Hospital</u>, 600 A.2d 616, 618 (Pa. Super. 1991).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Experts may not offer legal opinions because “[e]ach courtroom comes equipped with a ‘legal expert,’ called a judge, and it is his or her province alone to instruct the jury on the relevant legal standards.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Burkhart v. WMATA</u>, 112 F.3d 1207, 1213 (D.C. Cir. 1997) (citation omitted).<span style="mso-spacerun: yes;">&nbsp; </span>Precluding experts from offering legal conclusions prevents them from “usurping [the court’s] role.” <u>Bergman v. United Service Automobile Association</u>, 742 A.2d 1101, 1108 (Pa. Super. 1999) (excluding opinion defining “bad faith”) (footnote omitted); <u>see</u> <u>March v. Downingtown Area School District</u>, 775 A.2d 876, 880 (Pa. Commw. 2000) (affirming exclusion of expert opinion “more in the nature of argument on legal questions that were .&nbsp;.&nbsp;. for the court to decide”).<span style="mso-spacerun: yes;">&nbsp; </span>Thus, a legal standard is “not an issue of fact subject to expert testimony, but [is] an issue of law for the trial judge to decide.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Commonwealth v. Possinger</u>, 399 A.2d 1077, 1083 (Pa. Super. 1979).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">This rule was ignored in <u>Czimmer</u>, with the predictable effect that legal questions concerning FDA regulations were improperly submitted for a lay jury to decide.<span style="mso-spacerun: yes;">&nbsp; </span>The legal question involved the FDA’s classification of a drug (Topamax) “as a Category C drug in the FDA Pregnancy Category.”<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 1335511, at *2.<span style="mso-spacerun: yes;">&nbsp; </span>Two FDA pregnancy categories were at issue in <u>Czimmer</u>, categories C and D.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">According to <a href="http://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucm308982.pdf">information available on the FDA’s website</a>, “[i]n 1979, the A, B, C, D, and X category classification that is based on the adverse events and potential benefits of a particular drug was implemented in the United States in order to standardize pregnancy labeling.”<span style="mso-spacerun: yes;">&nbsp; </span>These are:<o:p></o:p></div><br /><div class="ListBulletJustified" style="margin: 0in 0.5in 12pt 1in; mso-list: l0 level1 lfo1; text-indent: -0.5in;"><span style="font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font-size-adjust: none; font-stretch: normal; font: 7pt/normal &quot;Times New Roman&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span>A − Adequate, well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities.<o:p></o:p></div><br /><div class="ListBulletJustified" style="margin: 0in 0.5in 12pt 1in; mso-list: l0 level1 lfo1; text-indent: -0.5in;"><span style="font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font-size-adjust: none; font-stretch: normal; font: 7pt/normal &quot;Times New Roman&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span>B − Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women or Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus.<o:p></o:p></div><br /><div class="ListBulletJustified" style="margin: 0in 0.5in 12pt 1in; mso-list: l0 level1 lfo1; text-indent: -0.5in;"><span style="font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font-size-adjust: none; font-stretch: normal; font: 7pt/normal &quot;Times New Roman&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span>C −<span style="mso-spacerun: yes;">&nbsp; </span>Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women; or no animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.<o:p></o:p></div><br /><div class="ListBulletJustified" style="margin: 0in 0.5in 12pt 1in; mso-list: l0 level1 lfo1; text-indent: -0.5in;"><span style="font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font-size-adjust: none; font-stretch: normal; font: 7pt/normal &quot;Times New Roman&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span>D − Studies, adequate well-controlled or observational, in pregnant women have demonstrated a risk to the fetus.<span style="mso-spacerun: yes;">&nbsp; </span>However, the benefits of therapy may outweigh the potential risk.<o:p></o:p></div><br /><div class="ListBulletJustified" style="margin: 0in 0.5in 12pt 1in; mso-list: l0 level1 lfo1; text-indent: -0.5in;"><span style="font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font-size-adjust: none; font-stretch: normal; font: 7pt/normal &quot;Times New Roman&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span>X − Studies, adequate well-controlled or observational, in animals or pregnant women have demonstrated positive evidence of fetal abnormalities.<span style="mso-spacerun: yes;">&nbsp; </span>The use of the product is contraindicated in women who are or may become pregnant.<o:p></o:p></div><br /><div class="ListBulletJustified" style="margin: 0in 0.5in 12pt 1in; mso-list: l0 level1 lfo1; text-indent: -0.5in;"><span style="font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font-size-adjust: none; font-stretch: normal; font: 7pt/normal &quot;Times New Roman&quot;;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span>NA − FDA pregnancy rating not available.<o:p></o:p></div><br /><div class="BodyTextContinued" style="margin: 0in 0in 0pt;"><u>Id.</u><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">In 2004, the drug was approved by the FDA under Category C.<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 1335511, at *2.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff used the drug in 2006.<span style="mso-spacerun: yes;">&nbsp; </span>According to the decision, however, the plaintiff offered evidence of “pregnancy reports in 2000, 2002, and 2005 in the possession of the Defendant indicating the contrary.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *2.<span style="mso-spacerun: yes;">&nbsp; </span>All this material was concededly submitted to the FDA in a timely fashion, <u>id.</u>, so we’re not sure what the point of it was, except as an attack on the FDA’s initial classification decision.<span style="mso-spacerun: yes;">&nbsp; </span>As we discuss below, attacks on FDA classification decisions in state-law should be preempted.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Here’s where the regulatory experts began running amok.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff’s regulatory expert “maintained that the Defendant was negligent in failing” to send a “Dear Doctor” letter (technically a “Dear Healthcare Provider” (DHCP) letter – but this is Philly CP) discussing these reports.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *2.<span style="mso-spacerun: yes;">&nbsp; </span>To us, allowing an expert to opine on whether a defendant is “negligent” is a no-no.<span style="mso-spacerun: yes;">&nbsp; </span>It’s no different than the opinion on what constituted “bad faith” in <u>Bergman</u>or on what was a “substantial factor” in <u>Gregg</u>.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">But compared to what follows, that was minor league.<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">The crux of [the expert’s] opinion dealt with the fact that although the FDA had in its possession the adverse studies/reports and did not order any labeling change, the Defendant was nonetheless obligated to inform physicians/healthcare providers of this information in order for these would be prescribers to make a knowing and intelligent decision as to whether or not to prescribe the drug to their patients.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">2014 WL 1335511, at *2.<span style="mso-spacerun: yes;">&nbsp; </span>That’s not even a proper negligence opinion.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA does not allow regulated companies to send Dear Doctor letters willy-nilly.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA has <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM233769.pdf%20">guidelines</a> on when such letters may be sent.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">According to the FDA, Dear Doctor letters are for “important new information” – they’re not for rehashing something that doctors already should know:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">[A] DHCP letter is used to inform health care practitioners about important new information about a drug.<span style="mso-spacerun: yes;">&nbsp; </span>In most cases, the new information is about an important new safety concern that could affect the decision to use a drug or require some change in behavior by health care practitioners, patients, or caregivers to reduce the potential for harm from a drug.<span style="mso-spacerun: yes;">&nbsp; </span>In some cases, the new information is about how to improve the effectiveness of a drug.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM233769.pdf%20">Draft guidance</a>, at 3 (emphasis added).<span style="mso-spacerun: yes;">&nbsp; </span>New.<span style="mso-spacerun: yes;">&nbsp; </span>New.<span style="mso-spacerun: yes;">&nbsp; </span>New.<span style="mso-spacerun: yes;">&nbsp; </span>New.<span style="mso-spacerun: yes;">&nbsp; </span>Moreover, Dear Doctor letters should “avoid discussion of non-critical information that could obscure the more important information.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at 4.&nbsp; The only other FDA-recognized use for a Dear Doctor letter is “to correct misinformation in advertising or other types of prescription drug promotion.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at 3.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA’s guidelines aren’t legally binding, but they are legal in nature.<span style="mso-spacerun: yes;">&nbsp; </span>The judge – not an expert – thus should have decided (after briefing by the parties) whether a Dear Doctor letter was required/permissible under the FDA’s standards.<span style="mso-spacerun: yes;">&nbsp; </span>Dear Doctor letters are drug labeling, so the FDA’s standards control<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">That’s one.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">The next relevant issue in <u>Czimmer</u> involved  a consent form from an FDA clinical trial concerning the drug.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff was never enrolled in this, or any other clinical trial.<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 1335511, at *3. <span style="mso-spacerun: yes;">&nbsp;</span>The FDA’s regulation of informed consent in clinical trials – and thus whether a clinical trial informed consent forms bear on anything outside such trials – is complex and detailed.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> 21 C.F.R. Parts 50.1, and 56.<span style="mso-spacerun: yes;">&nbsp; </span>Instead of deciding anything, however, the trial court allowed, indeed encouraged, expert witnesses to usurp its role:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">The use of the consent form in a clinical trial, where people volunteer to be subject of a study is much different from what information would be contained in the labeling of a drug. <span style="mso-spacerun: yes;">&nbsp;</span>.&nbsp;.&nbsp;.Defendant’s regulatory expert [] testified that the consent form warnings should never appear in the labeling because they are based on entirely different criteria. <span style="mso-spacerun: yes;">&nbsp;</span>It became clear to the Court based on the conflicting expert opinions that there existed a viable factual dispute as to the role the consent form played in the negligence issue. <span style="mso-spacerun: yes;">&nbsp;</span>It was therefore proper and correct of the Court to admit the consent form, leaving it to the jury to decide whether or not and to what extent it contributed to the negligence of the Defendant.<span style="mso-spacerun: yes;">&nbsp; </span>Keep in mind that the Defense countered [plaintiff’s expert’s] opinions through their regulatory expert [] who had worked for the FDA, who opined otherwise.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">2014 WL 1335511, at *3.<span style="mso-spacerun: yes;">&nbsp; </span>Whether or not the FDA’s informed consent regulations for clinical trials mandate pregnancy warnings in all consent forms, regardless of what is actually known to science, or whether the forms reflect the state of the art (and thus could be relevant) is again a legal issue for the court to decide.<span style="mso-spacerun: yes;">&nbsp; </span>Either the regs do, or they don’t.<span style="mso-spacerun: yes;">&nbsp; </span>Conversely, this question is not a matter for experts to dispute and a jury to decide.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">That’s two.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">The third legal question we think was improperly submitted to the jury involved pregnancy Category C versus pregnancy Category D.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff’s causation case hinged on the prescriber’s statement “that she would not have prescribed the drug in the first place if there had been a warning on the label that there were studies showing potential harm to human fetuses as contained in Category D.”<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 1335511, at *3.<span style="mso-spacerun: yes;">&nbsp; </span>The basic problem is that the drug <b style="mso-bidi-font-weight: normal;"><u>wasn’t</u></b> classified by the FDA as Category D.<span style="mso-spacerun: yes;">&nbsp; </span>It was classified as Category C (that’s since changed since, something not apparent from the opinion).<span style="mso-spacerun: yes;">&nbsp; </span>Once again, the trial court punted the issue – what was the proper classification of a drug – to expert regulatory witnesses:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Plaintiff's expert [] opined that merely because the FDA, in possession of the adverse event reports did not order a change in the labeling did not absolve the Defendant. <span style="mso-spacerun: yes;">&nbsp;</span>[] Defendant's regulatory expert, stated otherwise. <span style="mso-spacerun: yes;">&nbsp;</span>Thus, it was proper for the Court to leave it to the jury to decide which opinion to accept.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">2014 WL 1335511, at *5.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">That’s three, and this one is the worst of the bunch.<span style="mso-spacerun: yes;">&nbsp; </span>Not only is whether a drug meets the FDA’s regulatory criteria (set forth above) for Category C versus Category D a legal opinion based on those criteria – it is a legal decision beyond the competence of a state court to adjudicate.<span style="mso-spacerun: yes;">&nbsp; </span>What classification a regulated product falls into, whether it’s a drug’s pregnancy category or a device’s regulatory pedigree (pre-market approval, as opposed to §510k clearance), or whether it’s a combination product regulated as a “drug” or “device” – is a matter delegated solely to the discretion of the FDA.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">There doesn’t seem to be a fraud on the FDA claim underlying <u>Czimmer</u>, since there appears to be no dispute that everything the FDA should have considered was in fact in the hands of the Agency.<span style="mso-spacerun: yes;">&nbsp; </span>Otherwise, however, the claim being asserted in <u>Czimmer</u> shares the same pernicious effects as the claim in <u>Buckman Co. v. Plaintiffs Legal Committee</u>, 531 U.S. 341 (2001), that warrant an application of preemption.<span style="mso-spacerun: yes;">&nbsp; </span>At bottom the claim in <u>Czimmer</u> – the only one where there’s evidence of warning causation – has to be that the FDA got it wrong; that based on all the evidence that the FDA had before it (according to plaintiff’s experts) the drug should have been in Category D.<span style="mso-spacerun: yes;">&nbsp; </span>Otherwise, the prescriber’s testimony that a Category D warning would have made a difference in the prescribing decision, 2014 WL 1335511, at *3, is immaterial because no factual basis for that statement existed.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">But like a fraud on the FDA claim, a claim that the FDA made a mistake and should have placed the drug in Category D depends on the jury being allowed to accept a contrafactual assumption about the FDA:<span style="mso-spacerun: yes;">&nbsp; </span>that the Agency should have done something that it, in fact, did not.<span style="mso-spacerun: yes;">&nbsp; </span>The jury was permitted to find that the FDA should have taken a different regulatory action; specifically, that it should have classified the drug into Category D.<span style="mso-spacerun: yes;">&nbsp; </span>This finding, of course, ignores, what the FDA actually did at the relevant time, which is classify the drug into Category C.<span style="mso-spacerun: yes;">&nbsp; </span>This is a fundamental, inherent conflict between what the FDA did and what the jury found it should have done.<span style="mso-spacerun: yes;">&nbsp; </span>That has to be preempted under <u>Buckman</u>, because federal law, reflecting an in-force decision by the FDA, is supreme over any state-law jury’s supposition that the FDA should have done something else.<span style="mso-spacerun: yes;">&nbsp; </span>Even if plaintiff’s claim were not predicated on FDA having been wrong and Defendant needing to do things it could not have done by itself − and it was − the preemption principles at play here still should require exclusion of expert testimony like plaintiff offered.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Nor is this <u>Wyeth v. Levine</u>, 555 U.S. 555 (2009), as <u>Czimmer</u> held.<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 1335511, at *5.<span style="mso-spacerun: yes;">&nbsp; </span><u>Levine</u> turned on the defendant (supposedly) having the unilateral power under an FDA labeling regulation to change its label.<span style="mso-spacerun: yes;">&nbsp; </span>There’s no similar unilateral power for a drug manufacturer to change a drug’s classification.<span style="mso-spacerun: yes;">&nbsp; </span>That’s for the FDA to decide, not a manufacturer.<span style="mso-spacerun: yes;">&nbsp; </span>So the situation is closer to <u>PLIVA v. Mensing</u>, 131 S. Ct. 2567 (2011), as the defendant argued.<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 1335511, at *5.<span style="mso-spacerun: yes;">&nbsp; </span>But the conflict here is deeper than <u>Mensing</u>, since that case only dealt with a label change, whereas the plaintiff’s theory in <u>Czimmer</u> depended on the jury being told it could ignore the FDA’s basic classification of the drug, because based on all the information before it, the FDA got it wrong.<span style="mso-spacerun: yes;">&nbsp; </span><u>Mensing</u> is relevant, because a drug’s classification can be changed only after the FDA says so.&nbsp; To us, however, the case is much closer to <u>Buckman</u>, because <u>Buckman</u> shares the same type of fundamental conflict – a state-law jury cannot be allowed to ignore what the FDA actually did in the real world in favor of what that jury thinks that the FDA should have done, or what the law should be –&nbsp;in whatever fantasy world the plaintiff in <u>Czimmer</u>concocted from her experts’ unfettered legal conclusions.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:82:"http://druganddevicelaw.blogspot.com/2014/04/the-perils-of-letting-regulatory.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-10T14:58:40.603-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:3;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-5916365100064060203";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Wed, 09 Apr 2014 11:30:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:2:{i:0;a:5:{s:4:"data";s:7:"Daubert";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:16:"Expert Witnesses";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:37:"A Good Daubert Ruling in Any Language";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:12614:"<br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">Our two favorite television shows occasionally force us to follow subtitles while&nbsp;a character is&nbsp;speaking a harsh (to our ears, anyway) foreign language.<span style="mso-spacerun: yes;">&nbsp; </span>In <b>The Americans</b>, the spies in the Russian embassy treat us to long exchanges in their mother tongue, reminding us of the bad old days of Kruschev, Brezhnev, and Tretiak, and also bringing to mind the bad new days of the former KGB guy currently&nbsp;running the Kremlin.<span style="mso-spacerun: yes;">&nbsp; </span>The Drug and Device Law Son is studying Russian in school, but refuses to watch <strong>The Americans</strong>, which is surprising and too bad because (a) the show is certainly violent and sexy enough, and (b) we’d like to find out whether our tuition dollars are really working.<span style="mso-spacerun: yes;">&nbsp; </span>Meanwhile, on <b>Game of Thrones</b>, <span style="mso-spacerun: yes;">&nbsp;</span>the Mother of Dragons likes to show off her not-quite-mastery of Dothraki.<span style="mso-spacerun: yes;">&nbsp; </span>No DDL heir, as far as we know, is studying Dothraki, but there are websites with in-depth instruction in that language.<span style="mso-spacerun: yes;">&nbsp; </span>Did we mention that Dothraki is a fictional language?<span style="mso-spacerun: yes;">&nbsp; </span>We find all of this a bit hard to understand.<o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">The inability of a non-English speaker to understand English pops up in the legal biz a lot.<span style="mso-spacerun: yes;">&nbsp; </span>We remember prosecuting a hapless fellow many years ago for solicitation of prostitution.<span style="mso-spacerun: yes;">&nbsp; </span><span style="mso-spacerun: yes;">&nbsp;</span>That is, of course, a crime of words (and sometimes gestures).<span style="mso-spacerun: yes;">&nbsp; </span>As per usual, the key witness was a female police officer who was (sadly for the defendant) only pretending to be a prostitute.<span style="mso-spacerun: yes;">&nbsp; </span>She had no trouble reciting the explicit cacophony uttered by the randy miscreant.<span style="mso-spacerun: yes;">&nbsp; </span><span style="mso-spacerun: yes;">&nbsp;</span>The jury took less than 30 minutes to convict.<span style="mso-spacerun: yes;">&nbsp; </span>But sentencing got rather complicated.<span style="mso-spacerun: yes;">&nbsp; </span>It turns out that ten months earlier the same idiot showed up on the same street corner and asked the exact same nasty question ...<span style="mso-spacerun: yes;">&nbsp;t</span>o a police officer.<span style="mso-spacerun: yes;">&nbsp; </span>Unbelievably bad luck or unbelievable stupidity?<span style="mso-spacerun: yes;">&nbsp; </span>Either way, the prior conviction was going to increase the sentence significantly. It would probably turn a two week stint in an orange Caltrans outfit, with him enjoying the fresh air whilst collecting litter alongside the 405, into a 90 day stint in county jail where he would don a slightly different orange suit.&nbsp;<span style="mso-spacerun: yes;">&nbsp;</span></span></span><br /><span style="font-family: Calibri;"><span style="font-size: large;"></span></span><br /><span style="font-family: Calibri;"><span style="font-size: large;"></span></span><br /><span style="font-family: Calibri;"><span style="font-size: large;">Desperate to avoid incarceration, the defendant challenged the validity of the prior conviction on the grounds that he had been denied access to an interpreter.<span style="mso-spacerun: yes;">&nbsp; </span><span style="mso-spacerun: yes;">&nbsp;</span>He claimed he spoke only Farsi.<span style="mso-spacerun: yes;">&nbsp; </span>He had an interpreter during the more recent trial, but to anybody paying attention in the courtroom, including the Judge, he didn’t need one.<span style="mso-spacerun: yes;">&nbsp; </span>He spent a lot of time reacting immediately to testimony and chatting with his attorney, without any aid from the interpreter.<span style="mso-spacerun: yes;">&nbsp; C</span>hallenging the prior conviction essentially meant that the public defender had to argue that the earlier public defender had rendered ineffective assistance of counsel.<span style="mso-spacerun: yes;">&nbsp; </span>Why didn’t the earlier PD ask for an interpreter?<span style="mso-spacerun: yes;">&nbsp; </span>The current PD, by the way, was the son of a very well known lawyer. <span style="mso-spacerun: yes;">&nbsp;</span>She was known, at the very least, by the Judge in our case.<span style="mso-spacerun: yes;">&nbsp; </span>After a brief hearing, the Judge denied the challenge to the prior conviction, and did so via a remarkably heated speech that still rings in our ears.<span style="mso-spacerun: yes;">&nbsp; </span>It went something like this:<span style="mso-spacerun: yes;">&nbsp; </span>“(a) Mr. Defendant, I have been watching you throughout all these proceedings and it is clear to me that you are a liar, and you are a liar who speaks English; (b) I am so outraged by this farce that I will delay the sentencing so that I have time to get over my anger, which is profound; and (c) Mr. Public Defender, your attacks on the prior conviction and on the competence of your own office are disgraceful.<span style="mso-spacerun: yes;">&nbsp; </span>I am telling your mother.” <span style="mso-spacerun: yes;">&nbsp;</span><span style="mso-spacerun: yes;">&nbsp;</span>Wow.<span style="mso-spacerun: yes;">&nbsp; </span>We weren’t sure whether we felt sorrier for the defendant or his hapless lawyer.<span style="mso-spacerun: yes;">&nbsp; </span>Okay – the truth is that we felt sorry for neither.<span style="mso-spacerun: yes;">&nbsp; </span>The absence of an interpreter in the earlier case did not make any difference.<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></span></span></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">The absence of an interpreter also made no difference for the plaintiff in <i>Basanti v. Metcalf, et al</i>., 2014 U.S. Dist. LEXIS 43463 (D. Col. March 28, 2014), a medical malpractice action.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff claimed that her primary language was Punjabi and that she was a person with limited English proficiency (“LEP”).<span style="mso-spacerun: yes;">&nbsp; </span>Her treating doctor, who was one of the defendants, apparently did not speak Punjabi.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiffs claimed that the doctor should have brought in an interpreter.<span style="mso-spacerun: yes;">&nbsp; </span>Failure to bring in an interpreter, according to the plaintiff and her expert witness, caused the treater to fail to diagnose a congenital cyst on her thoracic spine, a condition&nbsp;that ultimately resulted in paraplegia of her lower extremities.<span style="mso-spacerun: yes;">&nbsp; </span>Naturally, the defendant doctor said that he was able to communicate effectively with the plaintiff regarding her medical condition.<o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">This is a <i>Daubert</i> case because the plaintiff tendered an expert on language issues in healthcare.<span style="mso-spacerun: yes;">&nbsp; </span>That expert opined that the provision of adequate language services “likely would have resulted in timely diagnosis and treatment of her thoracic intradural cyst and in preventing her subsequent cord compression, paraplegia and neurogenic shock.” <span style="mso-spacerun: yes;">&nbsp;</span><i>Basanti</i>, 2014 U.S. Dist. LEXIS 43463 at *3.<span style="mso-spacerun: yes;">&nbsp; </span>That expert was a doctor, but he was a pediatrician.<span style="mso-spacerun: yes;">&nbsp; The plaintiff was an adult.&nbsp; </span>Still, the expert offered research showing that a higher rate of clinically significant errors occur when an ad hoc interpreter is used in treating an LEP patient as opposed to when physicians used a trained medical interpreter.<span style="mso-spacerun: yes;">&nbsp; </span>He opined that language barriers “can be a major cause of patient safety incidents and adverse outcomes.” <span style="mso-spacerun: yes;">&nbsp;</span><i>Id.</i> at *14. <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">Just like in that old criminal case, the issue was whether the absence of an interpreter made a difference.<span style="mso-spacerun: yes;">&nbsp; </span>But while the plaintiff’s expert could generally say that absence of an interpreter can alter diagnoses – a sort of general causation opinion – he was incapable of showing that an interpreter would have prompted a different diagnosis and treatment course in the plaintiff’s specific case.<span style="mso-spacerun: yes;">&nbsp; </span>The expert admitted that he lacked expertise and experience treating and diagnosing adults with endodermal cysts in the thoracic spine or compressive lesions.<span style="mso-spacerun: yes;">&nbsp; </span>Further, the plaintiff provided no indication that the expert possessed the expertise to determine what additional information may have been necessary to diagnose or treat the plaintiff’s condition earlier and more effectively.<span style="mso-spacerun: yes;">&nbsp; </span>Accordingly, the court excluded the expert’s opinions on whether adequate language services would have resulted in earlier diagnosis, more effective treatment, or would have prevented plaintiff’s injuries.<span style="mso-spacerun: yes;">&nbsp; </span>The gap in the expert’s medical expertise meant that the jury’s consideration of the <span style="mso-spacerun: yes;">&nbsp;</span>theory of liability would amount to speculation on the issue of causation.<span style="mso-spacerun: yes;">&nbsp; <span style="color: #1f497d; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;; font-size: 11pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;"><span style="color: black;"><span style="font-size: large;">It is analogous to those cases where the plaintiff and/or plaintiff expert indulge in, or the jury is invited to engage in,&nbsp;speculation about how a difference in the warning on a drug would have produced a different result.</span>&nbsp;<span style="font-size: large;"> An expert&nbsp;needs to connect the causation dots.&nbsp; When an expert cannot do so,</span> </span></span></span><span style="color: black;">the</span> expert’s “opinions on the appropriate standard of care do not logically advance a material aspect of this case and, as such, will not assist the trier of fact.”<span style="mso-spacerun: yes;">&nbsp; </span><i>Id.</i> at *20.<span style="mso-spacerun: yes;">&nbsp; </span><span style="mso-spacerun: yes;">&nbsp;</span><o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">We call that a good result.<span style="mso-spacerun: yes;">&nbsp; </span>The DDLS would call it “khorosho.”<span style="mso-spacerun: yes;">&nbsp; </span>The Dothraki Queen (Khaleesi) would call it “Davra.”<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:87:"http://druganddevicelaw.blogspot.com/2014/04/a-good-daubert-ruling-in-any-language.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:37:"noreply@blogger.com (Steve McConnell)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-09T07:30:00.035-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:4;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-8774523503149107366";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Tue, 08 Apr 2014 13:15:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:6:{i:0;a:5:{s:4:"data";s:5:"Iqbal";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:20:"Learned Intermediary";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:17:"Negligence Per Se";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:21:"Personal Jurisdiction";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:4;a:5:{s:4:"data";s:8:"Pleading";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:5;a:5:{s:4:"data";s:22:"Statute Of Limitations";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:102:"An OxyContin Decision That Addresses Everything from Negligence Per Se Claims to Personal Jurisdiction";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:29664:"<!--[if gte mso 9]><xml> <o:OfficeDocumentSettings>  <o:AllowPNG/> </o:OfficeDocumentSettings></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:EnableOpenTypeKerning/>   <w:DontFlipMirrorIndents/>   <w:OverrideTableStyleHps/>  </w:Compatibility>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="&#45;-"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267">  <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin-top:0in;  mso-para-margin-right:0in;  mso-para-margin-bottom:10.0pt;  mso-para-margin-left:0in;  line-height:115%;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:"Calibri","sans-serif";  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:"Times New Roman";  mso-bidi-theme-font:minor-bidi;} </style><![endif]--> <br /><div class="MsoNormal">What’s left of the OxyContin litigation produced a recent decision that addresses a myriad of procedural and substance issues, some of which we often see and others not so much.<span style="mso-spacerun: yes;">&nbsp; </span>If you don’t recall, in 2007, Purdue Frederick Corp. and some of its executives pled guilty to criminal charges related to the marketing of OxyContin and paid approximately $600 million in fines.<span style="mso-spacerun: yes;">&nbsp; </span>That was almost 7 years ago.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff in <u>Luberda v. Purdue Frederick Corp.</u>, 2014 U.S. Dist. LEXIS 41951 (D.S. Car. Mar. 28, 2014), on the other hand, filed his complaint in 2013 in South Carolina – six years after those guilty pleas and ten years after he became addicted to OxyContin.<span style="mso-spacerun: yes;">&nbsp; </span>Although the court’s opinion doesn’t provide much detail on the background of the case, it appears that the plaintiff was asserting negligent and fraudulent failure to warn claims and attempting to assert a private right of action under South Carolina’s criminal statute on misbranding.<span style="mso-spacerun: yes;">&nbsp; </span>He sued nine companies within the Purdue Frederick family of companies and almost two-dozen executives.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">This history created a background ripe for motion practice.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Personal Jurisdiction</i></div><div class="MsoNormal"><br /></div><div class="MsoNormal">Many of the individual defendants moved to be dismiss for insufficient service of process and/or lack of personal jurisdiction. <span style="mso-spacerun: yes;">&nbsp;</span>Two of them won their insufficient service of process motions.<span style="mso-spacerun: yes;">&nbsp; </span>They never signed for the certified mail that carried their summons and complaint.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *12-13.<span style="mso-spacerun: yes;">&nbsp; </span>Those two defendants and approximately 20 others also won dismissal because they did not have sufficient minimum contacts with South Carolina to be sued there.<span style="mso-spacerun: yes;">&nbsp; </span>The court laid out a useful primer on the procedure for analyzing personal jurisdiction:</div><div class="MsoNormal"><br /></div><div class="MsoNormal" style="margin-left: .5in;">The party seeking to invoke personal jurisdiction over a nonresident defendant bears the burden of proving the existence of personal jurisdiction. <span style="mso-spacerun: yes;">&nbsp;</span><i style="mso-bidi-font-style: normal;">ESAB Group, Inc. v. Centricut, LLC, 34 F.Supp.2d 323, 328 (D.S.C.1999)</i>. <span style="mso-spacerun: yes;">&nbsp;</span>At the pretrial stage, the burden of proving personal jurisdiction over a nonresident is met by a <i style="mso-bidi-font-style: normal;">prima facie</i>showing of jurisdiction either in the complaint or in affidavits. In determining whether a <i style="mso-bidi-font-style: normal;">prima facie</i>showing has been made, the Court may consider the uncontroverted allegations in Plaintiff's pleading. <span style="mso-spacerun: yes;">&nbsp;</span>However, whenever the allegations in Plaintiff's pleading are contested by sworn affidavit, Plaintiff can no longer rest on those allegations. <span style="mso-spacerun: yes;">&nbsp;</span>Instead, it then becomes Plaintiff's burden to present an affidavit or other evidence proving that jurisdiction exists over the nonresident defendant. <span style="mso-spacerun: yes;">&nbsp;</span><i style="mso-bidi-font-style: normal;">See Wolf v. Richmond Cnty. Hosp. Auth., 745 F.2d 904, 908 (4th Cir. 1984)</i>; <i style="mso-bidi-font-style: normal;">Clark v. Remark, 993 F.2d 228 (table), 1993 WL 134616, at *2 (4th Cir. 1993)</i>.</div><div class="MsoNormal" style="margin-left: .5in;"><br /></div><div class="MsoNormal">The Court summarily dismissed a multitude of defendants because plaintiff simply didn’t make a <i style="mso-bidi-font-style: normal;">prima facie</i> showing of personal jurisdiction. <span style="mso-spacerun: yes;">&nbsp;</span><u>Id.</u> at *11-12.<span style="mso-spacerun: yes;">&nbsp; </span>For four of the defendants, however, the court determined that their affidavits and the complaint didn’t clarify whether they were involved in company’s decision-making regarding the marketing of OxyContin.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u>at *15.<span style="mso-spacerun: yes;">&nbsp; </span>So the court denied the motions of these defendants, but without prejudice to their raising the arguments again at the summary judgment stage after the plaintiff had a chance for “jurisdictional discovery.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *16.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Learned Intermediary Doctrine</i></div><div class="MsoNormal"><br /></div><div class="MsoNormal">The court also applied the learned intermediary doctrine to the plaintiff’s negligent failure to warn claim.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff’s allegations were, in essence, this: "Defendants owed Plaintiff a duty to properly warn of the potential for and/or risk of addiction associate (sic) with their product."<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *17.<span style="mso-spacerun: yes;">&nbsp; </span>That’s wrong.<span style="mso-spacerun: yes;">&nbsp; </span>South Carolina recognizes the learned intermediary doctrine, and as we all know under that doctrine the manufacturer’s duty to warn runs to the prescribing doctor, not the patient.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *17-18.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff has the burden to show – and allege – that the “undisclosed risk was sufficiently high that it would have changed the doctor’s [prescribing] decision.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *18.<span style="mso-spacerun: yes;">&nbsp; </span>The court dismissed the claim but gave the plaintiff a chance to amend his pleading to add factual allegations suggesting that his doctor would have changed his prescribing decision had there been a different warning.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u></div><div class="MsoNormal"><br /></div><div class="MsoNormal">The plaintiff also appears to have brought a failure to warn claim sounding in fraud.<span style="mso-spacerun: yes;">&nbsp; </span>Fraud claims must satisfy a heightened pleading standard under FRCP 9(b), one that is more demanding than the ordinary <u>TwIqbal</u> pleading standard.<span style="mso-spacerun: yes;">&nbsp; </span>Given that plaintiff’s complaint didn’t sufficiently state a negligent failure to warn claim, it certainly didn’t sufficiently state a fraud claim.<span style="mso-spacerun: yes;">&nbsp; </span>The court dismissed this claim too.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Negligence Per Se</i></div><div class="MsoNormal"><br /></div><div class="MsoNormal">The plaintiff tried to manufacturer a negligence <i style="mso-bidi-font-style: normal;">per se </i>claim from South Carolina’s criminal code on the misbranding of drugs.<span style="mso-spacerun: yes;">&nbsp; </span>But a statute, simply by its existence, does not come with a private right to enforce it in civil court.<span style="mso-spacerun: yes;">&nbsp; </span>The legislature must have intended that.<span style="mso-spacerun: yes;">&nbsp; </span>In fact, South Carolina applies a three-part test – the statutory purpose doctrine – to determine whether a plaintiff has such a private right of action:</div><div class="MsoNormal"><br /></div><div class="MsoNormal" style="margin-left: .5in;">(1) whether the legislature intended to create a private rather than public liability; (2) whether the person injured is a person or member of a class for whose benefit the law was intended to protect; and (3) whether the injury complained of was the type the statute was intended to prevent.&nbsp;</div><div class="MsoNormal" style="margin-left: .5in;"><br /></div><div class="MsoNormal"><u>Id.</u> at *22.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff didn’t get past step one.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff could point to no authority “indicating that South Carolina intended to create a private cause of action for violating the statute.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> <span style="mso-spacerun: yes;">&nbsp;</span>The court dismissed this claim – no right to amend.&nbsp;</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Statute of Limitations</i></div><div class="MsoNormal"><br /></div><div class="MsoNormal">Finally, defendants moved to dismiss the entire action under South Carolina’s three-year statute of limitations.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff had pled in his complaint that he became addicted to OxyContin by 2004.<span style="mso-spacerun: yes;">&nbsp; </span>But he didn’t sue until 2013.<span style="mso-spacerun: yes;">&nbsp; </span>So, defendants argued that plaintiff filed his complaint well after the limitations period had run.<span style="mso-spacerun: yes;">&nbsp; </span>That seems like a reasonable argument.<span style="mso-spacerun: yes;">&nbsp; </span>But it lost.<span style="mso-spacerun: yes;">&nbsp; </span>The court saw a small window: maybe the plaintiff didn’t know he was addicted:&nbsp;</div><div class="MsoNormal"><br /></div><div class="MsoNormal" style="margin-left: .5in;">[T]he allegations of the Amended Complaint in this case are not sufficiently clear that the case is barred by the statute of limitations. <span style="mso-spacerun: yes;">&nbsp;</span>It merely alleges that Plaintiff became involuntarily addicted by October of 2004, not that the plaintiff knew he was addicted or that a reasonable person in his circumstances would have known that he was addicted. <span style="mso-spacerun: yes;">&nbsp;</span>This may at a later time in the case be a viable defense. <span style="mso-spacerun: yes;">&nbsp;</span>However, the motions to dismiss under <i style="mso-bidi-font-style: normal;">Rule 12(b) (6)</i> based upon the statute of limitations, at this stage, are denied.</div><div class="MsoNormal" style="margin-left: .5in;"><br /></div><div class="MsoNormal"><u>Id.</u> at *27.<span style="mso-spacerun: yes;">&nbsp; </span>Now, the plaintiff had been engaged in drug-seeking behavior and using OxyContin that was not prescribed to him, so it seems hard to imagine that he didn’t know that he was addicted.<span style="mso-spacerun: yes;">&nbsp; </span>But the court saw it differently, denied the motion, and gave the defense the opportunity to take discovery on the issue and possibly try again at a later date.</div><div class="MsoNormal"><br /></div><div class="MsoNormal">All in all, this was not a bad outcome for most defendants.<span style="mso-spacerun: yes;">&nbsp; </span>Many of the defendants were dismissed, the failure to warn and negligence <i style="mso-bidi-font-style: normal;">per se </i>claims were dismissed, and defendants will have the opportunity later in the litigation, if they need it, to address the jurisdictional issues that they lost.<span style="mso-spacerun: yes;">&nbsp; </span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:86:"http://druganddevicelaw.blogspot.com/2014/04/an-oxycontin-decision-that-addresses.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:38:"noreply@blogger.com (John J. Sullivan)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-08T09:15:00.509-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:5;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-5989772887297143214";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Mon, 07 Apr 2014 15:13:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:2:{i:0;a:5:{s:4:"data";s:9:"Causation";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:6:"Infuse";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:55:"Breaking News:  Summary Judgment Granted in Infuse Case";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:20678:"<!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:DontVertAlignCellWithSp/>   <w:DontBreakConstrainedForcedTables/>   <w:DontVertAlignInTxbx/>   <w:Word11KerningPairs/>   <w:CachedColBalance/>  </w:Compatibility>  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="--"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267">  <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" Priority="0" Name="Hyperlink"/>  <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-qformat:yes;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin-top:0in;  mso-para-margin-right:0in;  mso-para-margin-bottom:12.0pt;  mso-para-margin-left:0in;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:"Calibri","sans-serif";  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-fareast-font-family:SimSun;  mso-fareast-theme-font:minor-fareast;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:"Times New Roman";  mso-bidi-theme-font:minor-bidi;} </style><![endif]--> <br /><div class="MsoNormal">This post is from the non-Reed Smith side of the blog.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>We’ve been updating you regularly on the equally regular dismissal of the majority of claims in the Infuse litigation on the grounds of preemption and <i style="mso-bidi-font-style: normal;">TwIqbal</i>.<span style="mso-spacerun: yes;">&nbsp; </span>Well, here’s a quick reminder that preemption isn’t the only arrow in device manufacturers’ quivers.<span style="mso-spacerun: yes;">&nbsp; </span>All those allegations of off-label promotion that Infuse plaintiffs rely upon to avoid dismissal?&nbsp; It looks like they may have severe problems proving them.<span style="mso-spacerun: yes;">&nbsp; </span>On the eve of trial and after several days of pretrial motions, summary judgment was entered in Medtronic’s favor in what was scheduled to be the first Infuse case to go to trial.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Cabana v. Medtronic, Inc.</i>, <a href="https://drive.google.com/file/d/0B-lYJagi-p7vSXdzWDV0VndFLWc/edit?usp=sharing%20" target="_blank">No. BC465313</a> (Cal. Super. Apr. 4, 2014). &nbsp;<span style="mso-spacerun: yes;"> </span>Significantly, the court ruled, and plaintiff in the end did not even dispute, that plaintiff lacked both sufficient evidence of causation to support any of her claims and sufficient evidence that&nbsp;the device caused her any injury.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>That’s not all.<span style="mso-spacerun: yes;">&nbsp; </span>Even without the causation ruling, the court granted several significant in limine rulings:<span style="mso-spacerun: yes;">&nbsp; </span>(1) excluding any evidence that Medtronic allegedly violated any federal law or regulation; (2) that the Infuse device was misbranded; (3) that off label promotion was expressly prohibited; or (4) that any warning other than the FDA approved warning should have been given.<span style="mso-spacerun: yes;">&nbsp; </span>Together these seem to signal that the case would ultimately have been barred by preemption.<span style="mso-spacerun: yes;">&nbsp; </span>Without such evidence we don’t see how plaintiff could establish a parallel claim.<span style="mso-spacerun: yes;">&nbsp; </span>No parallel claim, no escaping <i style="mso-bidi-font-style: normal;">Riegel</i>preemption.<span style="mso-spacerun: yes;">&nbsp; </span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:88:"http://druganddevicelaw.blogspot.com/2014/04/breaking-news-summary-judgment-granted.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Michelle Yeary)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-10T15:02:25.866-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:6;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-4172073297356665197";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Fri, 04 Apr 2014 11:59:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:9:"Minnesota";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:11:"Mississippi";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:16:"Warning Adequacy";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:41:"Common Sense Contraceptive Warnings Cases";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:14818:"  <span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Even a casual reader of the blog would know that we like it when drug or device manufacturers defeat dubious claims.<span style="mso-spacerun: yes;">&nbsp; </span>It is also no secret that we are enamored of the learned intermediary doctrine and challenging the link of proximate cause for failure to warn.<span style="mso-spacerun: yes;">&nbsp; </span>We also value decisions that use common sense, at least what our biased perspective allows us to see as common and sensical.<span style="mso-spacerun: yes;">&nbsp; </span>When these things come together, we are as pleased as a robin finding juicy, wriggling worms after the spring thaw.<o:p></o:p><br />  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The decisions in <i style="mso-bidi-font-style: normal;">Averhart v. Ortho-McNeil Pharm., Inc.</i>, No. 3:09 oe 40028, 2014 U.S. Dist. LEXIS 38446 (N.D. Ohio Mar. 24, 2014), and <i style="mso-bidi-font-style: normal;">Casso v. Ortho-McNeil Pharm.</i>,<i style="mso-bidi-font-style: normal;"> Inc., </i>No. 1:11 oe 40006, 2014 U.S. Dist. LEXIS 38443 (N.D. Ohio Mar. 24, 2014), largely satisfy our annelid cravings.<span style="mso-spacerun: yes;">&nbsp; </span>First, the defense won summary judgment on the warnings claims they moved on in each case.<span style="mso-spacerun: yes;">&nbsp; </span>(The defense moved for judgment on the pleadings on some other claims and apparently raised some new arguments for summary judgment in reply briefs.<span style="mso-spacerun: yes;">&nbsp; </span>Defendants were rebuffed in almost all of those attempts.<span style="mso-spacerun: yes;">&nbsp; </span>We cannot tell from the decisions why summary judgment was not sought across the board or if the plaintiffs had any evidence for their non-warnings claims, so we will focus of the warnings part of the decisions.)<span style="mso-spacerun: yes;">&nbsp; </span>Second, the warnings claims fell because the prescribers testified to their understanding of the risk at issue and the plaintiffs had nothing else suggesting that the warnings were inadequate in any material way.<span style="mso-spacerun: yes;">&nbsp; </span>Third, the warnings analysis, despite some quirks of the phrasing of the applicable Mississippi and Minnesota law, was pretty straightforward, focusing on the actual testimony of the prescribers and some of the basics of how drugs are prescribed to patients.<o:p></o:p></div><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The drug at issue in these cases was Ortho-Evra, a combination hormonal contraceptive patch; “combination” means that there is estrogen with the progestin.<span style="mso-spacerun: yes;">&nbsp; </span>It has long been common knowledge in the medical community, and, we think, the population of patients who use hormonal contraceptives, that this class of products has a risk of blood clots.<span style="mso-spacerun: yes;">&nbsp; </span>Patient package inserts started forty years ago because of this risk with these products.<span style="mso-spacerun: yes;">&nbsp; </span>Advertisements for these products on television and in popular magazines have identified this risk since the 1990s.<span style="mso-spacerun: yes;">&nbsp; </span>There has been litigation for decades over various hormonal contraceptives and their risk of blood clots (among other things).<span style="mso-spacerun: yes;">&nbsp; </span>Because of this, to say nothing of medical journals, medical schools, and medical education, it is hard to imagine healthcare providers making decisions on prescribing hormonal contraceptives without being aware of the risk of blood clots and at least thinking about what to tell the patient about the risk with the product or products that might be prescribed.<span style="mso-spacerun: yes;">&nbsp; </span>Because of the nature of hormonal contraception, it is particularly important that the prescriber and patient work together to identify the particular medication that the patient will actually use as directed.<span style="mso-spacerun: yes;">&nbsp; </span>The risk of blood clots present in all marketed prescription combination hormonal contraceptives goes up with pregnancy--that is, when contraception fails—so the risk-benefit decision for prescribing a particular contraceptive is very much tied up patient-specific considerations.<span style="mso-spacerun: yes;">&nbsp; </span>Thus, for warnings claims on blood clots, there are some obvious challenges for plaintiffs:<span style="mso-spacerun: yes;">&nbsp; </span>(1) that the claims are for inadequate warnings rather than failure to warn completely, (2) that prescribers will typically be well-versed in the risks regardless of the label, and (3) decisions to prescribe one combination hormonal contraceptive instead of another will usually not be based on a comparison of their blood clot risk.<span style="mso-spacerun: yes;">&nbsp; </span>This means the manufacturers of these products should have a good chance of getting <a href="http://druganddevicelaw.blogspot.com/2013/05/the-new-jersey-nuvaring-litigation.html%20" target="_blank">summary judgment</a> on inadequate warnings claims for the risk of blood clots.<br />  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The principal hurdle to summary judgment in <i style="mso-bidi-font-style: normal;">Averhart</i>was the argument, based on a minor consent statute, that Mississippi’s codification of the learned intermediary doctrine did not cover prescriptions written by a nurse practitioner.<span style="mso-spacerun: yes;">&nbsp; </span>The argument goes something like this:<span style="mso-spacerun: yes;">&nbsp; (</span>1) in Mississippi, “contraceptive supplies and information may be furnished by physicians to any minor<span style="mso-spacerun: yes;">&nbsp; </span>. . . who has the consent of his or her parent or legal guardian”; (2) plaintiff, a minor at the time, had written consent from her mother when she went to the Health Department clinic to get contraception; (3) after an exam and counseling, plaintiff selected the Ortho Evra patch and received samples from a nurse practitioner without the direct involvement of any physician; (4) it does not matter what warnings went to the nurse practitioner or what she knew about the risk of blood clots, because she was not a physician; and (5) the focus, absent a learned intermediary, is on the plaintiff, who denies being warned of the risk by the nurse practitioner.<span style="mso-spacerun: yes;">&nbsp; </span>There are many things wrong with this argument, without even addressing the wisdom of limiting contraception to minors in Mississippi.<span style="mso-spacerun: yes;">&nbsp; Among them, the decision rightly</span> focused on the leap from a consent statute saying “may be furnished by physicians” to concluding that nurse practitioner do not count as learned intermediaries for contraceptives prescribed to minors.<span style="mso-spacerun: yes;">&nbsp; </span>“Nurse Practitioners have the authority to write such prescriptions.<span style="mso-spacerun: yes;">&nbsp; </span>This statute allows nurse practitioners to write prescriptions for most medication, and, most importantly, neither the administrative code nor the statute than enables it limits a Mississippi nurse practitioner’s ability to prescribe contraceptives to minors.” 2014 U.S. Dist LEXIS 38446, **9-10 (internal citations omitted).<o:p></o:p></div><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>We quibble with the decision’s characterization of the learned intermediary doctrine as a “defense” and its suggestion that a genuine question of fact as to the adequacy of the warning to the learned intermediary means that the manufacturer of a prescription drug has a duty to warn the patient directly, but this decision clearly came to the right result.<span style="mso-spacerun: yes;">&nbsp; </span>If state law allows a non-physician healthcare professional to prescribe a drug, then she is a learned intermediary.<span style="mso-spacerun: yes;">&nbsp; </span>For contraceptives, prescriptions are often written at clinics, run by the state Health Department or otherwise, and the clinics by necessity provide a chunk of their services by nurse practitioners.<span style="mso-spacerun: yes;">&nbsp; </span>Prescription drug manufacturers do not pick who prescribes their drug.<span style="mso-spacerun: yes;">&nbsp; </span>Different law for two lawsuits over prescriptions of the same drug at the same clinic on the same day, one written by a physician and one written by a nurse practitioner, would create more problems than we could list here.<o:p></o:p><br />  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>That is not necessary, though, because the focus was properly on whether the nurse practitioner was adequately warned.<span style="mso-spacerun: yes;">&nbsp; </span>While the NP testified that she read the package insert and was aware of the relevant risk, plaintiff countered with the NP’s lack of recollection of reading a particular Dear Health Care Provider letter.<span style="mso-spacerun: yes;">&nbsp; </span>(They are not generally called “Dear Doctors” letters anymore because drugs are prescribed by other providers.<span style="mso-spacerun: yes;">&nbsp; </span>Such foolish consistency, plaintiffs.)<span style="mso-spacerun: yes;">&nbsp; </span>This did not amount to “evidence indicating did not adequately warn NP Dedeaux.” <span style="mso-spacerun: yes;">&nbsp;</span><i style="mso-bidi-font-style: normal;">Id. </i>at *11.<span style="mso-spacerun: yes;">&nbsp; </span>“Since NP Dedeaux testified she understood that Ortho Evra created a risk of the very thing that happened to Ms. Averhart, Defendants have shown they warned the learned intermediary (through whatever means) adequately.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i><span style="mso-spacerun: yes;">&nbsp; </span>We read this as also cutting off proximate cause—“where a different warning to the prescribers would have changed the prescribing decision”—because the NP’s knowledge of the risk makes additional warnings pointless.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *7.<span style="mso-spacerun: yes;">&nbsp; </span>We also note that plaintiff’s expert evidence on the adequacy of warnings, if she had any, was not addressed.<span style="mso-spacerun: yes;">&nbsp; </span>This also makes sense.<span style="mso-spacerun: yes;">&nbsp; </span>If the prescriber knew the risk, then expert opinions about additional or different warnings of that risk do not have much chance of changing the analysis.<o:p></o:p></div><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The <i style="mso-bidi-font-style: normal;">Casso</i> case involves a prescription written by a physician, so it skips the first part of <i style="mso-bidi-font-style: normal;">Averhart</i>.<span style="mso-spacerun: yes;">&nbsp; </span>Like <i style="mso-bidi-font-style: normal;">Averhart</i>, we could quibble with the idea that Minnesota law provides that “[a] proper warning of a drug’s danger to the prescribing doctor obviates the duty to disclose the danger directly to the consumer,” but we do not get to where that matters because the prescriber’s testimony ended the inquiry.<span style="mso-spacerun: yes;">&nbsp; </span>2014 U.S. Dist. LEXIS 38443, *8.<span style="mso-spacerun: yes;">&nbsp; </span>The prescribing physician testified that he was “familiar with and took into consideration all of the information” in the most recent label and Dear Healthcare Professional letter.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at **8-9.<span style="mso-spacerun: yes;">&nbsp; </span>As often happens with prescribers, his testimony was that he did not “have a specific recollection” of receiving the letter, but “it is my practice to read all of the letters from manufacturer [of drugs] that I’m prescribing.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *9.<span style="mso-spacerun: yes;">&nbsp; </span>In response to this and the prescriber’s “acknowledgement that he understood each [danger of Ortho Evra] at the time he prescribed the drug to Ms. Casso,” plaintiff could just offer a spin on testimony about offering the patient choices.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *10. <span style="mso-spacerun: yes;">&nbsp;</span>As we noted earlier, patient choice plays a significant role in the prescription of contraceptives.<span style="mso-spacerun: yes;">&nbsp; </span>The prescriber “would have stated to her that the IUD was a safer option for her than combination hormonal contraception” as part of “practice to discuss relative safety of contraceptive options.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at **10-11.<span style="mso-spacerun: yes;">&nbsp; </span>The court rightly rejected the argument that this testimony suggested he did not understand the risk of blood clots when he prescribed Ortho Evra to plaintiff or that the warnings at that time were inadequate.<span style="mso-spacerun: yes;">&nbsp; </span>So, the warnings claim did not survive summary judgment.<o:p></o:p><br />  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>It will be interesting to see how far these cases can go on their surviving non-warnings claims.<span style="mso-spacerun: yes;">&nbsp; </span>To our eye, given the prescribers’ respective knowledge of the risk of blood clots and the existence of revised warnings about the risk based on post-approval interaction with FDA, those claims do not have legs.<span style="mso-spacerun: yes;">&nbsp; </span>Much like worms.<span style="mso-spacerun: yes;">&nbsp; </span>(And we are not talking about polychaetes.<span style="mso-spacerun: yes;">&nbsp; </span>Those things are just weird.)<o:p></o:p></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:85:"http://druganddevicelaw.blogspot.com/2014/04/common-sense-contraceptive-warnings.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Eric Alexander)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-04T07:59:00.710-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:7;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-3277175601575093839";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Thu, 03 Apr 2014 21:00:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:4:{i:0;a:5:{s:4:"data";s:3:"FDA";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:13:"Generic Drugs";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:10:"spoliation";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:53:"The More Things Change, The More They Remain The Same";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:6938:"Not too long ago (March 28, and April 2) we read with interest a couple of&nbsp;<a href="http://www.law360.com/productliability/articles/522902?nl_pk=fa4579ff-4700-4430-bb6e-9475f719d490&amp;utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=productliability">articles</a> <a href="http://www.law360.com/productliability/articles/520833?nl_pk=fa4579ff-4700-4430-bb6e-9475f719d490&amp;utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=productliability">on 360</a>  that brought back unpleasant memories.<span style="mso-spacerun: yes;">&nbsp; </span>The articles discussed congressional inquiries to the FDA (including “pointed questioning” of FDA Commissioner Margaret Hamburg) about undisclosed (to the public, anyway) meetings between “FDA officials” and the plaintiff’s bar concerning its current extremely controversial <a href="http://druganddevicelaw.blogspot.com/2013/11/a-closer-look-at-some-aspects-of-fdas.html">proposal</a> to change its generic drug regulations in an effort to eliminate preemption of product liability claims involving such drugs.<span style="mso-spacerun: yes;">&nbsp; </span>Because 360 requires a subscription, we’ve hunted around on the Internet and found the same matter discussed <a href="http://washingtonexaminer.com/trial-lawyers-helped-fda-with-rule-opening-generic-drug-firms-to-suits/article/2546415">here</a>.<o:p></o:p><br /><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">We’re not sure at the moment whether the FDA provided equal access to those with opposing views, but we wouldn’t be surprised if it didn’t.<span style="mso-spacerun: yes;">&nbsp; </span>Why not?<span style="mso-spacerun: yes;">&nbsp; </span>Because we’ve seen this all before.<span style="mso-spacerun: yes;">&nbsp; </span>Back in 1997, shortly after <u><span style="layout-grid-mode: line;">Medtronic, Inc. v. Lohr</span></u><span style="layout-grid-mode: line;">, 518 U.S. 470 (1996), and long before <u>Riegel v. Medtronic, Inc.</u>, 552 U.S. 312 (2008), courts were just beginning to draw the distinction between 510k clearance and FDA pre-market approval that the Supreme Court ultimately found critical in <u>Riegel</u>.<span style="mso-spacerun: yes;">&nbsp; </span>Then as now, from our perspective, anyway, it appears(ed) the FDA suffered what is sometimes called “agency capture” by pro-plaintiff elements.<span style="mso-spacerun: yes;">&nbsp; </span>So then as now, the FDA did what the other side wanted and issued a proposal to change its regulations designed to thwart preemption in product liability litigation.<span style="mso-spacerun: yes;">&nbsp; </span>That proposed rule was published at 60 Fed. Reg. 65384 (FDA Dec. 12, 1997).<span style="mso-spacerun: yes;">&nbsp; </span>Less than a year later, however, the FDA was forced to withdraw its proposal to gut preemption.<o:p></o:p></span></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><span style="layout-grid-mode: line;">Why?<o:p></o:p></span></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><span style="layout-grid-mode: line;">You guessed it.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA was exposed as having had improper, one-sided contact with the plaintiffs’ bar concerning its 1997 anti-preemption proposal.<span style="mso-spacerun: yes;">&nbsp; </span>As the FDA ultimately admitted:<o:p></o:p></span></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">FDA has decided to withdraw the rulemaking to amend its regulations regarding preemption of State and local requirements applicable to medical devices.<span style="mso-spacerun: yes;">&nbsp; </span>FDA is taking this action because .&nbsp;.&nbsp;. [c]oncerns have been raised by industry and congressional representatives that the agency did not share its thinking on its interpretation of [the relevant provisions], even though an early draft of the proposed rule was shared during the spring of 1997 with attorneys for Public Citizen Litigation Group, who represented Lohr in the <u>Lohr</u> case. The remedy under FDA’s regulations for disclosure of a draft regulation is ordinarily to issue a notice in the Federal Register.&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>Such a contemporaneous notice was not, however, provided in this case.<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Because of the great policy significance of these preemption issues, the concern that Congress was not aware of the agency’s thinking during [its] deliberations, and the potential interplay between the [relevant] device provisions and device preemption, <b style="mso-bidi-font-weight: normal;"><u>the agency believes that it is imperative for all interested parties to have confidence that the agency is addressing their concerns in an impartial manner.<span style="mso-spacerun: yes;">&nbsp; </span>Therefore, the agency is taking the unusual step of withdrawing the proposed rule.</u></b><o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">63 Fed. Reg. 39789, 39789 (FDA July 24, 1998) (emphasis added).&nbsp; <span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-ansi-language: EN-US; mso-bidi-font-size: 14.0pt; mso-bidi-language: AR-SA; mso-fareast-font-family: &quot;Times New Roman&quot;; mso-fareast-language: EN-US;">Déjà vu all over again?</span><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">If it turns out that the FDA was meeting with the plaintiffs’ side, but not with the defense/industry side (a point that is not yet clear), then we have an example of history repeating itself – the FDA would yet again have exhibited institutional favoritism towards the plaintiffs’ bar with respect to a proposed regulatory change intended to adversely affect defense positions on preemption.<span style="mso-spacerun: yes;">&nbsp; </span>One would hope that, should such favoritism turn out to have occurred, the current FDA would have the good sense to do what the FDA did back in 1998, when the Agency’s impartiality was similarly subject to question.<span style="mso-spacerun: yes;">&nbsp; </span>Thus, if the FDA has indeed been meeting with plaintiffs’ lobbyists, but not their defense/industry counterparts, then the pending proposal to do away with generic preemption should be withdrawn – never again to see the light of day.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Whenever the other side starts cranking out the crocodile tears about the FDA being a supposed “puppet” of industry, just remember that we’re not the ones that have been caught – now, it looks like twice – with our hands stuck in the FDA preemption cookie jar.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:89:"http://druganddevicelaw.blogspot.com/2014/04/the-more-things-change-more-they-remain.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-03T17:32:42.348-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"1";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:8;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-2844603396607832374";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Thu, 03 Apr 2014 12:00:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:2:{i:0;a:5:{s:4:"data";s:9:"Discovery";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:11:"E-Discovery";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:23:"Litigation Holds Matter";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:44052:"This post discusses  litigation holds.<span style="mso-spacerun: yes;">&nbsp; </span>Litigation holds aren’t sexy.<span style="mso-spacerun: yes;">&nbsp; </span>They aren’t going to take counsel to the Supreme Court.<span style="mso-spacerun: yes;">&nbsp; </span>They aren’t going to make the nightly news – at least we hope.<span style="mso-spacerun: yes;">&nbsp; </span>But you know and we know that in a mass tort between 90 and 99% of the cases generated by plaintiffs’ solicitation machines aren’t worth very much.<span style="mso-spacerun: yes;">&nbsp; </span>So how do plaintiffs engage in the litigation equivalent of turning dross into gold?<span style="mso-spacerun: yes;">&nbsp; </span>Pretty much anything they can to divert attention from the lousy merits of most of their claims to something, anything&nbsp;else.<o:p></o:p><br /><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Speaking of something else, here’s another notorious characteristic of mass torts.<span style="mso-spacerun: yes;">&nbsp; </span>The great bulk of the expense, particularly to defendants, is in discovery – mostly responding to discovery.<span style="mso-spacerun: yes;">&nbsp; </span>Even though we advocate <a href="http://druganddevicelaw.blogspot.com/2011/11/e-discovery-for-defendants-cheat-sheet.html">ediscovery for defendants</a>, the inescapable fact remains that our side has most of the documents, and even a greater percentage of the electronically stored information (“ESI”), that are going to be at issue in any given litigation.<span style="mso-spacerun: yes;">&nbsp; </span>So discovery is the other side’s number one target for diverting attention from the lousy merits of most of their claims.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiffs would much rather bring motions alleging spoliation of ESI than defend motions concerning <u>Daubert</u>, preemption, or heaven help us all, the merits.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Plaintiffs’ counsel, particularly in mass torts, are very good at what they do.<span style="mso-spacerun: yes;">&nbsp; </span>A defendant’s litigation holds, therefore, need to be carefully prepared not to provide the other side with fodder for discovery disputes.<span style="mso-spacerun: yes;">&nbsp; </span>The contretemps we’ve seen in three recent prescription medical product MDLs illustrates some of the problems – defendants end up getting sanctioned over discovery that, if done correctly, probably wouldn’t have amounted to very much.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> <u>In re Actos (Pioglitazone) Products Liability Litigation</u>, 2014 WL 355995 (W.D. La. Jan. 30, 2014) (“<u>Actos</u>”); <u>In re Ethicon, Inc. Pelvic Repair Systems Products Liability Litigation</u>, ___ F.R.D. ___, 2014 WL 439785 (S.D. W.Va. Feb. 4, 2014) (“<u>PRS</u>”), and <u>In re Pradaxa (Dabigatran Etexilate) Products Liability Litigation</u>, 2013 WL 6486921 (S.D. Ill. Dec. 9, 2013) (“<u>Pradaxa</u>”).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">In each of these MDLs, plaintiffs have blown discovery disputes that, in individual cases might well not have even been litigated, out of proportion to shift the focus from the merits of their cases to defendants’ supposed “bad faith” in the preservation of relevant evidence. <span style="mso-spacerun: yes;">&nbsp;</span>Plaintiffs predictably sought sanctions that went to the merits of the litigation – to bolster their silent majority of weak cases – rather than just discovery-related issues – demanding default judgments, adverse inference jury instructions, and of course even more cost-shifting, when defendants are already saddled with the great majority of the cost of producing far more information and data than is ever used in any trial.<span style="mso-spacerun: yes;">&nbsp; </span>That’s in addition to the predictable pursuit of attorneys’ fees and costs.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Unfortunately, in each of these three recent MDLs, plaintiffs were at least partially successful – and litigation holds were featured prominently every time.<o:p></o:p></div><br /><div class="Centered" style="margin: 0in 0in 12pt; text-align: center;"><u><strong>Actos<o:p></o:p></strong></u></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Proceeding alphabetically, we’ll start our brief and unsettling survey with <u>Actos</u>.<span style="mso-spacerun: yes;">&nbsp; </span>A couple of months ago, the <u>Actos</u> MDL court ordered a number of sanctions for what it considered spoliation of ESI.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The <u>Actos</u> MDL was created in late 2011.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> <u>In re<span style="mso-spacerun: yes;">&nbsp; </span>Actos Products Liability Litigation</u>, 840 F. Supp. 2d 1356 (J.P.M.D.L. Dec. 29, 2011).<span style="mso-spacerun: yes;">&nbsp; </span>The litigation hold that the defendant in <u>Actos</u>was sanctioned for allegedly violating, however, dates from&nbsp;well before this litigation began&nbsp;– and that’s the first problem.<span style="mso-spacerun: yes;">&nbsp; </span>It’s dangerous to draft any litigation hold so broadly that it can be flipped<span style="mso-spacerun: yes;">&nbsp; </span>from one litigation to a completely different matter.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The primary issue was sales rep files – notoriously difficult to keep current because of staff turnover.<span style="mso-spacerun: yes;">&nbsp; </span>and because sales reps are a mobile workforce without benefit of offices within corporate headquarters.&nbsp; The sanctions in <u>Actos</u> involved (in part) the efiles of four sales representatives who had left the defendant’s employ “between 2001 and 2006,” 2014 WL 355995, at *2.<span style="mso-spacerun: yes;">&nbsp; </span>That’s right, the <u>Actos</u> plaintiffs sought – and obtained – sanctions involving the destruction of emails involving personnel that left the company <b style="mso-bidi-font-weight: normal;"><u>between five and ten years before</u></b> any of the litigation in the MDL was ever filed.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> <u>Actos</u>, 840 F. Supp.2d at 1357 (docket numbers reflecting 2011 filing dates).<span style="mso-spacerun: yes;">&nbsp; </span>We’re talking about records of sales reps who left the defendant well beyond the expiration of all but the most extreme statutes of limitations.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">There were also some missing electronic files for substitute sales reps (for whom dates of departure are not clear) and non-American employees (Japanese and European) who also left the company “between 2001 and 2011.”<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 355995, at *2.<span style="mso-spacerun: yes;">&nbsp; </span>Not as egregious (at least some of the requests) as to time, but it looks like any overseas defendant now must also import American discovery standards anytime they export goods.<span style="mso-spacerun: yes;">&nbsp; </span>Some of the stuff being discussed goes back to 1993 – and it’s from Japan.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *4.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">And the defendant gets sanctioned for this?<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">You bet.<span style="mso-spacerun: yes;">&nbsp; </span>In this crazy, ridiculously expensive post-<u>Zubulake</u>era of ediscovery, defendants can be sanctioned for routine recycling of electronic equipment, even though literally thousands of relevant emails were available from other sources and were produced.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *4-5 nn. 13-18 (numbers of emails actually produced).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">So how did sanctions in <u>Actos</u> come about?<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The primary culprit was overly broad and vague litigation holds from prior litigation.<span style="mso-spacerun: yes;">&nbsp; </span>The defendant issued a litigation hold for <u>Actos</u>/bladder cancer (we assume that’s the major injury at issue) on February 15, 2011.<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 355995, at *6.<span style="mso-spacerun: yes;">&nbsp; </span>This timing compares to the first bladder cancer “claim [being] made known to the company” in September, 2010; and “the first bladder lawsuit was filed during the summer of July 2011.”<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 355995, at *16.<span style="mso-spacerun: yes;">&nbsp; </span>There was apparently one screw up with respect to that hold, 2014 WL 355995, at *6, *16, in a company with employees on at least three continents.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">It turns out there was a prior litigation hold from <b style="mso-bidi-font-weight: normal;"><u>2002</u></b>– having nothing to do with the current litigation or injuries – involving a variety of drugs “including Actos.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u>at *7.<span style="mso-spacerun: yes;">&nbsp; </span>The hold was drafted very broadly, “preserve any and all documents and electronic data which discuss, mention, or relate to Actos,” and instead of being allowed to expire when whatever prior litigation was concluded, it was simply “refreshed” several times (in 2003, 2006, 2007, and 2008) prior to the current litigation.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *8.<span style="mso-spacerun: yes;">&nbsp; </span>Sure, in some ways it’s simpler, easier to administer, and more conservative to draft very general litigation holds, rather than to tailor them to particular litigation.<span style="mso-spacerun: yes;">&nbsp; </span>The same concerns might also lead to leaving a hold in place, instead of rethinking matters, when different litigation comes along.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">We fully appreciate the heads-you-win, tails-I-lose position in which attorneys drafting litigation holds find themselves:<span style="mso-spacerun: yes;">&nbsp; </span>Define their preservation terms too narrowly and our side risks being second-guessed down the road for “under-preserving” or, worse yet, spoliation.<span style="mso-spacerun: yes;">&nbsp; </span>If we go too broad, our side faces create substantial preservation burdens, perhaps unnecessarily and perhaps for a very long time.<span style="mso-spacerun: yes;">&nbsp; </span>All things considered, we can sympathize with the cautious attorneys in the trenches who prefer erring on the side of preserving too much, rather than too little.<span style="mso-spacerun: yes;">&nbsp; </span>After all, it’s ordinarily better to have and not need than to need and not have.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">But when a litigant is ultra-conservative with litigation holds, then it may well be obligating itself to save everything, essentially for forever.<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">[Defendant’s] argument is undercut by the fact that [its American subsidiaries], nonetheless, chose to institute a litigation hold sweeping in its scope and breadth, and containing no .&nbsp;.&nbsp;. limitation to or identification of a particular malady, in 2002. <span style="mso-spacerun: yes;">&nbsp;</span>The 2002 Litigation Hold is, by its own language, sweeping in nature and instructed to be broadly interpreted to encompass “any and all documents and electronic data which discuss, mention, or relate to Actos.” <span style="mso-spacerun: yes;">&nbsp;</span>[Defendant’s] own language in no way limits the hold to, or references in any fashion, one specific malady above any other; rather, the scope is defined as that “which discuss, mention, or relate to Actos” and specifically instructs the hold is to be interpreted “in its broadest sense.”<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Actos</u>,&nbsp;2014 WL 355995, at *17.<span style="mso-spacerun: yes;">&nbsp; </span>With this kind of litigation hold language, a litigant runs the risk (as here) of obligating itself to produce the same stuff repeatedly – along with whatever’s necessary to keep information compiled on obsolete technology accessible.<span style="mso-spacerun: yes;">&nbsp; </span>As in <u>Actos</u>, these obligations can include electronic data for people who leave the litigant’s employ years, even a decade, before the litigation in which production is demanded.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Defendants, who issue broad litigation holds and conservatively keep them in place for years without regard to the litigation that originally spawned them, better follow them to the letter or risk being declared “spoliators” years later in unrelated litigation that happens to fall within the broad, vague terms of the original hold.<span style="mso-spacerun: yes;">&nbsp; </span>If a party places a litigation hold this way, the lesson of <u>Actos</u> is it’s going to have to live with it.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *21 (“[defendant’s] attempt to alter the clear and unambiguous language and instruction of the hold in the face of its clear language of the hold, itself, and the evolution of the holds, is wholly unpersuasive”).<o:p></o:p></div><br /><div class="Centered" style="margin: 0in 0in 12pt; text-align: center;"><u><strong>Pelvic Repair Systems<o:p></o:p></strong></u></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The first ESI litigation hold relevant to <u>PRS</u> was issued in 2003, for a single case in Oregon.<span style="mso-spacerun: yes;">&nbsp; </span>The MDL was not created until 2012, almost a decade later.<span style="mso-spacerun: yes;">&nbsp; </span>2014 WL 439785, at *1.<span style="mso-spacerun: yes;">&nbsp; </span>The initial hold “was somewhat ambiguous as to whether documents prepared after [the date of the hold] were subject to a litigation hold and did not specify the nature of the claims or the injuries alleged in the civil action.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><span style="mso-spacerun: yes;">&nbsp; </span>After the Oregon case was settled, the hold “was not explicitly withdrawn.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">A litigation hold in&nbsp;a second case, three years later, “essentially covered the same type and category of documents outlined in the 2003 notice,” but added an instruction to employees to create a litigation-specific computer file folder for “all relevant e-mails and attachments.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *2.<span style="mso-spacerun: yes;">&nbsp; </span>Once again, when that case was resolved, “[t]here is no indication that this document hold was ever withdrawn.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Additional cases involving different products filed in 2008 resulted in another hold “specific to the complaint and applicable to all documents involving [that product].”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *2.<span style="mso-spacerun: yes;">&nbsp; </span>After the number of cases expanded to the point where plaintiffs sought “centralized management,” the defendant issued a “consolidated” hold that incorporated “the original dates on which ‘company-wide’ hold notices had been issued for various products involved in litigation.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">In <u>PRS</u>, the plaintiffs sought sanctions because, for “22 current or former employees,” the defendant’s “productions of custodial files contained few, if any, documents.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *3. <span style="mso-spacerun: yes;">&nbsp;</span>These people were at all levels of corporate responsibility from the “worldwide president” down to “sales representatives.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *4-5.<span style="mso-spacerun: yes;">&nbsp; </span>We don’t know how pervasive the problem was, because <u>PRS</u> doesn’t say how many defendant employees’ files were sought during discovery, so it could be 10% − it could be 0.1% − we can’t say.<span style="mso-spacerun: yes;">&nbsp; </span>But the court found these 22 missing or partially missing files sufficient to impose spoliation sanctions.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Precedent provided “minimal guidance .&nbsp;.&nbsp;. as to the effect that an isolated product liability action has on a manufacturer's duty to preserve evidence that may be relevant to different plaintiffs in future litigation based on the same or similar product.”<span style="mso-spacerun: yes;">&nbsp; </span><u>PRS</u>, 2014 WL 439785, at *8.<span style="mso-spacerun: yes;">&nbsp; </span><u>PRS</u> cited <u>Actos</u>as the only example of a case holding “that the duty to preserve evidence for the benefit of subsequent plaintiffs was triggered by the broad and sweeping language of a litigation hold notice.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><u>PRS</u> rejected the <u>Actos</u> ruling as overbroad as incompatible with the “litigation is reasonably anticipated” Fifth Circuit standard for when a duty to preserve arises.<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Although [defendant’s] legal department did not expressly withdraw the [2003 litigation hold], key personnel in the company would have known that the lawsuit was resolved, which then eliminated the duty to segregate and preserve.&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>Nothing before this court suggests that [defendant] had any reason in 2003 to anticipate additional litigation relating to its .&nbsp;.&nbsp;. products. <span style="mso-spacerun: yes;">&nbsp;</span>Indeed, it was two years after the 2003 complaint was dismissed before another lawsuit was filed. <span style="mso-spacerun: yes;">&nbsp;</span>Moreover, an isolated lawsuit, or even two, would not reasonably lead [defendant] to believe that large scale nationwide products liability litigation was down the road.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">2014 WL 439785, at *11.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Instead of earlier dates involving one-off cases, the court picked a later date as when large-scale litigation was “reasonably anticipated” under the Fifth Circuit standard.<span style="mso-spacerun: yes;">&nbsp; </span>However, that date (2007/2008) was still dangerously early, significantly preceding the first FDA notice suggesting problems with these devices.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *12.<span style="mso-spacerun: yes;">&nbsp; </span><u>PRS</u> chose this date in reliance on what the defendant had stated in a “consolidated” litigation hold issued in 2011 – three to four years (depending on product) after the fact:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">The undersigned determines the .&nbsp;.&nbsp;. dates to be appropriate in this case given that those were the triggering dates identified in a “Consolidated Hold Notice .&nbsp;.&nbsp;. issued on February 18, 2011. <span style="mso-spacerun: yes;">&nbsp;</span>The consolidated notice was prepared by [defendant’s] in-house counsel, the corporate individual most knowledgeable about the corporation's litigation exposures, and the one responsible for preparing and disseminating document preservation notices. <span style="mso-spacerun: yes;">&nbsp;</span>.&nbsp;.&nbsp;.[I]in the Consolidated Notice, counsel described litigation as “ongoing” and reminded employees that “[h]old notices relating to the individual products previously have been distributed company-wide on the following dates:” [citing to hold notices from 2007 and 2008].<span style="mso-spacerun: yes;">&nbsp; </span>Considering that this notice was issued at a time when sixty cases were being consolidated [in] New Jersey for centralized management, the only reasonable interpretation of the notice is that counsel for [defendant] believed that documents relating to [the products] were already being preserved company-wide for the purpose of large scale litigation. <span style="mso-spacerun: yes;">&nbsp;</span>Accordingly, the February 2011 hold notice was intended to “refresh” the 2007 and 2008 document preservation notices.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at *12.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;"><u>PRS</u> also relied on the defendant’s litigation hold language in finding a breach of duty, even though the defendant’s preservation efforts might otherwise have satisfied the federal rules’ “proportionality” standard:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">[Defendant] contends that it had no reason to keep the e-mails of every employee, the drafts found on their hard drives, and other incidental records before the case consolidation in 2010. <span style="mso-spacerun: yes;">&nbsp;</span>While this position <b style="mso-bidi-font-weight: normal;"><u>could potentially have merit, the undersigned need not address it</u></b>because the scope of the preservation was established by [defendant’s] in-house counsel in the document preservation notices. <span style="mso-spacerun: yes;">&nbsp;</span>In each case, counsel instructed employees to segregate and hold “all documents, memoranda, notes, files, emails, etc.” relating to the device at issue and pertaining to labeling; pharmacovigilence; regulatory; discovery, research and development; product communications; marketing and sales; manufacturing; and distribution.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at *13 (emphasis added).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">With both the date and scope of the duty to defend in <u>PRS</u> established, even the sanctioning court conceded that the litigation holds at issue could well have exceeded any preservation obligation required by the relevant rules.<span style="mso-spacerun: yes;">&nbsp; </span>Thus, the missing files (nine of the 22 employees remained with the defendant for at least some period after the 2007/2008 litigation holds) resulted in spoliation sanctions.<span style="mso-spacerun: yes;">&nbsp; </span>The defendant was sanctioned even though “no specific loss ha[d] been identified,” and the missing information could well have been duplicated elsewhere, particularly in “common source” locations where “most employees stored or transferred such information.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *19.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">However, because neither scienter nor prejudice was established, sanctions in <u>PRS</u> were limited to monetary sanctions (currently being briefed), which could be substantial given the intensity with which issues, particularly discovery issues, are litigated (we would say over-litigated) in MDL proceedings.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *23; <u>see</u><u>id.</u> at *20 (“[p]laintiffs have not provided the court with any concrete evidence of prejudice to their cases”).<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></div><br /><div class="Centered" style="margin: 0in 0in 12pt; text-align: center;"><u><strong>Pradaxa<o:p></o:p></strong></u></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The discovery disputes in <u>Pradaxa</u> involved more than preservation, but with respect to that issue, they focused on ESI&nbsp;in the possession of certain employees (similarly to <u>Actos</u> and <u>PRS</u>) and failure to preserve business-related text messages from certain employees’ cell phones. <span style="mso-spacerun: yes;">&nbsp;</span>Some of the relief granted – requiring witnesses in a foreign country to come to the United States – was declared beyond the power of the MDL court in a mandamus decision.<span style="mso-spacerun: yes;">&nbsp; </span><u>In re Petition of Boehringer Ingelheim Pharmaceuticals, Inc.</u>, , ___ F.3d ___, 2014 WL 274084 (7th Cir. Jan. 24, 2014).<span style="mso-spacerun: yes;">&nbsp; </span>For purposes of this post, we’re interested in the effect of litigation holds on the finding of spoliation, rather than these other issues.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The litigation hold issue in <u>Pradaxa</u> was primarily related to the extent of the hold issued in response to the MDL rather than on the pernicious effect of previous hold orders.<span style="mso-spacerun: yes;">&nbsp; </span>“[Defendant’s] duty to preserve material relevant to this litigation arose in February 2012 when it received a lean letter regarding the first post-launch <u>Pradaxa</u> product liability suit. <span style="mso-spacerun: yes;">&nbsp;</span>[Defendant] has indicated that it issued a litigation hold shortly thereafter − in April 2012.”<span style="mso-spacerun: yes;">&nbsp; </span>2013 WL 6486921, at *6.<span style="mso-spacerun: yes;">&nbsp; </span>In June, a motion to create an MDL stated that there would be “at least 500” cases.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *7.<span style="mso-spacerun: yes;">&nbsp; </span>This was enough for defendant to “understand the size and scope of this litigation.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">One aspect of the discovery problems in <u>Pradaxa</u> was the administration, rather than the scope, of the defendants’ overall litigation hold.<span style="mso-spacerun: yes;">&nbsp; </span>“The Court has examined the defendants’ ‘holds,’ .&nbsp;.&nbsp;. and does not take umbrage with the language or scope thereof.”<span style="mso-spacerun: yes;">&nbsp; </span>2013 WL 6486921, at *6.<span style="mso-spacerun: yes;">&nbsp; </span>Rather: <o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">The defendants have taken a too narrow and an incremental approach to its “company-wide” litigation hold.<span style="mso-spacerun: yes;">&nbsp; </span>The Court has been relying on the common meaning of the words that that the defendants have a company-wide litigation hold on all persons who have custody of any documentation relevant to Pradaxa.  The production requests of the plaintiffs are so broad as to cover any possible<span style="mso-spacerun: yes;">&nbsp;</span>derivation of means to document someone’s thoughts, words and deeds.&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>[A]ll of the materials that are discussed in this order were clearly covered by production requests and further anticipated by the Court as subject to the “company-wide” litigation hold.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u><span style="mso-spacerun: yes;">&nbsp; </span><u>Pradaxa</u>thus rejected the defendants’ explanation that employees who had “not been identified [by plaintiffs] as custodians” when they left their employ were not subject to the hold.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *10 (discussing failure to preserve “custodial files”).<span style="mso-spacerun: yes;">&nbsp; </span>Rather, the duty to preserve was not “limited” to material “that has actually been requested by the opposing party.” <span style="mso-spacerun: yes;">&nbsp;</span><u>Id.</u> at *12.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The litigation hold specifically concerning sales representatives’ ESI, however, was held to be “grossly inadequate.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *14.<span style="mso-spacerun: yes;">&nbsp; </span>The <u>Pradaxa</u> opinion identifies several deficiencies – all of which involved events occurring after the MDL’s creation:<span style="mso-spacerun: yes;">&nbsp; </span>(1) the hold was “initially applied” only to information generated by “the specific sales representatives who detailed specific plaintiff's physicians,” and “nothing” was done to preserve information before these persons were identified; (2) the hold was initially expanded only to “sales representatives currently detailing” the drug; (3) after 13 months, the hold was expanded to “all sales representatives who had ever detailed” the drug; (4) detailing by persons not classified as sales representatives was not included in the hold until several more months had passed, and then only incrementally, as with the sales reps; and (5) “the defendants’ hold .&nbsp;.&nbsp;. did not expressly extend to text messages” for more than a year after such messages had been sought in discovery.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u>at *14, 16. <span style="mso-spacerun: yes;">&nbsp;</span>The court concluded:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">The litigation hold described by the defendants is wholly inadequate in light of the size and scope of this litigation. <span style="mso-spacerun: yes;">&nbsp;</span>The defendants were under a duty to preserve information that they knew or reasonably could foresee would be relevant to imminent or pending litigation.&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>Once the duty to preserve was triggered, the defendants owed a duty to preserve evidence that may be sought during discovery and should have implemented an adequate plan to find and preserve relevant evidence.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u><span style="mso-spacerun: yes;">&nbsp; </span>Given the size of the developing litigation, this court opined that anything short of a hold extending to all detailing personnel was inadequate.<span style="mso-spacerun: yes;">&nbsp; </span><u>Pradaxa</u> was not a “regional case .&nbsp;.&nbsp;. with no indication of the litigation expanding into nationwide litigation,” and “nothing in any case management order .&nbsp;.&nbsp;. can be interpreted as suggesting such a tailored litigation hold was acceptable.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at 15.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><u>Pradaxa</u> further held that text messages should have been explicitly mentioned in the hold, to ensure that “employees understood that text messages were included.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *17.<span style="mso-spacerun: yes;">&nbsp; </span>Further, defendant should have taken affirmative steps “to intervene in the automated deletion of employee text messages on company issued phones,” since “intervention in the routine operation of an information system is one aspect” of a litigation hold. <span style="mso-spacerun: yes;">&nbsp;</span><u>Id.</u><o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><u>Pradaxa</u>ultimately concluded that defendants’ actions and omissions with respect to both the scope and administration of litigation holds were in “bad faith.” <span style="mso-spacerun: yes;">&nbsp;</span>2013 WL 6486921, at *18-19 (identifying potential loss of some of a key witnesses’ files; the “inadequate” hold on detailing employees, and “failure to preserve text messages” as examples).<span style="mso-spacerun: yes;">&nbsp; </span>The extent of sanctions in <u>Pradaxa</u> has yet to be fully determined, but included almost $1 million in fines as well as a threat of “remedies yet to be addressed.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at 20.<o:p></o:p></div><div style="text-align: center;"></div><div class="Centered" style="margin: 0in 0in 12pt; text-align: center;"><span style="font-weight: normal; mso-bidi-font-weight: bold;">*<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>*<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>*<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>*<o:p></o:p></span></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">So what take-aways can we offer from the adverse experiences of the defendants in <u>Actos</u>, <u>PRS</u>, and <u>Pradaxa</u> with respect to litigation holds?<span style="mso-spacerun: yes;">&nbsp; </span>We see several.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>First</u></b>, litigation holds are too important – their consequences too grave – to be left solely to in-house counsel, unless such counsel have significant mass-tort litigation experience under their belts.<span style="mso-spacerun: yes;">&nbsp; </span>Ideally (yeah, we’re litigators), litigation holds should be drafted by litigators, since litigators understand the consequences of getting things wrong, and will be in the line of fire if that happens.<span style="mso-spacerun: yes;">&nbsp; </span>For good reason, increasing numbers of litigators subspecialize in electronic discovery, including the formulation of preservation terms, custodian lists, and the like.<span style="mso-spacerun: yes;">&nbsp; </span>We consult with these specialists liberally when undertaking this sometimes-complicated task.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>Second</u></b>, litigation holds should always be proportionate to the potential scope of the litigation for which they are issued.<span style="mso-spacerun: yes;">&nbsp; </span>Opposing counsel relish playing Monday morning quarterback in litigation hold decisions and will seek to persuade a court to use hindsight to judge defendants. <span style="mso-spacerun: yes;">&nbsp;</span>What might be a proportionate scope at one point can become vulnerable as litigation evolves/expands into something (like <u>Pradaxa</u>) requiring a broader hold.<span style="mso-spacerun: yes;">&nbsp; </span>Salami slicing litigation holds when a mass tort is potentially (at least in hindsight) apparent – or worse already underway – can get a defendant sanctioned.<span style="mso-spacerun: yes;">&nbsp; </span>On the other hand, imposing a mass-tort-sized litigation hold for one-off cases, without clearly thinking it through, is asking for trouble down the road.<span style="mso-spacerun: yes;">&nbsp; </span>Employees won’t take it seriously, and the effort to enforce that kind of hold according to its terms is difficult to maintain over time.<span style="mso-spacerun: yes;">&nbsp; </span>And believe us, the already substantial burdens of overly broad preservation only get worse as time passes<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>Third</u></b>, litigation holds should conform to the products and injuries at issue and should be reviewed frequently so that their scope and implementation remain tailored to the needs of the litigation.<span style="mso-spacerun: yes;">&nbsp; </span>That sounds easier than it is – we’re taking for granted that the products and alleged injuries are readily apparent, which isn’t always so, even though one would think a preservation obligation would require it (just reread the cases we discussed).<span style="mso-spacerun: yes;">&nbsp; </span>Experience shows that this effort also requires some careful thought.<span style="mso-spacerun: yes;">&nbsp; </span>It can be expensive and asking for trouble to use conservative, catch-all language where only one of a number of related products or product risks is at issue.<span style="mso-spacerun: yes;">&nbsp; </span>A defendant issuing an overbroad litigation hold is likely to be held to its terms, even when they exceed the scope of any legal preservation duty, and as years pass those terms can be quite painful.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>Fourth</u></b>, we’d like to think that litigation holds can end. <span style="mso-spacerun: yes;">&nbsp;</span>Ideally they would, but perpetual preservation is one of the practical problems motivating the <a href="http://druganddevicelaw.blogspot.com/2013/09/everybody-bitches-about-ediscovery-but.html">current effort</a>  to modify the discovery rules, including Rule 37 concerning sanctions. <span style="mso-spacerun: yes;">&nbsp;&nbsp;</span>If placing a litigation hold is difficult, the decision to <b style="mso-bidi-font-weight: normal;"><u>lift</u></b> a litigation hold is downright vexing, and requires fully considering the hypothetical landscape of “reasonably anticipated” disputes.<span style="mso-spacerun: yes;">&nbsp; </span>It’s no easy task to say when:<span style="mso-spacerun: yes;">&nbsp; </span>When is litigation truly over? &nbsp;After a settlement is signed?<span style="mso-spacerun: yes;">&nbsp; </span>After the last dismissal is filed? <span style="mso-spacerun: yes;">&nbsp;</span>After the last objector’s appeal is dismissed? <span style="mso-spacerun: yes;">&nbsp;</span>After the statute of limitations expires?&nbsp; Such decisions ought never be made alone.&nbsp;<span style="mso-spacerun: yes;">&nbsp;</span>In drafting litigation holds, consideration ought to be given to how, when, and under what circumstances it is proper to end them.<span style="mso-spacerun: yes;">&nbsp; </span>Similarly, when a case is over, litigation holds related to it should be revisited in light of the defendant’s litigation environment at that time.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>Fifth</u></b>, don’t expect employees to understand legal terminology or to make inferences from broad terms such as “documents” or “electronic information.”<span style="mso-spacerun: yes;">&nbsp; </span>Spell, it out. <span style="mso-spacerun: yes;">&nbsp;</span>Follow up. <span style="mso-spacerun: yes;">&nbsp;</span>Tell them the full scope of what they are expected to preserve.<span style="mso-spacerun: yes;">&nbsp; </span>Offer technical support to make sure that it’s easy for employees to do the right thing.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>Sixth</u></b>, corporate culture needs to be taken into account in the issuance of litigation holds.<span style="mso-spacerun: yes;">&nbsp; </span>Particularly if the hold extends to corporate entities outside the United States, it must be drafted – and internally enforced – to make sure that personnel unfamiliar with (and, indeed, resistant to) American mass tort litigation do what the letter of the hold requires them to do.<span style="mso-spacerun: yes;">&nbsp; </span>Whoever is responsible for issuing the hold must take ownership of it on an ongoing basis.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>Seventh</u></b>, expect every litigation hold to be enforced to the full extent of its terms, and plan for this.<span style="mso-spacerun: yes;">&nbsp; </span>What a defendant writes in a litigation hold, it will have to live with it − even if, in the absence of the hold’s language the other side wouldn’t have a leg to stand on.<span style="mso-spacerun: yes;">&nbsp; </span>This is a classic description of a “gotcha game,” but we can make it harder for the other side to play.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><b style="mso-bidi-font-weight: normal;"><u>Finally</u></b>, plaintiffs should have to practice what they preach (see our&nbsp;<a href="http://druganddevicelaw.blogspot.com/2008/02/e-discovery-for-defendants.html">ediscovery</a>  <a href="http://druganddevicelaw.blogspot.com/2011/05/e-discovery-for-defendants-20.html">for</a>  <a href="http://druganddevicelaw.blogspot.com/2011/11/e-discovery-for-defendants-cheat-sheet.html">defendants</a>  <a href="http://druganddevicelaw.blogspot.com/2013/08/omg-i-have-to-produce-what-four-steps.html">posts</a>).<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiffs have computers, too.<span style="mso-spacerun: yes;">&nbsp; </span>After the claims of each plaintiff in the MDL have accrued, are they deleting their Internet search history (relevant, at least, to the statute of limitations), and letting their own email autodelete functions continue unabated.<span style="mso-spacerun: yes;">&nbsp; </span>Have they “sanitized” their social media accounts?<span style="mso-spacerun: yes;">&nbsp; </span>It’s high time that plaintiffs are held to the same standards as defendants in the ediscovery arena.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">We thank <a href="http://www.reedsmith.com/david_cohen/">Dave Cohen</a>, <a href="http://www.reedsmith.com/patricia_antezana/">Pat Antezana</a>, and <a href="http://www.reedsmith.com/linda_werner/">Linda Werner</a>, all of <a href="http://www.reedsmith.com/">Reed Smith</a>, whose recent client alert, “To Hold and To Have:&nbsp; Issuing a Legal Hold is Not Enough,” inspired this post.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:73:"http://druganddevicelaw.blogspot.com/2014/04/litigation-holds-matter.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-03T17:26:01.822-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"2";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:9;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-8410223916557602271";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Wed, 02 Apr 2014 11:30:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:6:{i:0;a:5:{s:4:"data";s:9:"Causation";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:5:"Conte";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:13:"Generic Drugs";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:9:"Louisiana";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:4;a:5:{s:4:"data";s:13:"Off-Label Use";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:5;a:5:{s:4:"data";s:8:"Warnings";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:63:"Causation Requirement Trips Up Off-Label End-Run Around Mensing";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:8372:"<br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">Happy Birthday LEXIS/NEXIS, whose legal research service went up on this date back in 1973.&nbsp; There’s no doubt that LEXIS/NEXIS has made our professional lives considerably easier.&nbsp; We’ve long since given up our campaign to persuade young lawyers to venture beyond computerized research.&nbsp; What’s the point of suggesting that lawyers occasionally cuddle up with digests or ALRs when we’ll inevitably be greeted with blank looks?&nbsp; Such legal texts have been exiled from too many&nbsp;modern law offices.&nbsp; Pity.&nbsp; Be that as it may, we are grateful for all the information, insight, and, every once in a while, merriment we’ve received from LEXIS/NEXIS over the years, just as we are grateful to Marvin Gaye and Leon Russell (also with birthdays on April 2) for a very different sort of information, insight, and merriment -- all ready on instant notice to pulse forth from our iPod.&nbsp; <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">It’s LEXIS/NEXIS’s birthday, so by all rights we should be the one bearing gifts.&nbsp; Instead, we get this gift from LEXIS/NEXIS:&nbsp; <em>Whitener v. Pliva, Inc</em>., 2014 U.S. Distr. LEXIS 41121(E.D. La. March 27, 2014), where the court halts an effort by generic plaintiffs to make an off-label end-run around <em>Mensing</em> preemption.&nbsp; The plaintiffs alleged injuries from metoclopramide, the generic form of Reglan.&nbsp; They sued both the manufacturer of the generic metoclopramide, which had been used in this case, and the manufacturer of the brand name Reglan, which had not.&nbsp; The original complaint was dismissed on preemption grounds.&nbsp; The plaintiffs tried again.&nbsp; (We have written about the preemption rulings in <em>Whitener</em> <a href="http://druganddevicelaw.blogspot.com/2011/12/latest-generic-preemption-decision.html">before</a>.)&nbsp; After the amended complaint was filed, the pharmaceutical entities filed a joint motion to dismiss.&nbsp; According to the defendants, the amended complaint persisted in asserting a failure-to-warn theory that was preempted by <em>Mensing</em>.&nbsp; In response, the plaintiffs argued that the defendants violated federal regulations by promoting metoclopramide for off-label use and by failing to warn of the risks associated with that off-label use.&nbsp; That is a somewhat creative argument.&nbsp; It was also, at least temporarily, successful.&nbsp; <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">The court denied the motion to dismiss, holding that the plaintiffs “ha[d] (barely) pleaded enough facts to raise a reasonable expectation that discovery will reveal evidence of such conduct.”&nbsp; <em>Whitener</em>, 2014 U.S. Dist. LEXIS 41121 at *3.&nbsp; The court believed that the application of Mensing to a straight failure to warn claim was easy enough, but the “harder question…is whether the Mensing analysis changes if a generic defendant actively promises the drug for off-label use in violation of federal law.&nbsp; [T]here is something troubling about permitting a generic defendant to violate federal law by actively and aggressively promising a drug for a purpose not contemplated by the label approved by the FDA while also hiding behind an inability to provide warnings connected to that off-label use because it cannot change the approved label.”&nbsp; <em>Id.</em> at *4.&nbsp;&nbsp; We find the court’s refusal to dismiss the case “troubling.”&nbsp; But there’s always summary judgment.&nbsp; &nbsp;&nbsp;<o:p></o:p></span></span></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">True to form, the defendants filed for summary judgment.&nbsp; Sounds like we’re in for an interesting preemption analysis, doesn’t it?&nbsp; Not really.&nbsp; The court’s opinion dodges the preemption question and holds that any off-label promotion was non-causal as a matter of law.&nbsp; The court closely reviewed the prescriber’s deposition, and concluded that it was “clear that his decision to prescribe the drug to Ms. Whitener was made independently of any alleged conduct by the pharmaceutical entities.”&nbsp; <em>Id.</em> at *16.&nbsp; The doctor testified “unambiguously that his decision to prescribe the drug to Ms. Whitener was only based on his own experience.”&nbsp; Id. The plaintiffs argued that the prescriber’s deposition was “misinterpreted or that his statements have been taken out of context.”&nbsp; <em>Id.</em> at *17.&nbsp; During oral argument, the court “perused the entire deposition and sees no reason to consider the designation provided as exhibits to the papers as aberrations or misrepresentations.”&nbsp; <em>Id.</em> at *17-18.&nbsp; That quote reminds us of Judge Keller in C.D. Cal., who liked to remind lawyers that the word “perused” is often misused to suggest some sort of casual or careless review, when in fact it denotes an especially careful reading.&nbsp; <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">The prescriber also testified that it did not matter that metoclopramide had not been approved by the FDA for use in treating pregnant women, because “I don’t rely on the FDA to make those decisions” and “[i]t’s a clinical decision and a professional decision based on guidelines from the people that practice my sort of medicine.”&nbsp; Instead, what matters is that he use “a medication that helps a problem.”&nbsp; <em>Id.</em> at *18.&nbsp; Just so.&nbsp; Most doctors will say that.&nbsp; Consequently, the generic manufacturer gets out on lack of warning causation.&nbsp; <em>Mensing</em> preemption remained just off-stage. It’s still a win.&nbsp; <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">It’s also a win for the manufacturer of the brand name drug, because under Louisiana’s product liability law, “recovery is not available against a manufacturer if the manufacturer did not produce the offending product.&nbsp; Accordingly, a drug manufacturer may not be held liable where a plaintiff has not been injured from ingesting another drug manufacturer’s drug.”&nbsp; Further, even if the Louisiana product liability statute did not apply, under Louisiana law “there is no duty of care owned by name-brand manufacturers to consumers of generic products.”&nbsp; <em>Id.</em> at *20. &nbsp;The dreaded <em>Conte </em>doctrine makes no inroads in the Pelican State.&nbsp; (As shown in our&nbsp;<a href="http://druganddevicelaw.blogspot.com/2009/11/scorecard-non-manufacturer-name-brand.html">Conte Scorecard</a>,&nbsp;this is not the first time that <em>Conte</em> has been chased out of the bayou.)&nbsp; It’s not quite the classic pro-<em>Mensing</em>/anti-<em>Conte</em> two-fer, but it’s a good result nonetheless.&nbsp; Because of LEXIS/NEXIS, that result showed up conveniently on our computer screen.&nbsp; We didn’t have to hear it through the grapevine.&nbsp; It’s a good start to the day.&nbsp; Now back to the iPod.&nbsp; “Delta Lady” is cued up.&nbsp; &nbsp;<o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:84:"http://druganddevicelaw.blogspot.com/2014/04/causation-requirement-trips-up-off.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:37:"noreply@blogger.com (Steve McConnell)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-07T21:52:37.206-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:10;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-1736826008091294172";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Tue, 01 Apr 2014 19:38:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:6:"Infuse";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:13:"Off-Label Use";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:21:"An Infusion of Infuse";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:33648:"<!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:DontVertAlignCellWithSp/>   <w:DontBreakConstrainedForcedTables/>   <w:DontVertAlignInTxbx/>   <w:Word11KerningPairs/>   <w:CachedColBalance/>  </w:Compatibility>  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="--"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267">  <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" Priority="0" Name="Block Text"/>  <w:LsdException Locked="false" Priority="0" Name="Hyperlink"/>  <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-qformat:yes;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin-top:0in;  mso-para-margin-right:0in;  mso-para-margin-bottom:12.0pt;  mso-para-margin-left:0in;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:"Calibri","sans-serif";  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-fareast-font-family:SimSun;  mso-fareast-theme-font:minor-fareast;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:"Times New Roman";  mso-bidi-theme-font:minor-bidi;} </style><![endif]--> <br /><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>This post is from the non-Reed Smith side of the blog only.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Since September we’ve been bringing you news from the Infuse litigation on about a monthly basis.<span style="mso-spacerun: yes;">&nbsp; </span>The overwhelming majority of that news has been positive.<span style="mso-spacerun: yes;">&nbsp; </span>And, when you’ve got a good thing going, you want to keep it going.<span style="mso-spacerun: yes;">&nbsp; </span>You also don’t want to bore your audience, so here are a bunch of links if you are interested in what’s transpired so far (<a href="http://druganddevicelaw.blogspot.com/2013/09/the-infuse-litigation-making-good-off.html" target="_blank">here</a>,<a href="http://druganddevicelaw.blogspot.com/2013/10/an-infuse-update.html" target="_blank"> here</a>, <a href="http://druganddevicelaw.blogspot.com/2013/11/more-infuse-news.html" target="_blank">here</a>, and <a href="http://druganddevicelaw.blogspot.com/2014/01/another-infuse-off-label-win.html" target="_blank">here</a>).  </div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In a nutshell, plaintiffs largely have been ineffective in getting courts to overlook preemption simply because the PMA medical device at issue was used off-label by plaintiffs’ surgeons.<span style="mso-spacerun: yes;">&nbsp; </span>That really is the crux of their argument – that off-label use should take the case outside the realm of <i style="mso-bidi-font-style: normal;">Riegel</i> express preemption and <i style="mso-bidi-font-style: normal;">Buckman</i> implied preemption because the use was not one reviewed and approved by the FDA.<span style="mso-spacerun: yes;">&nbsp; </span>But, the FDA approves devices for indications and in so doing, “contemplates that approved [devices] will be used in off-label ways.” <span style="mso-spacerun: yes;">&nbsp;</span><i style="mso-bidi-font-style: normal;">United States v. Caronia</i>, 703 F.3d 149, 166 (2d Cir. 2012).<span style="mso-spacerun: yes;">&nbsp; </span>“[O]ff-label usage of medical devices . . . is an accepted and necessary corollary of the FDA’s mission to regulate in this area without directly interfering with the practice of medicine.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Buckman Co. v. Plaintiffs’ Legal Comm.</i>, 531 U.S. 341, 350 (2001).<span style="mso-spacerun: yes;">&nbsp; </span>With that, most of the courts that have considered the Infuse cases start their analysis from the same place they would start in any PMA medical device case – acknowledging that very few causes of action survive the “narrow gap” between <i style="mso-bidi-font-style: normal;">Riegel</i>preemption and <i style="mso-bidi-font-style: normal;">Buckman</i> preemption.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Today’s cases are no different.<span style="mso-spacerun: yes;">&nbsp; </span>They are <i style="mso-bidi-font-style: normal;">Schouest v. Medtronic, Inc.</i>, 2014 U.S. Dist. LEXIS 38123 (S.D. Tex. Mar. 24, 2014) and <i style="mso-bidi-font-style: normal;">Blankenship v. Medtronic, Inc.</i>, 2014 U.S. Dist. LEXIS 39063 (E.D. Mo. Mar. 25, 2014).<span style="mso-spacerun: yes;">&nbsp; </span>In both cases, plaintiffs tether their claims to allegations of off-label promotion and failure to warn of risks associated with off-label uses.<span style="mso-spacerun: yes;">&nbsp; </span>As the <i style="mso-bidi-font-style: normal;">Schouest</i>court put it, plaintiffs essentially bring two claims:<span style="mso-spacerun: yes;">&nbsp; </span>“on the one hand, that Medtronic did not do enough [failure to warn], and on the other, that Medtronic did too much [off-label promotion].”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Schouest</i>, 2014 U.S. Dist. LEXIS 38123 at *16.<span style="mso-spacerun: yes;">&nbsp; </span>Both theories present problems for plaintiffs.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Failure to warn is probably the easiest claim for court’s to dismiss.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal"><br /></div><blockquote class="tr_bq"><div class="MsoBlockText">The FDA proscribed the precise labeling that the device was required to carry. Medtronic cannot deviate from that labeling without the FDA's permission. Under <i style="mso-bidi-font-style: normal;">Riegel</i>, a . . . jury finding that labeling inadequate would be tantamount to a requirement that Medtronic do something “different from, or in addition to,” what the FDA already approved.</div></blockquote><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Id.</i> at *22.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">See</i><i style="mso-bidi-font-style: normal;">Blankenship</i>, 2014 U.S. Dist. LEXIS 39063 at *17-18 (“Plaintiff’s failure to warn claim would establish labeling and warning requirements different from, or in addition to, federal requirements for the Infuse Device.”).<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Both courts likewise dismissed plaintiff’s design and manufacturing defect claims as expressly preempted “because [they] would require the Infuse device to be designed or manufactured differently that the FDA authorized.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Schouest, </i>at *33-34.<span style="mso-spacerun: yes;">&nbsp; </span>The <i style="mso-bidi-font-style: normal;">Blankenship</i> court directly addressed and rejected the notion that off-label use somehow changes the analysis:</div><div class="MsoNormal"><br /></div><blockquote class="tr_bq"><div class="MsoBlockText">Plaintiff's claim is that the manufacturing process became defective as a result of Medtronic's promoting the Infuse device for off-label uses. This argument purports to impose liability on the manufacturer despite the manufacturer's compliance with the applicable FDA design and manufacturing specification[s], as approved by the FDA during the pre-market approval process[.]<span style="mso-spacerun: yes;">&nbsp; </span>Thus, plaintiff is attempting to impose responsibilities on Medtronic that are different from, or in addition to, the federal requirements. </div></blockquote><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Blankenship</i>, at *16-17 (citations omitted); <i style="mso-bidi-font-style: normal;">see</i> <i style="mso-bidi-font-style: normal;">id</i> at *18-20 (dismissing design defect claim as preempted finding that “plaintiff does not allege the design of Infuse was anything other than the design approved by the FDA”).</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>In both cases, plaintiffs also brought negligence and negligence per se claims.<span style="mso-spacerun: yes;">&nbsp; </span>In <i style="mso-bidi-font-style: normal;">Blankenship</i>, the court described plaintiff’s claims as singularly based on improper off-label promotion.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id</i>. at *20-21.<span style="mso-spacerun: yes;">&nbsp; </span>And therefore, found them impliedly preempted because off-label promotion is not “conduct that would give rise to a recovery under state law [ ] in the absence of the FDCA.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *23 (citation omitted) (off-label promotion doesn’t exist except by virtue of the FDCA).<span style="mso-spacerun: yes;">&nbsp; </span>The <i style="mso-bidi-font-style: normal;">Schouest</i> court parsed out plaintiff’s negligence claims to apply what it determined was a critical distinction between truthful off-label promotion and negligent misrepresentations.<span style="mso-spacerun: yes;">&nbsp; </span>The former is expressly preempted because truthful off-label promotion may not violate federal law, <i style="mso-bidi-font-style: normal;">see</i>discussion at <i style="mso-bidi-font-style: normal;">Schouest</i>, *16-21, and therefore a jury finding may or may not impose requirements different from or in addition to FDA requirements.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *29.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal" style="margin-top: 12pt;">With respect to misrepresentations (negligent and fraudulent in <i style="mso-bidi-font-style: normal;">Schouest</i>and fraudulent in <i style="mso-bidi-font-style: normal;">Blankenship</i>), however, both courts found that such claims can survive preemption:</div><div class="MsoNormal"><br /></div><blockquote class="tr_bq"><div class="MsoBlockText">[M]aking false or misleading statements about medical devices is prohibited by federal law. This means that Schouest's state law fraud claims based on false off-label promotion would, if proven, also amount to a violation of federal law, and thus such claims could survive preemption.</div></blockquote><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Schouest</i> at *24-25; <i style="mso-bidi-font-style: normal;">Blankenship</i> at *28-29 (finding fraud and misrepresentation claims are parallel violation claims).<span style="mso-spacerun: yes;">&nbsp; </span>This is a fairly common result in these cases.<span style="mso-spacerun: yes;">&nbsp; </span>Both courts also found that Rule 9(b)’s pleading with particularity requirement applied to these claims.<span style="mso-spacerun: yes;">&nbsp; </span>In <i style="mso-bidi-font-style: normal;">Blankenship</i>, the court found the requirement was not met and dismissed the claims without prejudice.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *30.<span style="mso-spacerun: yes;">&nbsp; </span>Also a common result.<span style="mso-spacerun: yes;">&nbsp; </span>While the <i style="mso-bidi-font-style: normal;">Schouest</i> court chose not to undertake the analysis since plaintiff was going to be given an opportunity to amend her complaint anyway.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Schouest</i>at *43-44.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>One other quick note on both cases.<span style="mso-spacerun: yes;">&nbsp; </span>In each, it appears plaintiff premised a claim on allegations of failure to submit adverse event reports to the FDA.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Blankenship</i>, governed by Eighth Circuit law (<i style="mso-bidi-font-style: normal;">In re Medtronic, Inc., Sprint Fidelis Leads Prods. Liab. Litig.</i>, 623 F.3d 1200, 1205-06 (8th Cir. 2010)), found such a claim impliedly preempted as “an attempt by private parties to enforce the MDA.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Blankenship </i>at *18.<span style="mso-spacerun: yes;">&nbsp; </span>While <i style="mso-bidi-font-style: normal;">Schouest</i>, governed by Fifth Circuit law (<i style="mso-bidi-font-style: normal;">Hughes v. Boston Scientific Corp.</i>, 631 F.3d 762, 775 (5th Cir. 2011)), was required to allow such a claim.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Schouest</i>at *31-32.<span style="mso-spacerun: yes;">&nbsp; </span>We say was required, because the <i style="mso-bidi-font-style: normal;">Schouest</i> court acknowledged that the claim sure sounded like a preempted fraud-on-the-FDA claim to them, but that they were stuck with it anyway.<span style="mso-spacerun: yes;">&nbsp; </span>The <i style="mso-bidi-font-style: normal;">Schouest</i> court also seems to be requiring more detailed pleading of this claim, directing plaintiff in her amended complaint to “point to a state law duty to report adverse events, and, critically, what FDA reporting regulations Medtronic allegedly violated.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *31.<span style="mso-spacerun: yes;">&nbsp; </span>That’s about as good as we could hope for in the Fifth Circuit.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>While that’s it for <i style="mso-bidi-font-style: normal;">Blankenship</i>, <i style="mso-bidi-font-style: normal;">Schouest </i>also alleged express and implied warranty claims. <span style="mso-spacerun: yes;">&nbsp;&nbsp;</span>And again, the dividing line for the court was between a claim alleging that the defendant should have done more (implied warranty) and a claim that defendant made affirmative misrepresentations (express warranty).<span style="mso-spacerun: yes;">&nbsp; </span>A breach of implied warranty claim, therefore, was more like failure to warn -- preempted because “federal law governs all statements that Medtronic is obligated to make.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *35. <span style="mso-spacerun: yes;">&nbsp;</span>Whereas plaintiff’s</div><blockquote class="tr_bq"><div class="MsoBlockText">express warranty claim can survive to the extent she seeks to recover based on false warranties that Medtronic voluntarily and falsely made beyond the federally approved warning because [f]ederal law already requires [Medtronic] to ensure that any warranty statements it voluntarily makes are truthful, accurate, not misleading, and consistent with applicable federal and state law. </div></blockquote><div class="MsoNormal"><i style="mso-bidi-font-style: normal;">Id.</i><span style="mso-spacerun: yes;">&nbsp; </span>But this too is only theoretical because plaintiff’s complaint fails to include a description of the specific warranties allegedly made to her or her surgeon.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff is being given a chance to fix this in her amended complaint.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Both courts came at their decisions from different directions, but with the exception of where their hands were tied by circuit law, reached the same result.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiffs are getting a second bite at the apple, but it’s a much smaller apple.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:71:"http://druganddevicelaw.blogspot.com/2014/04/an-infusion-of-infuse.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Michelle Yeary)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-10T15:02:45.822-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:11;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-2144989954246734153";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Mon, 31 Mar 2014 15:57:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:10:"California";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:13:"Off-Label Use";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:96:"Opening Day Brings a Favorable Decision on Off-Label Use and California's Unfair Competition Law";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:26521:"<!--[if gte mso 9]><xml> <o:OfficeDocumentSettings>  <o:AllowPNG/> </o:OfficeDocumentSettings></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:EnableOpenTypeKerning/>   <w:DontFlipMirrorIndents/>   <w:OverrideTableStyleHps/>  </w:Compatibility>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="&#45;-"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267">  <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" Priority="0" Name="Body Text"/>  <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin:0in;  mso-para-margin-bottom:.0001pt;  mso-pagination:widow-orphan;  font-size:12.0pt;  font-family:"Times New Roman","serif";  mso-bidi-font-family:"Times New Roman";  mso-bidi-theme-font:minor-bidi;} </style><![endif]--> <br /><div class="MsoBodyText">It’s opening day here in NYC.<span style="mso-spacerun: yes;">&nbsp; </span>The Nationals are in town to play the Mets.<span style="mso-spacerun: yes;">&nbsp; </span>And the sun is supposed to emerge just before game time.<span style="mso-spacerun: yes;">&nbsp; </span>A perfect day.<span style="mso-spacerun: yes;">&nbsp; </span>In fact, as all ragged and abused Mets fans know, opening day is the highlight of the year.<span style="mso-spacerun: yes;">&nbsp; </span>And it’s generally downhill from there.<span style="mso-spacerun: yes;">&nbsp; </span>But on opening day, the Mets are the best team in baseball.<span style="mso-spacerun: yes;">&nbsp; </span>It’s a fact: 34-18 (.654) on opening days.<span style="mso-spacerun: yes;">&nbsp; </span>And that’s after having been so bad in the 1960s that they lost their first 8 opening day contests.<span style="mso-spacerun: yes;">&nbsp; </span>Since then, they’re 34-10 (.772).<span style="mso-spacerun: yes;">&nbsp; </span>So it’s imperative to see the first game.<span style="mso-spacerun: yes;">&nbsp; </span>It’s not likely to get any better.<span style="mso-spacerun: yes;">&nbsp; </span>So this post will be quick.</div><div class="MsoBodyText"><br /></div><div class="MsoBodyText"><u>Zeltiq Aesthetics, Inc. v. BTL Indus.</u>, 2014 U.S. Dist. LEXIS 40402 (N.D. Cal Mar. 25, 2014), is another business-on-business decision with favorable implications for product liability litigation, particularly cases involving off-label claims and medical devices.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff markets a medical device named CoolSculpting, which lowers the temperature of fat cells and then somehow eliminates them. <span style="mso-spacerun: yes;">&nbsp;</span><u>Id.</u> at *4-5. <span style="mso-spacerun: yes;">&nbsp;</span>That’s a nice deal if it works.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA cleared it under §510(k).<span style="mso-spacerun: yes;">&nbsp; </span>The defendant firm markets a device called Vanquish, which the FDA cleared under §510(k) for treating muscle aches and pain.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *5-7.<span style="mso-spacerun: yes;">&nbsp; </span>That’s nice too.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoBodyText"><br /></div><div class="MsoBodyText">The plaintiff alleged that the defendant firm didn’t market Vanquish for treating muscle aches and pains.<span style="mso-spacerun: yes;">&nbsp; </span>Instead, it marketed Vanquish for fat reduction.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *6-7.<span style="mso-spacerun: yes;">&nbsp; </span>That’s not the use for which the FDA cleared it.<span style="mso-spacerun: yes;">&nbsp; </span>But it <i style="mso-bidi-font-style: normal;">is</i> the use for which the FDA cleared CoolSculpting, the plaintiff’s device.<span style="mso-spacerun: yes;">&nbsp; </span>So now you see the dispute.</div><div class="MsoBodyText"><br /></div><div class="MsoBodyText">Plaintiff filed for a preliminary injunction, asserting claims for false advertising under the Lanham Act and, more important, for misleading and deceptive advertising under California’s ubiquitous Unfair Competition Law (“UCL”).<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *21.<span style="mso-spacerun: yes;">&nbsp; </span>After hearing evidence, the court denied the preliminary injunction.<span style="mso-spacerun: yes;">&nbsp; </span>It ruled that the plaintiff was not likely to succeed on its Lanham Act claim because it couldn’t show that the defendant’s advertising was either literally false or false by implication.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *24-34.<span style="mso-spacerun: yes;">&nbsp; </span>Since much of the plaintiff firm’s allegation concerned FDA clearance issues, we wonder whether the court might have simply barred application of the Lanham Act in favor of the FDCA, which is to be enforced solely by the United States, not private plaintiffs.<span style="mso-spacerun: yes;">&nbsp; </span>But we won’t dwell on that.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoBodyText"><br /></div><div class="MsoBodyText">More important is the court’s treatment of the plaintiff’s two UCL claims for off-label promotion.</div><div class="MsoBodyText"><br /></div><div class="MsoBodyText">First, plaintiff claimed that the defendant sold Vanquish without 510(k) clearance, violating California Health and Safety Code § 111550: “No person shall sell, deliver, or give away any ... new device unless ... [i]t is ... [a] device that is reported under Section 510(k) of the federal act (21 U.S.C. Sec. 360(k)) . . . .”<span style="mso-spacerun: yes;">&nbsp; </span>The problem is that the FDA did clear Vanquish under §510(k).<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff hoped that it could side step that clearance because Vanquish was cleared for treating aches and pains, not fat reduction.<span style="mso-spacerun: yes;">&nbsp; </span>Maybe, but that doesn’t matter.<span style="mso-spacerun: yes;">&nbsp; </span>Off-label use doesn’t turn a 510(k) device into a device that wasn’t cleared.<span style="mso-spacerun: yes;">&nbsp; </span>Even if California law tried to do that, it would almost certainly be preempted.<span style="mso-spacerun: yes;">&nbsp; </span>In fact, there are a number of ways that this law, if applied as plaintiff requested, would conflict with federal regulation.<span style="mso-spacerun: yes;">&nbsp; </span>Firms don’t have the authority to create instructions for off-label uses without FDA clearance.<span style="mso-spacerun: yes;">&nbsp; </span>And the FDA recognizes that cleared devices will be used off-label as part of the every-day practice of medicine. <span style="mso-spacerun: yes;">&nbsp;</span>And so disallowing off-label use or requiring distributors to use unapproved instructions would run head on into preemption.</div><div class="MsoBodyText"><br /></div><div class="MsoBodyText">Second, plaintiff claimed that Vanquish was unlawfully “misbranded” under California law, which requires devices to have “adequate instructions for use.”<span style="mso-spacerun: yes;">&nbsp; </span>Cal. Health &amp; Safety Code §111375.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiff got to this claim by arguing that Vanquish was misbranded because its labeling failed to include “adequate directions for” its off-label use, fat reduction.<span style="mso-spacerun: yes;">&nbsp; </span>But Vanquish was sold with instructions on the FDA cleared uses of the device.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u>at *37.<span style="mso-spacerun: yes;">&nbsp; </span>So plaintiff’s argument would require the defendant to add unapproved instructions on its own.<span style="mso-spacerun: yes;">&nbsp; </span>That’s preempted.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff also argued that once the defendant sold the device for an off-label use those actions rendered it misbranded because it didn’t have the required instructions for such use.<span style="mso-spacerun: yes;">&nbsp; </span>This is just a different way to make the same argument.<span style="mso-spacerun: yes;">&nbsp; </span>The labeling of the device is regulated by the FDA.<span style="mso-spacerun: yes;">&nbsp; </span>California law can’t change that.<span style="mso-spacerun: yes;">&nbsp; </span>It can’t be different.<span style="mso-spacerun: yes;">&nbsp; </span>The court rejected plaintiff’s argument:</div><div class="MsoBodyText"><br /></div><div class="MsoBodyText" style="margin-left: .5in;">[Plaintiff] has not cited any authority to suggest that a device may be “misbranded” by virtue of its overall promotional practices as opposed to the more obvious source of “labeling”: the Instructions for Use in the Operator's Manual.&nbsp;</div><div class="MsoBodyText" style="margin-left: .5in;">&nbsp; </div><div class="MsoBodyText"><u>Id.</u> at *38.</div><div class="MsoBodyText"><br /></div><div class="MsoBodyText">So we now have in the bucket a California federal court holding that the UCL cannot be used to create a misbranding claim from off-label allegations.<span style="mso-spacerun: yes;">&nbsp; </span>We’re certainly happy with that.</div><div class="MsoBodyText"><br /></div><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-theme-font: minor-bidi; mso-fareast-font-family: Calibri; mso-fareast-language: EN-US; mso-fareast-theme-font: minor-latin;">OK, done.<span style="mso-spacerun: yes;">&nbsp; </span>Now it’s off to the ballpark.<span style="mso-spacerun: yes;">&nbsp; </span></span>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:87:"http://druganddevicelaw.blogspot.com/2014/03/opening-day-brings-favorable-decision.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:38:"noreply@blogger.com (John J. Sullivan)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-31T11:57:16.023-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:12;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:58:"tag:blogger.com,1999:blog-36762711.post-874224575009707317";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Fri, 28 Mar 2014 18:58:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:2:{i:0;a:5:{s:4:"data";s:9:"Causation";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:8:"Warnings";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:40:"Warnings Causation Carries the Day Again";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:12502:"  <br /><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">The defendant in <i style="mso-bidi-font-style: normal;">Parkinson v. Novartis Pharmaceuticals Corp.</i>, No. 3:12-cv-02089, 2014 U.S. Dist. LEXIS 36677 (D. Or. Mar. 20, 2014), won summary judgment on warnings causation because the alleged inadequacy in the drug warnings didn’t make a lick of a difference.<span style="mso-spacerun: yes;">&nbsp; </span>That is the right result and is why we think warnings causation is such a useful concept.<span style="mso-spacerun: yes;">&nbsp; </span>Bexis likes to remind us that preemption is the king of all defenses because it eliminates entire cases, and in some instances <a href="http://druganddevicelaw.blogspot.com/2009/01/sprint-fidelis-preemption-decision.html">entire MDLs</a>, or an entire <a href="http://druganddevicelaw.blogspot.com/2014/03/breaking-news-fosamax-preemption-ruling.html">category of claims</a> within an MDL.<span style="mso-spacerun: yes;">&nbsp; </span>But if preemption is king, then warnings causation is a crown prince.<span style="mso-spacerun: yes;">&nbsp; </span>For one thing, warnings causation is not a defense.<span style="mso-spacerun: yes;">&nbsp; </span>Every plaintiff bringing a claim based on allegedly inadequate warnings bears the burden of proving that the alleged inadequacy proximately caused his or her injury.<span style="mso-spacerun: yes;">&nbsp; </span>That is to say, the plaintiff must prove that additional or “more adequate” warnings would have altered the physician’s decision to prescribe the drug or select the medical device.<span style="mso-spacerun: yes;">&nbsp; </span>For another thing, unlike preemption, causation is present and potentially a winning argument in most every drug and medical device case, depending on the case-specific evidence.<span style="mso-spacerun: yes;">&nbsp; </span>Sure, there are presumptions in certain states that doctors would have heeded stronger warnings if given, but presumptions can be overcome, and they often are.</span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">In <i style="mso-bidi-font-style: normal;">Parkinson</i>, the patient was taking the defendant’s bisphosphonates to treat cancer.<span style="mso-spacerun: yes;">&nbsp; </span>Bisphosphonates were the subject of an FDA Safety Alert explaining that osteonecrosis of the jaw (ONJ) was observed in cancer patients receiving treatment with intravenous bisphosphonates and that dental surgery may aggravate the condition in cancer patients who develop ONJ while on bisphosphonate therapy.<span style="mso-spacerun: yes;">&nbsp; </span>Although the order in <i style="mso-bidi-font-style: normal;">Parkinson</i> does not explain it, that seems to be the basis for the claims against the drug manufacturer.<span style="mso-spacerun: yes;">&nbsp; </span>The patient had two teeth extracted, which evidently resulted in ONJ or worsened ONJ.<span style="mso-spacerun: yes;">&nbsp; </span>At least that is what the order seems to say, and the plaintiff claimed that the defendant failed to warn adequately about that risk.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span><span style="mso-spacerun: yes;">&nbsp;</span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">The problem for the plaintiff—the survivor of the patient, who sadly died—is that the doctor who prescribed bisphosphonates “knew of thousands of scientific articles . . . that set out and described the various risks associated with [bisphosphonates] (including ONJ).”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *11.<span style="mso-spacerun: yes;">&nbsp; </span>Moreover, the evidence was undisputed that the doctor chose to prescribe the drugs “because the benefits to Plaintiff . . . outweighed the risk of ONJ.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i><span style="mso-spacerun: yes;">&nbsp; </span>The district court further noted that the prescribing physician continues to prescribe bisphosphonates despite the risk of ONJ because the benefits “greatly outweigh” the risks.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *12.<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">This is ironclad, and when we depose prescribing physicians, this is what we hope (and usually expect) them to say.<span style="mso-spacerun: yes;">&nbsp; </span>Such testimony cuts off causation because additional information about a risk about which the prescriber already knows cannot have had an impact on the prescribing decision.<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">The plaintiff had a few responses to this, but none held water.<span style="mso-spacerun: yes;">&nbsp; </span>First, the plaintiff argued that Oregon law provided a heeding presumption, but the only authority she cited was an unpublished (and thus uncitable) Ninth Circuit opinion applying Alaska law.<span style="mso-spacerun: yes;">&nbsp; </span>Maybe plaintiffs in Alaska can see Russia from their houses, but this Oregon plaintiff clearly could not see a heeding presumption in Oregon law.<span style="mso-spacerun: yes;">&nbsp; </span>Neither could the district court, because one does not exist.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at **9-10. <span style="mso-spacerun: yes;">&nbsp;</span>To the contrary, “the burden is on the plaintiff ‘to establish that [the alleged inadequate warning] proximately caused [her] injures or damages.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *10 (citing Oregon authority).<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">Second, the plaintiff argued that her late daughter (the patient) would not have consented to treatment with these bisphosphonates if she had known about the risk of ONJ. <span style="mso-spacerun: yes;">&nbsp;</span>But there was no competent evidence of that, and even if there were, the learned intermediary doctrine makes it beside the point.<span style="mso-spacerun: yes;">&nbsp; </span>As the district court explained,<o:p></o:p></span></div><br /><div class="MsoNormal" style="margin: 0in 0.5in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">[T]he Ninth Circuit has made clear that the relevant inquiry is not whether <i style="mso-bidi-font-style: normal;">Plaintiff</i>would have taken [the medicine], but whether <i style="mso-bidi-font-style: normal;">Dr. Seligman</i> would have prescribed [the medicine] if he had received a different warning related to the possibility of ONJ.<o:p></o:p></span></div><br /><div class="MsoNormal" style="margin: 0in 0in 10pt;"><i style="mso-bidi-font-style: normal;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">Id.</span></i><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">at **12-13 (emphasis in original).<span style="mso-spacerun: yes;">&nbsp; </span>This is ironclad too, and we wish every court were as vigilant in shutting down plaintiffs who claim after the fact they would not have used the product “if they had known.”<span style="mso-spacerun: yes;">&nbsp; </span>We take with a grain of salt any plaintiff’s statement that he or she would have rejected a doctor’s advice “if they had known,” especially a cancer patient for whom rejecting treatment could have had grave consequences.<span style="mso-spacerun: yes;">&nbsp; </span>But even if crediting those self-serving statements as true, they are immaterial where the learned intermediary doctrine applies, which the district court correctly found.<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">Third, the plaintiff claimed that the dentists who pulled the teeth “changed their practices with regards to going over treatment with patients” since the time they treated the decedent.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *15.<span style="mso-spacerun: yes;">&nbsp; </span>We’re not sure where the plaintiff was going with this argument.<span style="mso-spacerun: yes;">&nbsp; </span>She cited no authority for the idea that these “changed practices” made any difference, and the actual facts of the case demonstrated that they would not have made any difference:<span style="mso-spacerun: yes;">&nbsp; </span>The dentists agreed that there were no alternatives to extracting the teeth, which means that even if they had known more about bisphosphonates and ONJ, they would have treated the patient the same anyway.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *17.<span style="mso-spacerun: yes;">&nbsp; </span>To remove any doubt, it was undisputed that the patient did not tell her dentists that she had cancer or that she was using bisphosphonates until <b style="mso-bidi-font-weight: normal;"><i style="mso-bidi-font-style: normal;">after they pulled her teeth</i></b>.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at **18-19.<span style="mso-spacerun: yes;">&nbsp; </span>Unless the plaintiff had a time machine, what impact could additional information regarding bisphosphonates have had on her treatment when her dentists were unaware?<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">We have to admit, we have always considered warnings causation mainly in the context of the impact of warnings on prescribing physicians.<span style="mso-spacerun: yes;">&nbsp; </span>(See for example Bexis’s recent “<a href="http://druganddevicelaw.blogspot.com/2014/03/little-lists-2-warning-causation.html">little list</a>” of authorities dismissing warning claims for lack of causation where the prescribers were unavailable.</span><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">)<span style="mso-spacerun: yes;">&nbsp; </span>This plaintiff questioned the warnings and their impact (or lack thereof) both on prescribing physicians and treating physicians.<span style="mso-spacerun: yes;">&nbsp; </span>Hmm.<span style="mso-spacerun: yes;">&nbsp; </span>Maybe the next time we depose a treating physician, we will give that line of questioning some additional thought.<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; line-height: 115%;">So, we like warnings causation.<span style="mso-spacerun: yes;">&nbsp; </span>The argument may not always be there, and it may require marshaling evidence for a defendant to assert it (or perhaps not since, after all, proving causation is the plaintiff’s burden).<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Parkinson</i>is a good example of a defendant presenting the argument, the court understanding it, and the correct resulting following.<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:86:"http://druganddevicelaw.blogspot.com/2014/03/warnings-causation-carries-day-again.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:37:"noreply@blogger.com (Steven Boranian)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-28T14:58:14.196-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:13;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:58:"tag:blogger.com,1999:blog-36762711.post-380857583802515482";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Thu, 27 Mar 2014 19:04:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:2:{i:0;a:5:{s:4:"data";s:5:"Iqbal";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:8:"Pleading";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:25:"It’s Throwback Thursday";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:25190:"<!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:DontVertAlignCellWithSp/>   <w:DontBreakConstrainedForcedTables/>   <w:DontVertAlignInTxbx/>   <w:Word11KerningPairs/>   <w:CachedColBalance/>  </w:Compatibility>  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="&#45;-"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267">  <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-qformat:yes;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin-top:0in;  mso-para-margin-right:0in;  mso-para-margin-bottom:12.0pt;  mso-para-margin-left:0in;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:"Calibri","sans-serif";  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-fareast-font-family:SimSun;  mso-fareast-theme-font:minor-fareast;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:"Times New Roman";  mso-bidi-theme-font:minor-bidi;} </style><![endif]--> <br /><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>If you even dally in one or more of the most popular social media sites (Facebook, Twitter, instragram), then you’ve probably heard about Throwback Thursday -- or if you are super cool, #tbt.<span style="mso-spacerun: yes;">&nbsp; </span>Nobody is exactly sure when it started, but by 2013 it was thoroughly ensconced in our social media habits.<span style="mso-spacerun: yes;">&nbsp; </span>Purportedly there are somewhere around 23 million pictures tagged #throwbackthursday on Twitter alone.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>What is Throwback Thursday?<span style="mso-spacerun: yes;">&nbsp; </span>Some say it’s an excuse to post your most angelic baby picture or a photo of yourself from anytime in the past when you were thinner than you are now. Or, perhaps post an embarrassing old photo of a friend.<span style="mso-spacerun: yes;">&nbsp; </span>All are legitimate throwbacks.<span style="mso-spacerun: yes;">&nbsp; </span>The only real requirement seems to be a picture so old you actually had to snap a photo of a physical picture to be able to post it.<span style="mso-spacerun: yes;">&nbsp; </span>So, that means you probably need to reach back at least 5 years.<span style="mso-spacerun: yes;">&nbsp; </span><span lang="EN" style="mso-ansi-language: EN;"></span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Well, this post reaches back almost 20 years for some of us (Bexis and Yeary).<span style="mso-spacerun: yes;">&nbsp; </span>A time when not only were photos in hard copy, but so were our filings.<span style="mso-spacerun: yes;">&nbsp; </span>Mad dashes to the courthouse to beat the 4:00 pm closing rather than hitting the submit button at 11:59 pm.<span style="mso-spacerun: yes;">&nbsp; </span>Making dozens of copies to serve on all the parties rather than sending a pdf by email. <span style="mso-spacerun: yes;">&nbsp;&nbsp;</span>Ahh, the feel of warm pages fresh off the printer and the frenzy of cab rides to the airport to make the last Federal Express flight of the night.<span style="mso-spacerun: yes;">&nbsp; </span>Sweet memories.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>We’ve certainly on this blog taken more than one opportunity to discuss the many successes that came out of the <i style="mso-bidi-font-style: normal;">Orthopedic Bone Screw Litigation</i>, chief among them <i style="mso-bidi-font-style: normal;">Buckman</i>.<span style="mso-spacerun: yes;">&nbsp; </span>So, we couldn’t let Throwback Thursday pass without mentioning <i style="mso-bidi-font-style: normal;">Lonon v. Globus Medical, Inc.</i>, 2014 U.S. Dist. LEXIS 36218 (S.D. Ga. Mar. 18, 2014).<span style="mso-spacerun: yes;">&nbsp; </span>Yep, an actual pedicle screw case.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Plaintiff had spinal surgery in which eight pedicle screws were implanted in his spine.<span style="mso-spacerun: yes;">&nbsp; </span>About two years later, plaintiff started experiencing pain which led to a finding that two of the screws had fractured.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at *1-2.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff filed a single cause of action for negligence, alleging that defendant had a “duty to insure that the pedicle screws would not cause injury to Plaintiff” and “to provide Plaintiff with a pedicle screw that would not fracture.” <span style="mso-spacerun: yes;">&nbsp;&nbsp;</span><i style="mso-bidi-font-style: normal;">Id.</i>at *2.<span style="mso-spacerun: yes;">&nbsp; </span>And that’s it.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>You don’t have to have been involved in the bone screw litigation to know, that’s not enough.<span style="mso-spacerun: yes;">&nbsp; </span>In fact, the court’s description of the complaint as “spartan” might just be an understatement.<span style="mso-spacerun: yes;">&nbsp; </span>The court notes that nowhere in the complaint will you find any allegations about how the screws are supposedly defective.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id. </i><span style="mso-spacerun: yes;">&nbsp;</span>at *6-7.<span style="mso-spacerun: yes;">&nbsp; </span>Instead, plaintiff seems to solely rely on the “mere fact that they fractured as supporting the notion that Defendant breached some duty.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *7.<span style="mso-spacerun: yes;">&nbsp; </span>Not even close to <i style="mso-bidi-font-style: normal;">TwIqbal</i> compliant.<span style="mso-spacerun: yes;">&nbsp; </span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>And what duty is defendant alleged to have breached?<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiff’s sole allegation is that defendant owed a duty to provide a pedicle screw that was “correctly manufactured and would not fracture.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *6.<span style="mso-spacerun: yes;">&nbsp; </span>“As written, it appears that Plaintiff believes Defendant was obligated to provide him with an indestructible pedicle screw, which is not a duty recognized under Georgia law.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at *7.<span style="mso-spacerun: yes;">&nbsp; </span>So, not only are plaintiff’s very generalized legal conclusions not supported by any facts, the one duty he does allege isn’t a duty at all.</div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Given the extreme deficiencies of the complaint, the court also noted they shouldn’t be difficult to correct.<span style="mso-spacerun: yes;">&nbsp; </span>So, plaintiff was given a short time to amend his complaint.<span style="mso-spacerun: yes;">&nbsp; </span>We assume the claim will be re-filed given that the court found plaintiff’s counsel made better allegations in his response to the motion to dismiss than he asserted in the complaint.<span style="mso-spacerun: yes;">&nbsp; </span>And, if it does get re-filed, we’ll keep an eye out for further developments that may lead us to once again wax nostalgic.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:72:"http://druganddevicelaw.blogspot.com/2014/03/its-throwback-thursday.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Michelle Yeary)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-27T15:04:54.759-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:14;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-6823069861014580846";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Thu, 27 Mar 2014 12:00:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:18:"Express Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:18:"Implied Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:22:"That Theory Won't Hunt";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:19161:"Last week brought another example of the chaos being caused in preemption jurisprudence by the Supreme Court’s sloppily reasoned decision in <u>Wyeth v. Levine</u>, 555 U.S. 555 (2009).<span style="mso-spacerun: yes;">&nbsp; </span>Prior to <u>Levine</u>, the Court had repeatedly held that the doctrines of express (that is, where there’s an on-point statutory provision) preemption and implied (where no statute is dispositive, but state law conflicts in some way with federal law) preemption operate independently of each other.<span style="mso-spacerun: yes;">&nbsp; </span>That is, regardless of what any statute does or doesn’t say, implied preemption is still available to resolve conflicts between state and federal law.<o:p></o:p><br /><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The question whether express preemption language in a statute foreclosed the operation of implied conflict preemption arose in <u>Freightliner Corp. v. Myrick</u>, 514 U.S. 280 (1995), based on an express preemption clause in the National Traffic and Motor Vehicle Safety Act.<span style="mso-spacerun: yes;">&nbsp; </span>The Court rejected an argument that express preemption necessarily precluded implied preemption:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">[W]e must address the argument that we need not reach the conflict pre-emption issue at all.<span style="mso-spacerun: yes;">&nbsp; </span>According to respondents and the Court of Appeals .&nbsp;.&nbsp;. implied pre-emption cannot exist when Congress has chosen to include an express pre-emption clause in a statute.<span style="mso-spacerun: yes;">&nbsp; </span>This argument is without merit.<span style="mso-spacerun: yes;">&nbsp; </span>.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>The fact that an express definition of the pre-emptive reach of a statute “implies” − <i style="mso-bidi-font-style: normal;">i.e.</i>, supports a reasonable inference − that Congress did not intend to pre-empt other matters does not mean that the express clause entirely forecloses any possibility of implied pre-emption.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at 287-88 (citations omitted).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The court followed <u>Myrick</u>in <u>Geier v. American Honda Motor Co.</u>, 529 U.S. 861 (2000).<span style="mso-spacerun: yes;">&nbsp; </span>In <u>Geier</u>, also an automobile preemption case, the relevant statute contained both an express preemption clause and an express savings clause.<span style="mso-spacerun: yes;">&nbsp; </span>Discussing this issue at some length, the Court held that, whatever might be the effect of those arguably conflicting provisions on express preemption, neither statutory provision had any effect on the workings of implied preemption:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">We have just said that the saving clause at least removes tort actions from the scope of the express pre-emption clause.<span style="mso-spacerun: yes;">&nbsp; </span>Does it do more?<span style="mso-spacerun: yes;">&nbsp; </span>In particular, does it foreclose or limit the operation of ordinary pre-emption principles insofar as those principles instruct us to read statutes as pre-empting state laws (including common-law rules) that “actually conflict” with the statute or federal standards promulgated thereunder?<span style="mso-spacerun: yes;">&nbsp; </span>Petitioners concede, as they must in light of [<u>Myrick</u>], that the pre-emption provision, by itself, does not foreclose (through negative implication) any possibility of implied conflict pre-emption.<span style="mso-spacerun: yes;">&nbsp; </span>But they argue that the saving clause has that very effect.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at 869 (<u>Myrick</u> citation and quotation marks omitted).<span style="mso-spacerun: yes;">&nbsp; </span>The Court then explicitly extended the <u>Myrick</u> principle (which had focused only on the statute’s  preemption clause) to saving clauses:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">We now conclude that the saving clause (like the express pre-emption provision) does not bar the ordinary working of conflict pre-emption principles.<span style="mso-spacerun: yes;">&nbsp; </span>Nothing in the language of the saving clause suggests an intent to save state-law tort actions that conflict with federal regulations.&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>Moreover, this Court has repeatedly declined to give broad effect to saving clauses where doing so would upset the careful regulatory scheme established by federal law.<span style="mso-spacerun: yes;">&nbsp; </span>We find this concern applicable in the present case.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">529 U.S. at 869-70 (citations and quotation marks omitted). <span style="mso-spacerun: yes;">&nbsp;</span>Finally, <u>Geier</u> went on to base its holding – that neither savings nor preemption clauses affected implied preemption – firmly on policy grounds:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Neither do we believe that the pre-emption provision, the saving provision, or both together, create some kind of “special burden” beyond that inherent in ordinary pre-emption principles − which “special burden” would specially disfavor pre-emption here<span style="mso-spacerun: yes;">&nbsp; </span>.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>[W]e can find nothing in any natural reading of the two provisions that would favor one set of policies over the other where a jury-imposed safety standard actually conflicts with a federal safety standard.<span style="mso-spacerun: yes;">&nbsp; </span>Why, in any event, would Congress not have wanted ordinary pre-emption principles to apply where an actual conflict with a federal objective is at stake?<span style="mso-spacerun: yes;">&nbsp; </span>Some such principle is needed. In its absence, state law could impose legal duties that would conflict directly with federal regulatory mandates.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at 870-71 (citations and quotation marks omitted).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">These decisions were in turn applied to the FDCA by a unanimous court in <u>Buckman Co. v. Plaintiffs Legal Committee</u>, 531 U.S. 341 (2001), a medical device case that, of course, was also governed by 21 U.S.C. §306k.<span style="mso-spacerun: yes;">&nbsp; </span>The Court in <u>Buckman</u> did not address express preemption, 531 U.S. at 348 n.2, and instead based its decision on implied preemption, finding that nothing about the former could preclude the latter:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Respondent also suggests that we should be reluctant to find a pre-emptive conflict here because Congress included an express pre-emption provision in the MDA.<span style="mso-spacerun: yes;">&nbsp; </span>To the extent respondent posits that anything other than our ordinary pre-emption principles apply under these circumstances, that contention must fail in light of our conclusion .&nbsp;.&nbsp;. that neither an express pre-emption provision nor a saving clause bars the ordinary working of conflict pre-emption principles.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at 352 (citations and quotation marks omitted).<span style="mso-spacerun: yes;">&nbsp; </span><u>See also</u> <u>Sprietsma v. Mercury Marine</u>, 537 U.S. 51, 65 (2002) (“Congress’ inclusion of an express pre-emption clause does not bar the ordinary working of conflict pre-emption principles that find implied pre-emption”; finding no implied preemption either) (citing <u>Buckman</u>); <u>Medtronic, Inc. v. Lohr</u>, 518 U.S. 470, 503 (1996) (“Until such a case arises, we see no need to determine whether the statute explicitly pre-empts such a claim. <span style="mso-spacerun: yes;">&nbsp;</span>Even then, the issue may not need to be resolved if the claim would also be pre-empted under conflict pre-emption analysis”) (citing <u>Myrick</u>).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Then along came <u>Levine</u>.<span style="mso-spacerun: yes;">&nbsp; </span>Without even mentioning the rule that express and implied preemption operate independently (even though the Court in <u>Levine</u>elsewhere addressed other aspects of <u>Geier</u> and <u>Buckman</u>), <u>Levine</u>used the absence of any express preemption provision in the (drug portion of the) FDCA as a basis for holding that implied preemption did not exist either:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">If Congress thought state-law suits posed an obstacle to its objectives, it surely would have enacted an express pre-emption provision at some point during the FDCA’s 70-year history.<span style="mso-spacerun: yes;">&nbsp; </span>But despite its 1976 enactment of an express pre-emption provision for medical devices .&nbsp;.&nbsp;. Congress has not enacted such a provision for prescription drugs. <span style="mso-spacerun: yes;">&nbsp;</span>Its silence on the issue, coupled with its certain awareness of the prevalence of state tort litigation, is powerful evidence that Congress did not intend FDA oversight to be the exclusive means of ensuring drug safety and effectiveness.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">555 U.S. at 574-75 (citations omitted).<span style="mso-spacerun: yes;">&nbsp; </span>So in <u>Levine</u> we have an absence of affirmative Congressional action being used to establish a negative – that the absence of express preemption means no implied preemption either.<span style="mso-spacerun: yes;">&nbsp; </span>This result doesn’t fit with <u>Myrick</u>, <u>Geier</u>, and <u>Buckman</u>, all of which held that even <b style="mso-bidi-font-weight: normal;"><u>affirmative</u></b> congressional action, whether a preemption clause or a savings clause, did not preclude the operation of implied preemption.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">But after <u>Levine</u>, the Court appears to have reverted to the prior rule that express and implied preemption operate independently.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> <u>Arizona v. United States</u>, 132 S. Ct. 2492, 2504-05 (2012) (“the existence of an express pre-emption provision does not bar the ordinary working of conflict pre-emption principles or impose a special burden that would make it more difficult to establish the preemption of laws falling outside the clause”); <u>PLIVA, Inc. v. Mensing</u>, 131 S. Ct. 2567, 2577 (2011) (“the absence of express pre-emption is not a reason to find no conflict pre-emption”); <u>AT&amp;T Mobility LLC v. Concepcion</u>, 131 S. Ct. 1740, 1748 (2011) (“Although [the] saving clause preserves generally applicable contract defenses, nothing in it suggests an intent to preserve state-law rules that stand as an obstacle to the accomplishment of the [statute’s] objectives”); <u>Williamson v. Mazda Motor, Inc.</u>, 131 S. Ct. 1131, 1136 (2011) (“neither can the statute’s saving clause foreclose or limit the operation of ordinary conflict pre-emption principles”).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Due to the aberrant result in <u>Levine</u>, uniquely in the drug area courts are encouraged to disregard the general rule, followed both before and after by the Supreme Court, that express and implied preemption stand or fall on their own merits, and that the absence of express preemption does not impede the operation of implied preemption.<span style="mso-spacerun: yes;">&nbsp; </span>Such is the case with <u>Hunt v. McNeil Consumer Healthcare</u>, 2014 WL 1116358 (E.D. La. Mar. 11, 2014), which is what got us thinking about this issue once again.<span style="mso-spacerun: yes;">&nbsp; </span><u>Hunt</u> involves allegations that an over-the-counter (“OTC”) drug causes SJS/TENS (the same nasty condition at issue in <u>Mutual Pharmaceutical Co. v. Bartlett</u>, 133 S. Ct. 2466 (2013)).<span style="mso-spacerun: yes;">&nbsp; </span>The defendant in <u>Hunt</u> sought to apply <u>Mensing</u>/<u>Bartlett</u>to preempt a design defect claim.<span style="mso-spacerun: yes;">&nbsp; </span><u>Mensing</u>/<u>Bartlett</u>, of course, is based on a form of implied preemption – “impossibility” – positing that where federal law prohibits “unilateral[] alter[ation]” of a particular product attribute, state law cannot require such conduct.<span style="mso-spacerun: yes;">&nbsp; </span><u>Hunt</u>, 2014 WL 1116358, at *6.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Against the operation of implied preemption, <u>Hunt</u>interposed solely express preemption – doing what the Supreme Court implicitly allowed in <u>Levine</u>, but has expressly rejected (as already discussed) in more than a half-dozen decisions both pre- and post-dating that opinion.<span style="mso-spacerun: yes;">&nbsp; </span>As in <u>Geier</u>, the OTC drug statute contains an express savings clause (which <u>Hunt</u> also called a “non-preemption clause”).<span style="mso-spacerun: yes;">&nbsp; </span>That provision, 21 U.S.C. §379(e), exempts “action[s] .&nbsp;.&nbsp;. under the product liability law of any State”) from express preemption.<span style="mso-spacerun: yes;">&nbsp; </span>The court in <u>Hunt</u> held that this savings clause, precluding express preemption, also barred implied preemption under the impossibility rationale of&nbsp;<u>Mensing</u>/<u>Bartlett</u>:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Because the statute governing non-prescription drugs contains a non-preemption clause, Plaintiff’s design-defect claim is not preempted under <u>Bartlett</u>.<span style="mso-spacerun: yes;">&nbsp; </span>This result makes perfect sense, given that Congressional intent is the “ultimate touchstone” of any preemption analysis.<span style="mso-spacerun: yes;">&nbsp; </span>There are equally compelling policy justifications for reading <u>Bartlett</u>and <u>Mensing</u> narrowly so as to preserve the viability of products liability actions.<span style="mso-spacerun: yes;">&nbsp; </span>As the Court recognized in [<u>Levine</u>], statelaw [<i style="mso-bidi-font-style: normal;">sic</i>] tort suits play an important “complementary” role to federal drug regulation.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Hunt</u>, 2014 WL 1116358, at *7 (citations omitted).<span style="mso-spacerun: yes;">&nbsp; </span><u>Hunt</u> also read <u>Bartlett</u>– at least the part of it that bemoaned lack of Congressional guidance – as supporting a finding of no preemption.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u>(pointing out that <u>Bartlett</u> had “lamented the fact that Congress had not expressly addressed .&nbsp;.&nbsp;. difficult pre-emption questions” and “noted that Congress had <span style="font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-ansi-language: EN-US; mso-bidi-font-size: 14.0pt; mso-bidi-language: AR-SA; mso-fareast-font-family: &quot;Times New Roman&quot;; mso-fareast-language: EN-US;">‘</span>explicit[ly]’ addressed preemption in other drug laws” including OTC drugs).<span style="mso-spacerun: yes;">&nbsp; </span>However, absent from the analysis in <u>Hunt</u> was how <u>Bartlett</u> actually resolved the preemption question before it:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">[W]e are left to divine Congress’ will from the duties the statute imposes. <span style="mso-spacerun: yes;">&nbsp;</span>That federal law forbids [defendant] to take actions required of it by state tort law evinces an intent to pre-empt.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Mutual Pharmaceutical Co. v. Bartlett</u>, 133 S. Ct. 2466, 2480 (2013) (citation and quotation marks omitted).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">We think <u>Bartlett</u> was right on that point – the fact that federal law prohibits something is, in and of itself, indicative of “intent to pre-empt.” <span style="mso-spacerun: yes;">&nbsp;</span>We think that <u>Hunt</u>should not have ignored (to the point of never mentioning) the contrary Supreme Court rule about express vs. implied preemption.<span style="mso-spacerun: yes;">&nbsp; </span>So <u>Hunt</u> seems to us yet another example of anti-preemption wishful thinking – of courts doing strange things in tort preemption cases.<span style="mso-spacerun: yes;">&nbsp; </span>There is nothing in <u>Bartlett</u> stating that the Court was reversing, or even questioning, the holdings in <u>Myrick</u>, <u>Geier</u>, <u>Buckman</u>, <u>Sprietsma</u>, <u>Arizona</u>, <u>Mensing</u>, <u>Concepcion</u>, and <u>Williamson</u> that express and implied preemption operate independently.<span style="mso-spacerun: yes;">&nbsp; </span>Indeed, the majority in <u>Bartlett</u> expressly reaffirmed that implied preemption does operate where there is no express preemption.<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Even in the absence of an express pre-emption provision, the Court has found state law to be impliedly pre-empted where it is impossible for a private party to comply with both state and federal requirements.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at 2483.<span style="mso-spacerun: yes;">&nbsp; </span>And the dissent?<span style="mso-spacerun: yes;">&nbsp; </span>It understood that “[u]nder the majority’s approach, .&nbsp;.&nbsp;. design-defect claims are categorically displaced.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at 2595.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Maybe, at some point, the Supreme Court will decide to overturn almost two decades of preemption jurisprudence (except for <u>Levine</u>) and hold that lack of express preemption is dispositive of implied preemption as well.<span style="mso-spacerun: yes;">&nbsp; </span>But it certainly hasn’t done so yet. <span style="mso-spacerun: yes;">&nbsp;</span>Until then, we’ll be of the view that <u>Hunt</u> was wrongly decided.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:71:"http://druganddevicelaw.blogspot.com/2014/03/that-theory-wont-hunt.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-27T08:00:02.269-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:15;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:58:"tag:blogger.com,1999:blog-36762711.post-670260426551896061";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Wed, 26 Mar 2014 20:11:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:7:"Fosamax";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:6:"Levine";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:71:"Breaking News – Fosamax Preemption Ruling Extended To Other MDL Cases";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:6475:"  Last July we <a href="http://druganddevicelaw.blogspot.com/2013/07/a-preemption-win-for-innovator-drug.html">discussed</a>  a rare event, a preemption win for an innovator drug under the<span style="mso-spacerun: yes;">&nbsp; </span><u>Wyeth v. Levine</u>, 555 U.S. 555 (2009), “clear evidence” standard.<span style="mso-spacerun: yes;">&nbsp; </span>However, that case, <u>In re Fosamax Products Liability Litigation</u>, 951 F. Supp.2d 695 (D.N.J. June 27, 2013), occurred in the peculiar context of a preemption motion granted after the defendant won a trial of the same case.<span style="mso-spacerun: yes;">&nbsp; </span>Given that the plaintiff was extremely likely to lose anyway, given the verdict, that case was never appealed.<o:p></o:p><br />  <br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Now the <u>Fosamax</u>preemption ruling has been extended to other, similarly situated cases in the MDL.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> <u>In re Fosamax (Alendronate Sodium) Products Liability Litigation</u>, No. 3:08-cv-00008-JAP-LHG, <a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Fosamax_MDL-wide.pdf">slip op.</a>&nbsp;(D.N.J. March 26, 2014).<span style="mso-spacerun: yes;">&nbsp; </span>The court disposed of the MDL plaintiffs (mostly) procedural arguments against preemption and applied its earlier ruling to all cases in the MDL with injury dates before Sept. 14, 2010 – when the FDA last reaffirmed its position that it did not have enough evidence of a causal association to allow a warning change.<span style="mso-spacerun: yes;">&nbsp; </span><a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Fosamax_MDL-wide.pdf">Slip op.</a> at 7.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The court found no reason not to apply its preemption ruling to other similarly situated plaintiffs because: (1) the case in question had been selected as a bellwether; (2) preemption had been thoroughly briefed; and (3) plaintiffs had been repeatedly instructed to come forward with all their preemption related evidence.<span style="mso-spacerun: yes;">&nbsp; </span>Slip op. at 9-13.<span style="mso-spacerun: yes;">&nbsp; </span>The “newly discovered” evidence that the plaintiffs predictably asserted after they lost didn’t change anything.<span style="mso-spacerun: yes;">&nbsp; </span>It was an expert opinion based on the same facts that existed when the court decided the original bellwether preemption motion.<span style="mso-spacerun: yes;">&nbsp; </span>Slip op. at 15.<span style="mso-spacerun: yes;">&nbsp; </span>Further, all the expert testimony in the world about what might have happened, did not change the undisputed regulatory facts about what actually did happen.<span style="mso-spacerun: yes;">&nbsp; <a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Fosamax_MDL-wide.pdf">S</a></span><a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Fosamax_MDL-wide.pdf">lip op.</a> at 19-20.<span style="mso-spacerun: yes;">&nbsp; </span>The court pointed out (with a useful collection of cases) that preemption had repeatedly been addressed in similar fashion in other MDLs.<span style="mso-spacerun: yes;">&nbsp; </span><a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Fosamax_MDL-wide.pdf">Slip op.</a> at 16-17.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Plaintiffs attempted to claim that design defect claims were different and couldn’t be preempted.<span style="mso-spacerun: yes;">&nbsp; </span>The court again disagreed.<span style="mso-spacerun: yes;">&nbsp; </span>There was no way to change the chemical composition of Fosamax, so the “design” claims were merely warning claims in disguise.<span style="mso-spacerun: yes;">&nbsp; </span><a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Fosamax_MDL-wide.pdf">Slip op.</a> at 21-22.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">After disposing of various arguments rehashing what had already been decided, the court disposed of the plaintiffs’ final argument that “if fully informed” the FDA might have acted differently.<span style="mso-spacerun: yes;">&nbsp; </span>That claim was merely warmed over fraud on the FDA:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">[T]o the extent that Plaintiffs claim that [defendant] withheld information from the FDA and clear evidence does not exist as to whether the FDA, if fully informed, would have rejected a stronger label, this does not defeat Defendant’s showing that it is entitled to judgment as a matter of law on preemption grounds.&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>[E]ven assuming [defendant withheld information], Plaintiffs have failed to show that providing such information to the FDA would have changed the FDA’s conclusion that a Precaution was not warranted.&nbsp; Instead, Plaintiffs’ contention appears to be a fraud-on-the-FDA theory which was rejected by the Supreme Court in [<u>Buckman</u>], or alternatively, is based largely on speculation and cannot defeat summary judgment.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Fosamax_MDL-wide.pdf">Slip op.</a> at 29 (citations omitted).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">So this time, it appears, there is likely to be a <u>Fosamax</u>preemption appeal.<span style="mso-spacerun: yes;">&nbsp; </span>As we pointed out in our <a href="http://druganddevicelaw.blogspot.com/2013/07/a-preemption-win-for-innovator-drug.html">first post</a>, the regulatory facts supporting preemption look quite strong.<span style="mso-spacerun: yes;">&nbsp; </span>Thus, another avenue for eventual reconsideration of <u>Levine</u> – or at least some of its loopier aspects – appears to be presenting itself.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Thanks to <a href="http://www.blankrome.com/index.cfm?contentID=10&amp;bioID=2735">Terry Henry</a>  at <a href="http://www.blankrome.com/">Blank Rome</a>  for sending this decision along to us.<o:p></o:p></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:89:"http://druganddevicelaw.blogspot.com/2014/03/breaking-news-fosamax-preemption-ruling.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-26T16:11:39.898-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:16;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-1455309176273317068";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Wed, 26 Mar 2014 11:30:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:5:{i:0;a:5:{s:4:"data";s:17:"Negligence Per Se";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:25:"Parallel Violation Claims";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:8:"Pleading";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:4;a:5:{s:4:"data";s:6:"Riegel";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:170:"Better Late than Never:  We Look Back at a 2013 W.D. Okla. Application of TwIqbal to Dismiss a Hip Implant Case Premised on Vague Allegations of FDA Regulatory Violations";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:8439:"<br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">Time travel is on our mind today.&nbsp; We should hasten to add that it is not a topic that usually absorbs us – otherwise we might squander what little credibility we have with our serious-minded readers.&nbsp; But a trio of things prompted us to think about time-travel.&nbsp; First, we will (soon, we promise) be discussing a nice <em>TwIqbal</em> case that came out more than a year ago and somehow managed to evade our DDL radar screen.&nbsp; Second and third are a couple of things we heard from a couple of clients.&nbsp; In one instance, in a litigation even more far-fetched and meritless than usual, with no science or logic to support the plaintiffs’ allegations, we commiserated with a company executive over a bushel of stupid emails written by low-level employees who stated opinions contrary to those of the company or anybody in it with knowledge or authority.&nbsp; Still, those self-indulgent emails propped up the litigation and the possibility of settlement-extortion.&nbsp; The executive wished he could climb into a time machine and smack four or five employees on their noggins before they authored the offending emails.&nbsp; The litigation would disappear.&nbsp; It would be like the fading photos in <strong>Back to the Future</strong>.&nbsp; But talk about self-indulgent; it’s not as if the time machine idea helps us put together a litigation plan.&nbsp; Plus, the time machine scenario has very little traction with judges and juries.&nbsp; <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><o:p><span style="font-family: Calibri; font-size: large;">&nbsp;</span></o:p></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">We also heard something from an in-house lawyer that made us think of time travel.&nbsp; This in-house lawyer is someone who, as far as we can tell, is pretty much always the smartest person in the room and who has unerring judgment on all things legal, political, and aesthetic.&nbsp; So when he told us that we ought to take a peek at the 2013 film <strong>About Time</strong>, we headed for our local Redbox to rent the movie.&nbsp; As always, his recommendation was right on.&nbsp; <strong>About Time</strong> did just so-so with the critics and the audience, and its marketing message was almost completely confined to the fact that it was directed by the same guy who directed <strong>Love, Actually</strong>.&nbsp; But it is good, actually.&nbsp; It is a funny and clever film about a family where the men, and only the men, have the capacity to travel backwards in time to times and places they actually were in their lifetimes.&nbsp; (Thus: no ability to park a bullet in Hitler's head, or to stay the hand of George Eliot and stop her from writing those boring books inflicted on generations of hapless&nbsp;high school students.)&nbsp; As in <strong>Groundhog Day</strong>, the hero uses the great power of time travel to get a girl.&nbsp; Maybe there really is no higher use for time travel.&nbsp; As in <strong>The Butterfly Effect</strong>, there are unforeseen and unfortunate consequences to time-travel.&nbsp; Bill Nighy, who is incapable of looking or sounding uninteresting, is in it (just as he was in <strong>Love, Actually</strong>).&nbsp; Unlike most films, you won’t rue devoting two hours to watching it, muttering that you’ll never get that time back.&nbsp;&nbsp; When we think of the best all-time time-travel movies, we must now include <strong>About Time</strong>, along with the aforementioned <strong>Back to the Future</strong> and <strong>Groundhog Day</strong>, as well as <strong>The Terminator</strong>, <strong>Time After Time</strong>, <strong>Bill and Ted’s Excellent Adventure</strong>, <strong>Twelve Monkeys</strong>, and the 28 minute French film that inspired <strong>Twelve Monkeys</strong>, <strong>La Jette</strong>.&nbsp; &nbsp;&nbsp;<o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><o:p><span style="font-family: Calibri;">&nbsp;</span></o:p></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">And now on to our little time-capsule case, <em>Swisher v. Stryker Corp</em>., 2013 U.S. Dist. LEXIS 185998 (W.D. Okla. March 14, 2013). The plaintiff claimed injury from a hip implant.&nbsp; He asserted a negligence per se claim, alleging that he sustained a cascade of health problems requiring additional surgeries, all proximately caused by the defendants’ violation of various regulations promulgated by the FDA.&nbsp; The plaintiff was trying to avail himself of the “parallel claim”&nbsp; exception to <em>Riegel</em>preemption.&nbsp; The defendant filed a motion to dismiss under Rule 12(b)(6), arguing that the complaint was bereft of facts demonstrating how specific FDA regulations were violated and how such violations caused the injuries.&nbsp; <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><o:p><span style="font-family: Calibri; font-size: large;">&nbsp;</span></o:p></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">The court agreed with the defendant, applied <em>TwIqbal</em>, and dismissed the case.&nbsp; The court reasoned that “more is required to make out a parallel claim than conclusory statements that a defendant violated multiple regulations.”&nbsp; <em>Swisher</em>, 2013 U.S. Dist. LEXIS 185998 at *7.&nbsp; Actually, this plaintiff offered more than most parallel-claiming plaintiffs offer, but it was still not enough.&nbsp; The plaintiff alleged that he was diagnosed with abnormally high levels of chromium and cobalt in his bloodstream, that the cup and cap components of the hip implant system were made of those two alloys, that microscopic metallic particles rubbed off from the metal surfaces of the cap and cup components, and that such rubbing off resulted from the defendants’ violation of PMA specifications and applicable Good Manufacturing Practices (GMPs).&nbsp; <o:p></o:p></span></span></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><o:p><span style="font-family: Calibri; font-size: large;">&nbsp;</span></o:p></div><span style="font-size: large;"> </span><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;">The court held that the allusion to PMA specs and GMPs &nbsp;was “too conclusory to state a claim.” <em>Id</em>. at *8.&nbsp; The complaint did not specify the manufacturing defect, nor did it &nbsp;specify a causal connection between the failure of the specific manufacturing process and the specific defect in the process that caused the personal injury, nor did it state how the manufacturing process failed, or how it deviated from the FDA approved manufacturing process.&nbsp; In other words, the plaintiff supplied incantations, not facts.&nbsp; <o:p></o:p></span></span></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><o:p><span style="font-family: Calibri;">&nbsp;</span></o:p></div><br /><div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-family: Calibri;"><span style="font-size: large;"><em>Swisher</em> is an important case because, as the court acknowledges, different courts sit on different points along the spectrum as to how many facts are needed to state a parallel claim.&nbsp; <em>Swisher</em> is at the more rigorous end of the spectrum, so we like it just fine.&nbsp; Going back in time to retrieve the <em>Swisher</em> case will not help us attain romantic love, save the life of civilization’s savior, or even permit us to put on a school presentation where Abe Lincoln tells us to “<a href="https://www.youtube.com/watch?v=W0uVwVUVsbY">party on, dudes</a>,” but it is another piece of ammo that helps us terminate parallel claim cases.&nbsp; <o:p></o:p></span></span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:88:"http://druganddevicelaw.blogspot.com/2014/03/better-late-than-never-we-look-back-at.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:37:"noreply@blogger.com (Steve McConnell)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-26T07:30:00.908-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:17;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-7957781226838489996";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Tue, 25 Mar 2014 14:00:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:6:"Infuse";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:4:"RICO";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:52:"S.D. Ohio Blasts Med-Mal/Product Liability RICO Case";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:9060:"<div class="MsoNormal" style="margin: 0in 0in 0pt;"><span style="font-size: small;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;"><span style="font-size: large;">This post discusses an Infuse case and therefore, is from the non-Reed Smith side of the blog only. </span></span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">“Mother of mercy, is this the end of Rico?”&nbsp; Those are the <a href="https://www.youtube.com/watch?v=FEiOjH0v0oM">last words</a> uttered by the gangster in <i>Little Caesar</i>.&nbsp; That villain was played by Edward G. Robinson, who became well-known for playing tough-talking hoodlums, even though he was by all accounts a very sweet man.&nbsp; He showed up as a hero in a couple of films, such as <i>Double Indemnity</i> and <i>The Stranger</i>, but he will always be most remembered &nbsp;for his dastardly snarl.&nbsp; [Ah – who are we kidding?&nbsp; Today Edward G. Robinson’s voice is usually associated with the parody version mouthed by <a href="https://www.youtube.com/watch?v=tvcNCLZMKXA">Chief Wiggum</a> on <i>The Simpsons</i>.]&nbsp;&nbsp;</span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">Those same Rico-valedictory words often dance through the heads of wishful-thinking corporate defense attorneys as they pray for the demise of the much-abused RICO statute.&nbsp; A law ostensibly aimed at criminal enterprises has been tortured past any state of recognition, and is applied in all sorts of non-gangsterish contexts.&nbsp; Too many courts let this abuse go, but more and more do not.&nbsp; Recently, in <i>Aaron v. Abubakar Atiq Durrani, M.D., et al</i>., 2014 U.S. Dist. LEXIS 32693 (S.D. Ohio March 12, 2014), the court shot down an attempt to transform a garden variety med-mal and product liability case into a RICO case.&nbsp;&nbsp;</span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">The court was sorely irked by the plaintiffs' attorney, calling him out by name.&nbsp; What provoked this ire?&nbsp; To begin with, there is the matter of the form of the complaint.&nbsp; Or, rather, complaints.&nbsp; At least seven complaints were filed in these consolidated cases.&nbsp; A second amended complaint was erroneously labeled a first amended complaint.&nbsp; The court did not like any of this, not even a little:&nbsp;&nbsp;</span></span></div><div class="MsoNormal" style="margin: 0in 0in 0pt;"><blockquote class="tr_bq"><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">Despite having filed no fewer than seven complaints in these consolidated cases, Plaintiffs have never alleged facts supporting the existence of a plausible claim under RICO or Ohio RICO.&nbsp; Plaintiffs’ latest clumsy attempt to repackage medical malpractice and product liability claims is without any plausible basis, notwithstanding its prolixity.&nbsp;&nbsp;</span></span></blockquote><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;"><i>Id.</i> at *1.&nbsp;&nbsp;</span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">The complaint is “anything but a short and plain statement.”&nbsp; <i>Id.</i> at *9.&nbsp; &nbsp;That is one of the nicer things the court says about the plaintiff’s pleadings.&nbsp; The 159 page second amended complaint was “virtually incomprehensible,” containing “976 paragraphs of largely irrelevant factual summaries.”&nbsp; <i>Id.</i> at *10.&nbsp; The complaint also lumps the defendants together, thereby failing “to give the individual Defendants proper notice of what they have allegedly done wrong.”&nbsp; <i>Id.</i> at *11.&nbsp; Further, the plaintiffs’ attempt to incorporate its Exhibits A and B, one a criminal indictment and the other a Medtronic package insert, violates the Federal Rules of Civil procedure, “as to the former because it is a pleading in another case, and as to the latter because it is not an ‘instrument’ that can be attached pursuant to Civil Rule 10(b).”&nbsp; <i>Id.</i> at *14.&nbsp;&nbsp;&nbsp;</span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">The substantive deficiencies in the complaint were even more fundamental.&nbsp; The plaintiffs were seeking recovery in federal court under anti-racketeering laws for their own state law personal injury claims, a practice which the Sixth Circuit has expressly rejected because, “[s]imply stated, RICO is not a means for federalizing personal injury tort claims arising under state law.”&nbsp; <i>Id.</i> at *1.&nbsp; The court concluded that if it accepted the plaintiffs’ theory, “any hospital will have engaged in a pattern of racketeering activity when a credentialed physician of the hospital is accused of committing medical malpractice.&nbsp; This is nonsense.”&nbsp; <i>Id.</i>&nbsp;&nbsp;</span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">In any event, the plaintiffs failed to plead the most basic elements of a RICO claim, such as injury to one’s “business or property,” the existence of an “enterprise,” and specific frauds in furtherance of the enterprise.&nbsp; The plaintiffs alleged only personal injuries – which are not fair game under RICO</span><span style="font-family: Times,&quot;Times New Roman&quot;,serif;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;"> – </span>and “lost economic opportunities,” which are “mere expectancy interests” that cannot form the basis for damages under RICO.&nbsp; Plaintiffs never alleged the “time, place and content” of any claimed fraudulent communications by any defendant.&nbsp; Rather, the plaintiffs conclusorily alleged that “all named Defendants in this complaint knew” that wires and mails would be used “to further the scheme” and that the defendants used the mails and wires for their billing.&nbsp; Too vague.&nbsp; As for alleging an “enterprise,” the plaintiffs alleged nothing more than legal conclusions that the defendants constituted an enterprise, without any factual allegations of organization or coordinated behavior among the defendants, or that the organization was separate from the patterns of racketeering activity that the plaintiffs allege.&nbsp; And – no surprise here – the plaintiffs did not actually allege any “racketeering activity.” Instead, all that the plaintiffs alleged was that the defendant “hospitals, as a whole, conducted normal hospital activities such as allowing physicians to perform surgeries, ordering materials required by physicians for surgeries, and paying physician salaries.”&nbsp; <i>Id.</i> at *22. &nbsp;Remember how the court called the complaint “nonsense”?&nbsp; This is even more nonsense. &nbsp;Or, to draw inspiration from those <a href="https://www.youtube.com/watch?v=vXlST7il84I">double-talking Little Caesar pizza commercials</a>, “Nonsense nonsense.”&nbsp; &nbsp;&nbsp;&nbsp;</span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">Most noteworthy for DDL practitioners, the court held that any failure-to-warn claims alleged against the device company defendants were preempted under 21 U.S.C. §360(k)/<i>Riegel</i>.&nbsp; “Plaintiffs cannot avoid this preemption by recasting the failure to warn as a RICO claim.”&nbsp; <i>Id.</i> at *24.&nbsp; The FDA provides no private right of action, and what the FDCA did not create directly, even the crazily distorted RICO cannot create indirectly.&nbsp; (Plaintiff lawyers who try to invoke RICO in inappropriate fact scenarios remind us of another Edward G. Robinson bad guy, Johnny Rocco, who terrorizes people in a hotel in the great <i>Key Largo</i>.&nbsp; &nbsp;What does Rocco want out of life?&nbsp; “<a href="http://www.tcm.com/mediaroom/video/221312/Key-Largo-Movie-Clip-He-Wants-More.html">More</a>.”) </span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">The court did not want any more from this particular group of plaintiffs and their attorney.&nbsp; All of the plaintiffs’ claims against all named defendants were dismissed with prejudice, “as Plaintiffs have thoroughly demonstrated that any further leave to amend would be futile.”&nbsp; <i>Id.</i> at *26.&nbsp; Mother of mercy, that’s the end of this RICO case.&nbsp;</span></span><br /><br /><span style="font-size: large;"><span style="font-family: Times,&quot;Times New Roman&quot;,serif;">We offer a tip of the cyber cap to Frank Woodside of Dinsmore &amp; Shohl, who brought this case to our attention.&nbsp; </span></span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:92:"http://druganddevicelaw.blogspot.com/2014/03/sd-ohio-blasts-med-malproduct-liability_25.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Michelle Yeary)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-10T15:03:09.921-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:18;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-5528158993764982727";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Mon, 24 Mar 2014 13:34:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:14:"Medical Device";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:13:"Off-Label Use";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:87:"Preemption Applies Even Though the Device Was Cleared under §510(k) and Used Off-Label";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:43065:"<!--[if gte mso 9]><xml> <o:OfficeDocumentSettings>  <o:AllowPNG/> </o:OfficeDocumentSettings></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:EnableOpenTypeKerning/>   <w:DontFlipMirrorIndents/>   <w:OverrideTableStyleHps/>  </w:Compatibility>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="&#45;-"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"   DefSemiHidden="false" DefQFormat="false" DefPriority="99"   LatentStyleCount="371">  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 5"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 6"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 7"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 8"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index 9"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" Name="toc 9"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Normal Indent"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="footnote text"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="annotation text"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="header"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="footer"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="index heading"/>  <w:LsdException Locked="false" Priority="35" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="table of figures"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="envelope address"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="envelope return"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="footnote reference"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="annotation reference"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="line number"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="page number"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="endnote reference"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="endnote text"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="table of authorities"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="macro"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="toa heading"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Bullet"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Number"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List 5"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Bullet 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Bullet 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Bullet 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Bullet 5"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Number 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Number 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Number 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Number 5"/>  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Closing"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Signature"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="true"    UnhideWhenUsed="true" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text Indent"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Continue"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Continue 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Continue 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Continue 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="List Continue 5"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Message Header"/>  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Salutation"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Date"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text First Indent"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text First Indent 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Note Heading"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text Indent 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Body Text Indent 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Block Text"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Hyperlink"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="FollowedHyperlink"/>  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Document Map"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Plain Text"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="E-mail Signature"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Top of Form"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Bottom of Form"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Normal (Web)"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Acronym"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Address"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Cite"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Code"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Definition"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Keyboard"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Preformatted"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Sample"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Typewriter"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="HTML Variable"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Normal Table"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="annotation subject"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="No List"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Outline List 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Outline List 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Outline List 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Simple 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Simple 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Simple 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Classic 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Classic 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Classic 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Classic 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Colorful 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Colorful 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Colorful 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Columns 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Columns 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Columns 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Columns 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Columns 5"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 5"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 6"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 7"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Grid 8"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 4"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 5"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 6"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 7"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table List 8"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table 3D effects 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table 3D effects 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table 3D effects 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Contemporary"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Elegant"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Professional"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Subtle 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Subtle 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Web 1"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Web 2"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Web 3"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Balloon Text"/>  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"    Name="Table Theme"/>  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" QFormat="true"    Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" QFormat="true"    Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" QFormat="true"    Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" QFormat="true"    Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" QFormat="true"    Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" QFormat="true"    Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" SemiHidden="true"    UnhideWhenUsed="true" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" SemiHidden="true"    UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>  <w:LsdException Locked="false" Priority="46"    Name="Grid Table 1 Light Accent 1"/>  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>  <w:LsdException Locked="false" Priority="51"    Name="Grid Table 6 Colorful Accent 1"/>  <w:LsdException Locked="false" Priority="52"    Name="Grid Table 7 Colorful Accent 1"/>  <w:LsdException Locked="false" Priority="46"    Name="Grid Table 1 Light Accent 2"/>  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>  <w:LsdException Locked="false" Priority="51"    Name="Grid Table 6 Colorful Accent 2"/>  <w:LsdException Locked="false" Priority="52"    Name="Grid Table 7 Colorful Accent 2"/>  <w:LsdException Locked="false" Priority="46"    Name="Grid Table 1 Light Accent 3"/>  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>  <w:LsdException Locked="false" Priority="51"    Name="Grid Table 6 Colorful Accent 3"/>  <w:LsdException Locked="false" Priority="52"    Name="Grid Table 7 Colorful Accent 3"/>  <w:LsdException Locked="false" Priority="46"    Name="Grid Table 1 Light Accent 4"/>  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>  <w:LsdException Locked="false" Priority="51"    Name="Grid Table 6 Colorful Accent 4"/>  <w:LsdException Locked="false" Priority="52"    Name="Grid Table 7 Colorful Accent 4"/>  <w:LsdException Locked="false" Priority="46"    Name="Grid Table 1 Light Accent 5"/>  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>  <w:LsdException Locked="false" Priority="51"    Name="Grid Table 6 Colorful Accent 5"/>  <w:LsdException Locked="false" Priority="52"    Name="Grid Table 7 Colorful Accent 5"/>  <w:LsdException Locked="false" Priority="46"    Name="Grid Table 1 Light Accent 6"/>  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>  <w:LsdException Locked="false" Priority="51"    Name="Grid Table 6 Colorful Accent 6"/>  <w:LsdException Locked="false" Priority="52"    Name="Grid Table 7 Colorful Accent 6"/>  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>  <w:LsdException Locked="false" Priority="46"    Name="List Table 1 Light Accent 1"/>  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>  <w:LsdException Locked="false" Priority="51"    Name="List Table 6 Colorful Accent 1"/>  <w:LsdException Locked="false" Priority="52"    Name="List Table 7 Colorful Accent 1"/>  <w:LsdException Locked="false" Priority="46"    Name="List Table 1 Light Accent 2"/>  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>  <w:LsdException Locked="false" Priority="51"    Name="List Table 6 Colorful Accent 2"/>  <w:LsdException Locked="false" Priority="52"    Name="List Table 7 Colorful Accent 2"/>  <w:LsdException Locked="false" Priority="46"    Name="List Table 1 Light Accent 3"/>  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>  <w:LsdException Locked="false" Priority="51"    Name="List Table 6 Colorful Accent 3"/>  <w:LsdException Locked="false" Priority="52"    Name="List Table 7 Colorful Accent 3"/>  <w:LsdException Locked="false" Priority="46"    Name="List Table 1 Light Accent 4"/>  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>  <w:LsdException Locked="false" Priority="51"    Name="List Table 6 Colorful Accent 4"/>  <w:LsdException Locked="false" Priority="52"    Name="List Table 7 Colorful Accent 4"/>  <w:LsdException Locked="false" Priority="46"    Name="List Table 1 Light Accent 5"/>  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>  <w:LsdException Locked="false" Priority="51"    Name="List Table 6 Colorful Accent 5"/>  <w:LsdException Locked="false" Priority="52"    Name="List Table 7 Colorful Accent 5"/>  <w:LsdException Locked="false" Priority="46"    Name="List Table 1 Light Accent 6"/>  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>  <w:LsdException Locked="false" Priority="51"    Name="List Table 6 Colorful Accent 6"/>  <w:LsdException Locked="false" Priority="52"    Name="List Table 7 Colorful Accent 6"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin-top:0in;  mso-para-margin-right:0in;  mso-para-margin-bottom:8.0pt;  mso-para-margin-left:0in;  line-height:107%;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:"Calibri","sans-serif";  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;} </style><![endif]--> <br /><div class="MsoNormal">In <u>Bertini v. Smith &amp; Nephew, Inc.</u>, 2014 U.S. Dist. LEXIS 35837 (E .D.N.Y. March 17, 2014), the Eastern District of New York applied preemption to a device case that involved off-label use, even though the device didn’t receive FDA Pre-Market Approval (“PMA”) and wasn’t really used off-label.<span style="mso-spacerun: yes;">&nbsp; </span>Confusing?<span style="mso-spacerun: yes;">&nbsp; </span>Maybe.<span style="mso-spacerun: yes;">&nbsp; </span>But once untangled, it’s very, very good.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">The plaintiff had a total hip replacement.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *4.<span style="mso-spacerun: yes;">&nbsp; </span>His doctor implanted the Smith &amp; Nephew R3 System, which had received FDA §510(k) clearance.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> <span style="mso-spacerun: yes;">&nbsp;</span>The R3 System ultimately failed, and the plaintiff had revision surgery.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><span style="mso-spacerun: yes;">&nbsp;</span>The plaintiff and his wife then sued, claiming that the R3 device’s liner had loosened from the device’s acetabular shell.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><span style="mso-spacerun: yes;">&nbsp; </span>But §510(k) clearance of the R3 System does not trigger preemption.<span style="mso-spacerun: yes;">&nbsp; </span>Only PMA does.<span style="mso-spacerun: yes;">&nbsp; </span>So where does preemption enter the story?<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">Well, it enters through the approval of another Smith &amp; Nephew device: a hip resurfacing system.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> <span style="mso-spacerun: yes;">&nbsp;</span>Unlike the R3 System, the hip resurfacing system received PMA.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><span style="mso-spacerun: yes;">&nbsp;</span>More important, the liner from the R3 System also did – for use with the hip resurfacing system.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *3-4.<span style="mso-spacerun: yes;">&nbsp; </span>In other words, although the R3 System itself did not receive PMA, its liner later received PMA to be used with another system.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal" style="tab-stops: center 3.25in;">And that’s how preemption enters.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiffs’ claims targeted the R3 liner.<span style="mso-spacerun: yes;">&nbsp; </span>It had loosened.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiffs also pointed toward a locking mechanism that was intended to keep the liner in place inside the acetabular shell.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u> at *13.<span style="mso-spacerun: yes;">&nbsp; </span>While multiple parts of the R3 System are implicated in plaintiffs’ claims – the liner, the acetabular shell and the locking mechanism – the court determined that preemption was in play because the R3 liner, which had gone through the PMA process, was integral to each of those claims:</div><div class="MsoNormal" style="tab-stops: center 3.25in;"><br /></div><div class="MsoNormal" style="margin-left: .5in; tab-stops: center 3.25in;">[P]laintiffs would be unable to show that the R3 acetabular shell and its locking mechanism alone proximately caused plaintiffs’ injuries, because plaintiffs have plead that the R3 System and the R3 metal liner together were the cause of plaintiff’s injuries. <span style="mso-spacerun: yes;">&nbsp;</span>Plaintiffs would have to prove that the R3 acetabular shell did not stay attached to the R3 metal liner, without being able to argue, as they have repeatedly throughout this litigation, that this failure to attach was due in large part to the R3 metal liner improperly loosening from the R3 acetabular shell. <span style="mso-spacerun: yes;">&nbsp;</span><b style="mso-bidi-font-weight: normal;"><i style="mso-bidi-font-style: normal;">Therefore, if a claim involving the R3 metal liner’s alleged defect is preempted, the entire claim should be dismissed because plaintiffs will be unable to sufficiently plead the remainder of that claim.</i></b></div><div class="MsoNormal"><u>Id.</u> at *14 (emphasis added).</div><div class="MsoNormal"><br /></div><div class="MsoNormal">With that, plaintiffs’ design defect, warning, implied warranty, and negligence claims were preempted – not a bad result for a device that did not receive PMA.<span style="mso-spacerun: yes;">&nbsp; </span>The plaintiffs’ fraud claims were also dismissed for failure to plead sufficient facts.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">And how did off-label use play a role in this decision?<span style="mso-spacerun: yes;">&nbsp; </span>Well, the plaintiffs argued that preemption shouldn’t apply because the R3 liner received PMA only for the hip resurfacing system, not the R3 System implanted in plaintiff.<span style="mso-spacerun: yes;">&nbsp; </span>In other words, even though the R3 device had received §510(k) clearance, the liner’s use in the R3 System was off-label from the use for which it had received PMA. <span style="mso-spacerun: yes;">&nbsp;</span>But preemption doesn’t focus on use.<span style="mso-spacerun: yes;">&nbsp; </span>It focuses on whether the FDA approved and regulates the device.<span style="mso-spacerun: yes;">&nbsp; </span>More important, there’s simply nothing wrong with off-label use.<span style="mso-spacerun: yes;">&nbsp; </span>It’s necessary for the practice of medicine.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA recognizes that and knows it when it approves a device:</div><div class="MsoNormal"><br /></div><div class="MsoNormal" style="margin-left: .5in;">Plaintiffs stress that although the R3 metal liner was approved through the PMA process, it was only approved for use with the [hip resurfacing system], but defendant nonetheless marketed the R3 metal liner to be used with the R3 System. <span style="mso-spacerun: yes;">&nbsp;</span>However, preemption analysis is not concerned with how a particular device is used or whether there are federal requirements imposed on a particular use of the device. <span style="mso-spacerun: yes;">&nbsp;</span>Rather, preemption is focused on whether there are federal requirements applicable to the device itself. <span style="mso-spacerun: yes;">&nbsp;</span>Indeed, “‘off-label’ usage of medical devices (use of a device for some other purpose than that for which it has been approved by the FDA) is an accepted and necessary corollary of the FDA’s mission to regulate . . . without directly interfering with the practice of medicine,” <u>Buckman Co.</u>, 531 U.S. at 350, 121 S. Ct. at 1018; <u>see also United States v. Caronia</u>, 703 F.3d 149, 153 (2d Cir. 2012) (“Once FDA-approved, prescription drugs can be prescribed by doctors for both FDA-approved and - unapproved uses; the FDA generally does not regulate how physicians use approved drugs.”).<span style="mso-spacerun: yes;">&nbsp; </span>That the R3 metal liner was approved for use with the [hip resurfacing system] does not affect defendant’s preemption argument under the MDA, since the specific component at issue received PMA.</div><div class="MsoNormal" style="margin-left: .5in;"><br /></div><div class="MsoNormal"><u>Id.</u> at *17-18 (certain citations omitted).<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">So the court applied preemption to device claims that involved a device that hadn’t received PMA and off-label use that wasn’t all that off-label.<span style="mso-spacerun: yes;">&nbsp; </span>In more practical terms, the <u>Bertini</u>decision illustrates that claims can still be preempted, even if the device received only §510(k) clearance, so long as the alleged defect involves a part of the device that received PMA.<span style="mso-spacerun: yes;">&nbsp; </span>It’s also another opinion that forcefully states that off-label is appropriate and shouldn’t alter the preemption analysis.<span style="mso-spacerun: yes;">&nbsp; </span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:87:"http://druganddevicelaw.blogspot.com/2014/03/preemption-applies-even-though-device.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:38:"noreply@blogger.com (John J. Sullivan)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-24T09:34:44.711-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:19;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-2642303104110735901";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Fri, 21 Mar 2014 18:38:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:4:{i:0;a:5:{s:4:"data";s:8:"Arkansas";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:14:"Consumer Fraud";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:16:"False Claims Act";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:8:"Medicare";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:62:"Arkansas Supreme Court Delivers, But Can Others States Follow?";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:14060:"  <span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>We do this blog not just to tout good results, slam bad decisions, and relay our likes and dislikes on various subjects, but to provide information that can help drug and device manufacturer defendants get better results in the litigations they face.<span style="mso-spacerun: yes;">&nbsp; </span>We do not presume, except facetiously, that our posts really do move the needle much on how courts decide the issues we tend to highlight in our posts.<span style="mso-spacerun: yes;">&nbsp; </span>Courts pay attention to what other courts have done, though, so we like to do our part in passing on good decisions to use and ways to work around bad decisions.<span style="mso-spacerun: yes;">&nbsp; </span>When it comes to yesterday’s decision from the Arkansas Supreme Court in <i style="mso-bidi-font-style: normal;">Ortho-McNeil-Janssen Pharms., Inc.</i> <i style="mso-bidi-font-style: normal;">v. State</i>, 2014 Ark. 124 (Ark. 2014), <a href="http://opinions.aoc.arkansas.gov/WebLink8/0/doc/321287/Electronic.aspx" target="_blank">slip op.</a>, there is not much need for us to publicize the result.<span style="mso-spacerun: yes;">&nbsp; </span>A verdict for $1.2 billion going away will get some attention on its own.<span style="mso-spacerun: yes;">&nbsp; </span>We look at the decision, however, with an eye or two toward what it means for other cases. While the reversal is clearly the right result and spells the end of actions against drug and device companies based on the Arkansas Medicaid Fraud False Claims Act (“MFFCA”), the bases for the decision may be too sui generis (or “sooie” generis) to have as broad of implications as we had hoped.<o:p></o:p><br />  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The case started with “outside law firms and other states’ Attorney General offices” approaching the Arkansas AG about suing the manufacturers of second-generation antipsychotics, which had been the subject of FDA-mandated labeling changes and Dear Doctor Letters about the risk of hyperglycemia and diabetes back in 2003.<span style="mso-spacerun: yes;">&nbsp; </span>Slip. Op at 2-3 &amp; 7.<span style="mso-spacerun: yes;">&nbsp; </span>The letters that were sent out on Risperdal included language discussing how its risk of diabetes compared with the risk of diabetes with conventional psychotics and other atypical antipsychotics, which DDMAC deemed “false and misleading” in a Warning Letter it sent five months later.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at 3-4.<span style="mso-spacerun: yes;">&nbsp; </span>The Warning Letter led to a correction being sent out three months later, which DDMAC accepted as fully addressing the issue.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i> at 4-7.<span style="mso-spacerun: yes;">&nbsp; </span>Based on this basic fact pattern, the Arkansas AG sued Risperdal’s manufacturer under the theories that:<span style="mso-spacerun: yes;">&nbsp; </span>1) the MFFCA was violated by every Risperdal prescription filled in the State and submitted to Arkansas Medicaid for payment over a 43 month period when the drug’s labeling allegedly failed to comply with FDA’s prescription drug labeling requirements; and 2) the Arkansas Deceptive Trade Practices Act (“DTPA”) was violated by every copy of the first Dear Doctor Letter sent to a healthcare provider in the state.<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>at 7-8.<span style="mso-spacerun: yes;">&nbsp; </span>Based on the plaintiff verdict at trial, the results of a civil penalties hearing, and the denial of all the expected defense motions, the result was $1,194,370,000 on the first theory ($5000 times 238,874 prescriptions) and $11,422,500 on the second theory ($2500 times 4,569 letters).<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id</i>. at 8.<o:p></o:p></div><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The appeal challenged both theories, but according to the court’s opinion, did not raise some of the fundamental problems with them addressed in some of our prior posts on this sort of case.<span style="mso-spacerun: yes;">&nbsp; </span>Because the court reversed on the first argument it considered as to each theory, potentially broader issues were not resolved.<span style="mso-spacerun: yes;">&nbsp; </span>For instance, we would certainly question how a link between inadequate labeling, the writing/filling of prescriptions, and the submission of false claims could be <a href="http://druganddevicelaw.blogspot.com/2014/01/caldwell-reversal-satisfies.html" target="_blank">presumed</a>.<span style="mso-spacerun: yes;">&nbsp;</span><span style="mso-spacerun: yes;">&nbsp;</span>We would also wonder how a cause of action expressly based on a violation of the FDCA and an FDA regulation could escape preemption and how the mere sending of a letter, even if misleading in the abstract, could create liability without some proof that some relevant readers of the letter were misled by it.<span style="mso-spacerun: yes;">&nbsp; </span>Those questions were not answered in <i style="mso-bidi-font-style: normal;">O-M-J</i>.<o:p></o:p><br />  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The question that was answered as to the MFFCA was whether the trial court’s interpretation of it was “erroneous, overbroad, and untenable” in allowing it to be the basis of liability for claims for payment of a prescription drug with labeling allegedly in non-compliance with federal law.<span style="mso-spacerun: yes;">&nbsp; </span>In coming up with a resounding “hell yes” to that question, the court did something we do not think we have ever seen before:<span style="mso-spacerun: yes;">&nbsp; </span>it found the law had been miscodified by the Arkansas Code Revision Committee after it had been passed by the Arkansas General Assembly.<span style="mso-spacerun: yes;">&nbsp; <em>Id.</em> at 13-15.&nbsp; </span>Essentially, a subsection of the Act the legislature passed that was clearly about statements in connection with (re)certifying hospitals and other healthcare facilities was later broken up into two subsections, with the latter reading “information required pursuant to applicable federal and state law, rules, regulations, and provider agreements” without a mention of certification.<span style="mso-spacerun: yes;">&nbsp; </span>The State, represented by outside contingent fee counsel more interested in big bucks than in what Arkansas statutes really meant, sued under this subsection and claimed it could impose broad liability for claims for the cost of prescriptions of drugs with allegedly bad labeling.<span style="mso-spacerun: yes;">&nbsp; </span>Looking past the miscodification (and applying a strict construction in favor of the party to be penalized), the court interpreted the provision of the MFFCA under which the State had sued as <i style="mso-bidi-font-style: normal;">only</i>creating liability for false statements made in connection with (re)certification of hospitals and other healthcare facilities.<span style="mso-spacerun: yes;">&nbsp; <em>Id.</em> at 15-16.&nbsp; </span>In other words, this provision did not cover drugs or drug labeling at all.<o:p></o:p></div><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>We sometimes think of the state versions of the (federal) False Claims Act as being the same.<span style="mso-spacerun: yes;">&nbsp; </span>The False Claims Act is sometimes referred to as the Lincoln Law, because it was enacted during the Civil War to deal with contractors gouging the Union when it was busy with more important things.<span style="mso-spacerun: yes;">&nbsp; </span>Over the years, the False Claims Act has been used with regard to a range of claims for payment to the federal Government, not just the Medicare and Medicaid claims we have posted on before.<span style="mso-spacerun: yes;">&nbsp; </span>State versions of the False Claims Act do not all look the same and are not always addressed solely to preventing (and recouping for) Medicaid fraud.<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span>We do not know why the MFFCA—at least the part of it that the AG sued under here—was so focused on the part of the Medicaid world relating to certifying healthcare facilities, but it was.<span style="mso-spacerun: yes;">&nbsp; </span>So, the main part of the AG's case was never even conceivably tenable—it should have gone away on motion to dismiss—and $1,194,370,000 of the judgment for the State vanishes.<span style="mso-spacerun: yes;">&nbsp; </span>(With remand of the <a href="http://opinions.aoc.arkansas.gov/WebLink8/0/doc/321286/Electronic.aspx" target="_blank">companion case</a> on $480,000 attorney’s fees and costs, in light of the defendant’s win on appeal, the State may even end up in the hole.)<span style="mso-spacerun: yes;">&nbsp; </span>The result should mean that MFFCA suits against manufacturers are gone – the court did make sure the AG’s office could not do this again − but it is hard to project the highly specific nature of the decision outside of The Natural State.<span style="mso-spacerun: yes;">&nbsp; </span>By contrast, the decision in <i style="mso-bidi-font-style: normal;">Caldwell</i>has broader implications.<o:p></o:p><br />  <br /><div class="RSBodyText" style="margin: 0in 0in 12pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The decision on the DTPA claim also involved a rarity and may not affect similar cases in other states.<span style="mso-spacerun: yes;">&nbsp; </span>The reversal was based solely the finding that the trial court abused its discretion in admitting a single document, the DDMAC Warning letter.<span style="mso-spacerun: yes;">&nbsp; </span>The ASC held that letter was inadmissible hearsay because Arkansas’s version of the public records exception, unlike Fed. R. Evid. 803(8), expressly carves out “factual findings resulting from special investigation of a particular complaint, case, or incident” from the exception to hearsay.<span style="mso-spacerun: yes;">&nbsp; <em>Id.</em> at 19.&nbsp; </span>Thus, the inquiry under Ark. R. Evid. 803(8), which we think is fairly distinctive, was whether the DDMAC Warning Letter was the result of a “routine investigation” or “special investigation.”<span style="mso-spacerun: yes;">&nbsp; </span>As you would expect, the Warning Letter said it was because of the original Dear Doctor Letter, the AG’s expert (the pliable Laura Plunkett) testified that it was because of the original Dear Doctor Letter, and the close out letter from DDMAC said the Warning Letter was because of the original Dear Doctor Letter.<span style="mso-spacerun: yes;">&nbsp; </span>This was enough for a majority of the panel to conclude this was not sort of routine document that counts as an admissible public record under Arkansas law.<span style="mso-spacerun: yes;">&nbsp; <em>Id.</em> at 24-27.&nbsp; </span>It is easy to see that just about every DDMAC letter that criticizes Dear Doctor Letters or promotional materials would be inadmissible hearsay under this particular standard.<span style="mso-spacerun: yes;">&nbsp; </span>So the heart of the AG’s case was inadmissible.<o:p></o:p></div><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>As an additional ground for excluding the Warning Letter, the majority of the panel also concluded that it was unduly prejudicial (and admitted in an abuse of discretion).<span style="mso-spacerun: yes;">&nbsp; <em>Id</em>. at 26.&nbsp; </span>Part of its prejudice was because it was “referred to repeatedly throughout trial” and “was mentioned at least fifteen times” in closings.<span style="mso-spacerun: yes;">&nbsp; </span>In addition, “Reports issued by government agencies, because of their ‘official’ nature, may well carry inordinate weight in the minds of jurors.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Id.</i>(quoting <i style="mso-bidi-font-style: normal;">Boude v. Union Pac. R. Co.</i>, 277 P.3d 1221, 1225 (Mont. 2012)).<span style="mso-spacerun: yes;">&nbsp; </span>This analysis, while brief, can certainly apply beyond Arkansas.<span style="mso-spacerun: yes;">&nbsp; </span>It also gives a hint about what may happen next in this case.<span style="mso-spacerun: yes;">&nbsp; </span>The remaining $11,422,500 of the verdict was knocked out, but the DTPA claim (unlike the MFFCA claim) was not dismissed.<span style="mso-spacerun: yes;">&nbsp; </span>Maybe the AG (or rather those outside law firms who started the whole thing) will re-try the case without the key piece of evidence used in the first case.<span style="mso-spacerun: yes;">&nbsp; Then again, m</span>aybe the AG will look at the somewhat extraneous comments in the decision about the drug being “highly beneficial,” “a tremendous breakthrough,” and a “miracle drug”—the last is a quote from the State’s expert—as suggesting what the Arkansas Supreme Court might do if it tackles preemption or another <a href="http://druganddevicelaw.blogspot.com/2009/11/safe-harbor-in-arkansas.html" target="_blank">unresolved issue</a>&nbsp;on the DTPA claim down the road.<span class="msoIns"><ins cite="mailto:Alexander,%20Eric%20L." datetime="2014-03-21T14:04"><o:p></o:p></ins></span><br />  ";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:89:"http://druganddevicelaw.blogspot.com/2014/03/arkansas-supreme-court-delivers-but-can.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Eric Alexander)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-21T14:38:42.954-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:20;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-2124254062359322930";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Thu, 20 Mar 2014 15:04:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:3:{i:0;a:5:{s:4:"data";s:8:"Arkansas";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:14:"Consumer Fraud";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:8:"Medicare";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:77:"Breaking News -- Arkansas Supreme Court Reverses Ridiculous Risperdal Verdict";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:2180:"&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style="font-family: Calibri;">We are still trying to get our hands on the opinion [update - <a href="http://opinions.aoc.arkansas.gov/WebLink8/0/doc/321287/Electronic.aspx">here it is</a>], but we understand that the $1.2 billion verdict for the State of Arkansas over marketing of the antipsychotic drug Risperdal has been reversed.<span style="mso-spacerun: yes;">&nbsp; </span>We told you in our summary of the <a href="http://druganddevicelaw.blogspot.com/2013/12/2013s-greatest-hits-our-favorite.html" target="_blank">top cases of 2013</a> that we were following this appeal.<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span></span><span style="font-family: Calibri;"><span style="mso-spacerun: yes;">&nbsp;&nbsp; </span>Because we cannot yet quote from the Arkansas Supreme Court, we quote from an equally august group, ourselves.<span style="mso-spacerun: yes;">&nbsp; </span>In touting the reversal of a very similar <a href="http://druganddevicelaw.blogspot.com/2014/01/caldwell-reversal-satisfies.html" target="_blank">suit in Louisiana</a>&nbsp;</span><span style="font-family: Calibri;"><span style="mso-spacerun: yes;">&nbsp;</span>based on the criticisms we had made about the lower court decision, including basically presuming injury and causation from an allegedly misleading communication, we said "We hope that other courts will follow the lead of the Louisiana Supreme Court in requiring that plaintiffs prove the claims they assert.<span style="mso-spacerun: yes;">&nbsp; </span>Even statutes with avowed remedial purposes are not supposed to be mere vehicles for ringing up damages against deep pockets defendants.<span style="mso-spacerun: yes;">&nbsp; </span>We also hope that the state AGs who outsource their work to plaintiff lawyers, or other governmental lawyers who get in bed with plaintiff lawyers in the hopes of big settlements and verdicts, give a little more thought to the process going forward."<span style="mso-spacerun: yes;">&nbsp; </span>It looks like the Arkansas Supreme Court did its part.<span style="mso-spacerun: yes;">&nbsp; </span>Now for the state AGs to get the message.<o:p></o:p></span>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:86:"http://druganddevicelaw.blogspot.com/2014/03/breaking-news-arkansas-supreme-court.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Eric Alexander)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-21T08:22:04.882-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"1";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:21;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-8450032366568653882";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Thu, 20 Mar 2014 13:12:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:1:{i:0;a:5:{s:4:"data";s:17:"Country of Origin";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:38:"Ten Useful Points on Country of Origin";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:20628:"  This post is a little different.<span style="mso-spacerun: yes;">&nbsp; </span>For one thing it’s more or less a <a href="http://www.reedsmith.com/Country-of-Origin-Compliance-The-Top-10-Things-Pharmaceutical-Companies-Need-to-Know-02-06-2014/">rehash of a post</a>  by <a href="http://www.reedsmith.com/jeffrey_orenstein/">Jeff Orenstein</a>, one of Reed Smith’s regulatory enforcement types, on one of the firm’s “branded” blogs.<span style="mso-spacerun: yes;">&nbsp; </span>DDL by contrast, is notoriously unbranded, since we have bloggers from different law firms.<o:p></o:p><br />  <br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Still, when we heard Jeff give an oral presentation recently&nbsp;on his top ten list of “country of origin” issues for pharmaceutical products (a lot of which is also relevant to medical devices), we thought, first, “we didn’t know that,” and second, that if we didn’t, our readers might not know it either.<span style="mso-spacerun: yes;">&nbsp;&nbsp;A</span>s we listened to the presentation and learned about all the nasty problems that could befall a manufacturer that didn’t get these complicated&nbsp;“country of origin” (which we’re abbreviating “COO” from now on) rules right in its product information, we couldn’t help harking back to a phrase from our (or at least Bexis’) misspent youth – COO sounds like a “<a href="http://www.youtube.com/watch?v=vDkdVsN0keM">nexus of the crisis, and the origin of storms</a>.”<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">So we thought we’d pass along to our readers ten things that you ought to know (but may well not) about COO in the pharmaceutical context:<o:p></o:p></div><br /><div class="BodyTextContinued" style="margin: 0in 0in 0pt;"><b style="mso-bidi-font-weight: normal;">1.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>COO means different things to different federal agencies.</u><o:p></o:p></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">What the FDA requires drug labels to state about where a drug/device is manufactured isn’t going to help much with other federal agencies.<span style="mso-spacerun: yes;">&nbsp; </span>Except for prescription medical products produced essentially entirely in the United States, U.S. Customs and Border Protection (which we’ll call “Customs” for short) requires COO designations (technically referred to as “markings”).<span style="mso-spacerun: yes;">&nbsp; </span>For Customs purposes, a product’s COO isn’t what the FDA considers its place of manufacturer, but rather the country where all the various components (which may be a lot or a little) are “substantially transformed” into a new product.<span style="mso-spacerun: yes;">&nbsp; </span>What does that mean?<span style="mso-spacerun: yes;">&nbsp; Basically, </span>what comes out must have a different character and use from what went in. <span style="mso-spacerun: yes;">&nbsp;So, </span>a company might do a lot to a product, but if the aspect (for drugs, it’s called the “active pharmaceutical ingredient” or “API”) that creates the product’s medical benefit wasn’t changed, then the COO for Customs purposes remains the country from which that key aspect/API was imported. <span style="mso-spacerun: yes;">&nbsp;</span>Over-reliance on processing that doesn’t “substantially transform” APIs&nbsp;is the single most significant source of pharmaceutical COO mistakes.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">There’s more, the COO for Customs purpose can differ from the COO for purposes of selling the product to the government. <span style="mso-spacerun: yes;">&nbsp;</span>“Made in the USA” claims involve yet another standard. <span style="mso-spacerun: yes;">&nbsp;</span>Finally, selling the product abroad can require a COO certificate based on still other standards imposed by foreign governments.<span style="mso-spacerun: yes;">&nbsp; </span>This stuff is important.<span style="mso-spacerun: yes;">&nbsp; </span>Mess it up, and the fines can be pretty big (although, again they vary).<span style="mso-spacerun: yes;">&nbsp; </span>See below.<o:p></o:p></div><br /><div class="BodyTextContinued" style="margin: 0in 0in 0pt;"><b style="mso-bidi-font-weight: normal;">2.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>For Customs purposes the COO usually follows the source of clinical benefit/API.</u><o:p></o:p></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The “essence” of a drug (less clear with devices) for customs purposes is its API.<span style="mso-spacerun: yes;">&nbsp; </span>That ingredient may be imported in raw form, and undergo all sorts of costly processing before being suitable for human consumption, but if it still does the same thing (has the same biological effect) then all that processing doesn’t amount to a hill of beans from the Customs standpoint.<span style="mso-spacerun: yes;">&nbsp; </span>For processing to cause a “substantial transformation” means that the character of the active ingredient must actually change. <span style="mso-spacerun: yes;">&nbsp;</span>That’s about as much as we can say, since more detailed analysis is very fact-sensitive, and varies from product to product, so manufacturers need somebody who understands both the law and the specifics of the particular product’s manufacture.<o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">3.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>The more things change, the more they change; changing suppliers often changes the COO.</u><o:p></o:p></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Found a lower-cost supplier?<span style="mso-spacerun: yes;">&nbsp; </span>One better able to ship to your location?<span style="mso-spacerun: yes;">&nbsp; </span>Great, but remember to watch your COO.<span style="mso-spacerun: yes;">&nbsp; </span>If your new supplier is in a different country, and is supplying your active ingredient/API, the proper COO marking for the finished product probably changed too. <span style="mso-spacerun: yes;">&nbsp;</span>And God help you (or at least get legal help) if you buy the same API from multiple suppliers in different countries. <span style="mso-spacerun: yes;">&nbsp;</span>In that case, the proper COO for the product could vary from week to week, or from batch to batch – with all the attendant legal consequences of getting it wrong. <span style="mso-spacerun: yes;">&nbsp;</span>Customs doesn’t care about an importer’s logistics.<span style="mso-spacerun: yes;">&nbsp; </span>It requires each product, in the form it is shipped to the “ultimate purchaser,” to be marked with the proper COO.<o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">4.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>NAFTA has its own COO marking standard.</u><o:p></o:p></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">NAFTA – the North American Free Trade Agreement – has special COO marking rules for products originating in its member countries (United States, Canada and Mexico).<span style="mso-spacerun: yes;">&nbsp; </span>The “substantial transformation” test doesn’t apply.<span style="mso-spacerun: yes;">&nbsp; </span>NAFTA rules can be complex, but generally, where a product is manufactured from components originating in different countries, the COO will be a NAFTA country if all “foreign” (that is, non-NAFTA) materials used to make it have undergone processing that changed their tariff classification (another point where things can get complicated, but a change from a raw to a finished product usually does the trick). <span style="mso-spacerun: yes;">&nbsp;</span>For example, if the active ingredient/API is a German raw material, but it’s processed into a finished product in Mexico, then the NAFTA COO will most likely be Mexico, assuming other applicable requirements are met. <o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">5.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>Products with the wrong COOs are subject to high penalties.<o:p></o:p></u></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Customs can penalize a manufacturer that marked its products with the wrong COO with extra duties of 10% percent of the appraised value of the finished products – not the raw material that caused the error. <span style="mso-spacerun: yes;">&nbsp;</span>Customs can go back and audit products for five years.<span style="mso-spacerun: yes;">&nbsp; </span>And these penalties, unlike most other Customs violations, aren’t waivable.<span style="mso-spacerun: yes;">&nbsp; </span>Fessing up and filing a “prior disclosure” (that is, before getting caught) of the violation with Customs doesn’t help. <span style="mso-spacerun: yes;">&nbsp;</span>The only way to avoid these big fines is to get the COO right in the first place.<span style="mso-spacerun: yes;">&nbsp; </span>You only get one chance – it better be right.<o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">6.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>An FDA manufacturing place of business most likely isn’t a product’s COO.<o:p></o:p></u></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">It’s rare that you hear on this blog that what the FDA wants doesn’t matter.<span style="mso-spacerun: yes;">&nbsp; </span>This is one of those times.<span style="mso-spacerun: yes;">&nbsp; </span>Yes, the FDA requires the “conspicuous” inclusion of the “place of business of the manufacturer, packer, or distributor.” <span style="mso-spacerun: yes;">&nbsp;</span>Customs, like the <a href="http://www.liveleak.com/view?i=6f7_1305082486">honey badger</a>,&nbsp;doesn’t care.<span style="mso-spacerun: yes;">&nbsp; </span>What suffices for FDA purposes may or may not be the same country as the COO required by Customs. <span style="mso-spacerun: yes;">&nbsp;</span>An FDA “manufacturer” is a person performing “mixing, granulating, milling, molding, lyophilizing (look it up yourself if you don’t know), tableting, encapsulating, coating, sterilizing,” or certain other things. <span style="mso-spacerun: yes;">&nbsp;</span>A drug molded into tablets in the United States carries an FDA principal place of business in the US.<span style="mso-spacerun: yes;">&nbsp; </span>But if the API is imported (from a non-NAFTA country), then the “substantial transformation” test applies.<span style="mso-spacerun: yes;">&nbsp; </span>Tableting doesn’t usually change what the active ingredient does, so the Customs COO remains wherever the active ingredient was imported from.<span style="mso-spacerun: yes;">&nbsp; </span>Make sure to keep the two separate and distinct.<span style="mso-spacerun: yes;">&nbsp; </span>Use of the Customs COO in place of the FDA principal place of business might make the product “misbranded” under the FDCA.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA can levy fines and seize the product, too.<o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">7.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>Still other COO standards come into play when a drug or device is sold to the U.S. government.<o:p></o:p></u></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">We’re not done yet.<span style="mso-spacerun: yes;">&nbsp; </span>The United States government buys lots of prescription medical products, and something called the “Trade Agreements Act (‘TAA’)” requires all goods sold to the government have been made in the United States or in certain designated countries.<span style="mso-spacerun: yes;">&nbsp; </span>The TAA follows Customs’ “substantial transformation” test but beware; big players such as China and India aren’t “designated.”<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">There’s still another distinction.<span style="mso-spacerun: yes;">&nbsp; </span>The “substantial transformation” test – for government procurement purposes – only applies to supply contracts for product purchases exceeding $202,000 (strange number, but that’s the law). <span style="mso-spacerun: yes;">&nbsp;</span>Under $202,000, and the procurement contract is instead subject to the Buy American Act (“BAA”).<span style="mso-spacerun: yes;">&nbsp; </span>The BAA has yet a different COO standard.<span style="mso-spacerun: yes;">&nbsp; </span>It gives preference to “domestic” products, which means goods both: <span style="mso-spacerun: yes;">&nbsp;</span>(1) manufactured in the United States and (2) consisting of components, 50% or more (by cost) of which are also are manufactured in the United States.<o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">8.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>Non-compliance with TAA/BAA in government procurement also has severe consequences.<o:p></o:p></u></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Ever heard of the <a href="http://druganddevicelaw.blogspot.com/search/label/False%20Claims%20Act">False Claims Act</a>?<span style="mso-spacerun: yes;">&nbsp; </span>A prescription medical product manufacturer/seller supplying the federal government with products falsely identified as TAA/BAA-compliant can be sued under the FCA.<span style="mso-spacerun: yes;">&nbsp; </span>In addition, it can lose its contract and, if things really go south, be subject to suspension, debarment, and/or criminal penalties. <o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">9.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>“Made in USA” should be handled with care.</u><o:p></o:p></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Even if the correct COO of a product under the Customs’ tough&nbsp;“substantial transformation” test is the United States, be careful.<span style="mso-spacerun: yes;">&nbsp; </span>Manufacturers may understandably be eager to emphasize a product’s U.S. origin on the packaging or in marketing materials. <span style="mso-spacerun: yes;">&nbsp;</span>An even higher standard applies for “Made in the USA” claims (and equivalent statements). <span style="mso-spacerun: yes;">&nbsp;</span>These are governed by consumer protection laws administered by the FTC, and state attorneys general.<span style="mso-spacerun: yes;">&nbsp; </span>Only manufacturers of products “all or virtually all” made in the United States may legally represent those products as U.S.-made. <span style="mso-spacerun: yes;">&nbsp;</span>Customs only requires a COO when the product is foreign-made under its “substantial transformation” test. <span style="mso-spacerun: yes;">&nbsp;</span>The COO of a United States-origin (for Customs purposes) product can be left blank.<span style="mso-spacerun: yes;">&nbsp; </span>For prescription medical products that, while substantially transformed in the United States, aren’t “all or virtually all” U.S.-made, it’s probably best to do that – leave it blank.<span style="mso-spacerun: yes;">&nbsp; </span>Just as Customs doesn’t care about FDA standards, the FTC and state enforcement officers don’t care about Customs standards.<o:p></o:p></div><br /><div class="BodyTextContinued" style="line-height: normal; margin: 0in 0in 12pt 0.5in; text-indent: -0.5in;"><b style="mso-bidi-font-weight: normal;">10.<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><u>Exports of prescription medical products require COO statements meeting the relevant foreign trading partner’s standards.<o:p></o:p></u></b></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Exports (as opposed to imports) of prescription medical products also require compliance with the COO standards of the countries to which the products are being exported.<span style="mso-spacerun: yes;">&nbsp; </span>Foreign importers and customs authorities frequently demand their own “certificates of origin” − usually to establish eligibility for preferential tariffs under a particular free trade agreement <span style="mso-spacerun: yes;">&nbsp;</span>with the United States.<span style="mso-spacerun: yes;">&nbsp; </span>Here, exporters are at the mercy of each country’s divergent COO requirements.<span style="mso-spacerun: yes;">&nbsp; </span>Each free trade agreement is different.<span style="mso-spacerun: yes;">&nbsp; </span>Different standards for various categories of products have been negotiated by the signatory countries. <span style="mso-spacerun: yes;">&nbsp;</span>Even if there’s no free trade agreement at all, the country of export may still impose its own COO standard for some other reason. <span style="mso-spacerun: yes;">&nbsp;</span>The most common (but by no means universal) standard for many countries is that they accept COOs for the “United States” if at least 50 percent of the product’s production costs originate in the United States. <o:p></o:p></div><br /><div class="Centered" style="margin: 0in 0in 12pt; text-align: center;"><strong>*<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>*<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>*<span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>*<o:p></o:p></strong></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Companies making prescription medical products are especially vulnerable to COO errors for several reasons. <span style="mso-spacerun: yes;">&nbsp;</span>First, they are typically subject to all these different (FDA, Customs, NAFTA, government procurement, and export) regulatory regimes.<span style="mso-spacerun: yes;">&nbsp; </span>Applicability of multiple, divergent standards greatly increases the risk of error. <span style="mso-spacerun: yes;">&nbsp;</span>Second, prescription medical product (and particularly pharmaceutical) manufacturers often get their active ingredients/APIs from multiple sources in different countries, and switch suppliers of such ingredients frequently.<span style="mso-spacerun: yes;">&nbsp; </span>That makes the proper COO (particularly for Customs purposes) something of a moving target. <span style="mso-spacerun: yes;">&nbsp;</span>It is essential that such companies update their COO determinations constantly, to make sure that their current determinations correctly reflect supply chain changes and that labeling, packaging, and marketing materials are up to date. <span style="mso-spacerun: yes;">&nbsp;</span>Third, and finally, compliance programs must be sufficiently robust to ensure the appropriate standards are applied, are applied correctly, and are updated in timely, ongoing fashion to account for supply chain changes.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:88:"http://druganddevicelaw.blogspot.com/2014/03/ten-useful-points-on-country-of-origin.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-20T09:12:23.078-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:22;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-8191963115980224865";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Wed, 19 Mar 2014 20:19:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:4:{i:0;a:5:{s:4:"data";s:13:"Design Defect";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:18:"Implied Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:9:"Wisconsin";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:27:"Nice Try, But No Brass Ring";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:18048:"Ever since <u>Mutual Pharmaceutical Co. v. Bartlett</u>, 133 S. Ct. 2466 (2013), was decided, <a href="http://druganddevicelaw.blogspot.com/2013/06/bartlett-big-win-for-preemption.html">we’ve</a>  <a href="http://druganddevicelaw.blogspot.com/2013/07/major-drug-labeling-changes-that.html">pointed</a>  <a href="http://druganddevicelaw.blogspot.com/2013/09/more-on-arediazometa-innovator-drug.html">out</a>  <a href="http://druganddevicelaw.blogspot.com/2013/12/the-fda-preemption-and-warnings-about.html">at</a> <a href="http://druganddevicelaw.blogspot.com/2014/01/lance-if-this-is-negligence-who-needs.html">every</a> <a href="http://druganddevicelaw.blogspot.com/2014/02/mensing-its-not-just-about-generics.html">opportunity</a> that its basic principle – that an immediate state-law “duty” is incompatible with an FDA pre-approval requirement, and therefore subject to impossibility preemption – should apply to any FDA (and probably other government agency) pre-approval requirement for any product, not just generic drugs.<o:p></o:p><br /><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">We’ve highlighted some success, <u>see</u> <u>Thompson v. Allergan USA, Inc.</u>, ___ F. Supp.2d ___, 2014 WL 308794 (E.D. Mo. Jan. 28, 2014) (non-generic dosage claim preempted); <u>Guenther v. Novartis Pharmaceutical Corp.</u>, 2013 WL 4648449 (M.D. Fla. Aug. 29, 2013) (non-generic black box, dosage, comparative labeling claims either preempted or probably preempted), but we hadn’t seen any case actually taking on a design defect claim in the non-generic context.<span style="mso-spacerun: yes;">&nbsp; </span>Now we have.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> <u>Cassel v. ALZA Corp.</u>, 2014 WL 856023 (W.D. Wis. March 5, 2014).<span style="mso-spacerun: yes;">&nbsp; </span>While <u>Cassel</u> contains some hopeful signs, the bottom line was not good – preemption motion denied.<span style="mso-spacerun: yes;">&nbsp; </span>However, in order to avoid preemption, <u>Cassel</u> was forced to contort state law in novel ways that we don’t think most courts would countenance.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;"><u>Cassel</u>involved a peculiar sort of non-generic drug – at least that’s what we glean from the opinion – a fentanyl analgesic patch.<span style="mso-spacerun: yes;">&nbsp; </span>Such a product has some of the characteristics of a drug, in that there’s fentanyl in it, and that’s a substance that meets the observation in <u>Bartlett</u> that “as a matter of “basic chemistry,” “because of [the drug’s] simple composition, [it] is chemically incapable of being redesigned.”<span style="mso-spacerun: yes;">&nbsp; </span>133 S. Ct. at 2475.<span style="mso-spacerun: yes;">&nbsp; </span>On the other hand, the product’s mode of administration, being a patch, is capable of being redesigned, and in fact had been.<span style="mso-spacerun: yes;">&nbsp; </span><u>See</u> <u>Cassel</u>, 2013 WL 4648449, at *1 (discussing 2009 design change).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">Indeed, the plaintiffs in <u>Cassel</u> targeted this FDA-approved design change as creating a “defect” in the patch by eliminating a separate “rate-control membrane,” which they claim led to a fatal overdose.<span style="mso-spacerun: yes;">&nbsp; </span><u>Id.</u><span style="mso-spacerun: yes;">&nbsp; </span>The defendant manufacturer sought summary judgment against this design defect claim under <u>Bartlett</u>/<u>Mensing</u>/<u>Levine</u> impossibility preemption, asserting the claim was barred due to the requirement of FDA approval for any change in design.<span style="mso-spacerun: yes;">&nbsp; </span>2013 WL 4648449, at *2.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt; tab-stops: right 6.5in;">The first thing <u>Cassel</u>did to wiggle out of preemption was create a never-before-seen three-part test that provided an escape route from “impossibility” preemption as found in <u>Bartlett</u>and <u>Mensing</u> leading back into the nearly-impossible-to-satisfy <u>Levine</u>“clear evidence” of FDA rejection standard:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">First, the court must <b style="mso-bidi-font-weight: normal;"><u>identify the steps</u></b> a defendant should have taken to avoid liability under state tort law. <span style="mso-spacerun: yes;">&nbsp;</span>Next, the court must determine as a matter of law whether federal law <b style="mso-bidi-font-weight: normal;"><u>expressly prohibited</u></b> the defendant from taking these steps. <span style="mso-spacerun: yes;">&nbsp;</span>If the answer to this second question is ‘No,’ the court must determine whether the defendant has presented ‘<b style="mso-bidi-font-weight: normal;"><u>clear evidence</u></b>’ that the regulatory agency would have stepped in and exercised its discretionary authority to prohibit the defendant from taking the necessary steps under state law.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">2013 WL 4648449, at *3 (emphasis added).<span style="mso-spacerun: yes;">&nbsp; </span>In other words, when uncomfortable with what the Supreme Court decided, make up something new.&nbsp; Under this new test, the objective, from an anti-preemption standpoint, is to ensure that the answer to the second question is “no.”&nbsp; That’s precisely where <u>Cassel</u> went, although it had to chart a most unusual course to get there.</div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">The “identification” prong of the test is where things get really interesting.<span style="mso-spacerun: yes;">&nbsp; </span>Remember, we’re supposedly dealing with a state-law (here, Wisconsin) product liability claim.<span style="mso-spacerun: yes;">&nbsp; </span>So what is the “step“ that the defendant manufacturer was supposedly under a state-law duty to take?<span style="mso-spacerun: yes;">&nbsp; </span>Something else we’ve never seen before:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">plaintiffs were alleging a duty to design the patches differently <b style="mso-bidi-font-weight: normal;"><u>before FDA approval</u></b>(rather than to change the design after the fact)<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> (emphasis added).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">“Before FDA approval”?<span style="mso-spacerun: yes;">&nbsp; </span>Essentially <u>Cassel</u> is admitting that the defendant (and your DDL bloggers) are right about preemption of any claim involving a post-FDA-approval design change.<span style="mso-spacerun: yes;">&nbsp; </span>Such changes <strong><u>after</u></strong> a product is on the market would require FDA-pre-approval and thus would be preempted.<span style="mso-spacerun: yes;">&nbsp; T</span>he response in&nbsp;<u>Cassel</u> to avoid preemption was to read such allegations out of state law.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Not so fast.</div><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">&nbsp;</div><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Wisconsin is no different from most states in that its product liability law determines defect at the <strong><u>time of sale</u></strong>, or alternatively when the product left the manufacturer’s hands.<span style="mso-spacerun: yes;">&nbsp; </span>“[T]he plaintiff must prove (1) that the product was in defective condition when it left the possession or control of the seller.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Shawver v. Roberts Corp.</u>, 280 N.W.2d 226, 231 (Wis. 1979) (quoting <u>Dippel v. Sciano</u>, 155 N.W.2d 55, 63 (1967)).<span style="mso-spacerun: yes;">&nbsp; </span>Yeah, we <a href="http://druganddevicelaw.blogspot.com/2011/02/cheeseheads-enact-sweeping-tort-reform.html">know</a>  that Wisconsin recently enacted tort reform, but we don’t think that the statute changed something so fundamental as the defect-at-sale requirement, and there’s certainly no suggestion of any such change in <u>Cassel</u>.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Our principal response to this purported “duty“ is that it simply does not exist under any state’s product liability common law that we know of.<span style="mso-spacerun: yes;">&nbsp; </span>We are unaware of state having  a “defect” standard that evaluates the product’s condition&nbsp;at any point <strong><u>before</u></strong> it was sold to the particular plaintiff.<span style="mso-spacerun: yes;">&nbsp; </span>Indeed, the Third Restatement categorizes all the usual product liability claims as involving “defects at time of sale.”<span style="mso-spacerun: yes;">&nbsp; </span>Restatement (Third) of Torts, Products Liability, Chapter 1.<span style="mso-spacerun: yes;">&nbsp; That’s how fundamental the defect at sale element of product liability is.&nbsp; </span>The only other claims that the Restatement recognizes (in Chapter 2) are those based on:&nbsp; (1) &nbsp;misrepresentation (which is not defect-based), (2)&nbsp;post-sale duty to warn (which, involving matters occurring after sale, would not help a plaintiff on any <u>Bartlett</u>/<u>Mensing</u>/<u>Levine</u> preemption issue), and (3) duty to recall (which the Restatement rejects in the absence of prior government action).&nbsp; There’s no such thing as a pre-sale design defect claim under state law.</div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Our secondary response is:&nbsp; What is a “duty to design [a product] differently before FDA approval,” anyway?<span style="mso-spacerun: yes;">&nbsp; </span>First of all, it’s a direct attack on FDA approval.<span style="mso-spacerun: yes;">&nbsp; </span>The FDA approved this product.<span style="mso-spacerun: yes;">&nbsp; </span>The Agency found the design submitted to it safe and effective.<span style="mso-spacerun: yes;">&nbsp; </span>What is the basis of the state law duty?<span style="mso-spacerun: yes;">&nbsp; </span><u>Cassel</u> is a product liability case, so the “duty” involved has to pertain to the safety of the defendant’s design.<span style="mso-spacerun: yes;">&nbsp; </span>Thus, the purported state law “duty” is a claim that, because the design wasn’t safe enough under Wisconsin common-law standards, the defendant should not have submitted it to the FDA, even though the FDA determined that it fully satisfied federal standards for “safety and effectiveness.”  <span style="mso-spacerun: yes;">&nbsp;</span>That’s no more, and no less, than a state-law&nbsp;attack on the FDA’s approval – and is therefore an independently preempted claim.<span style="mso-spacerun: yes;">&nbsp; </span>A state simply cannot interfere that deeply in the interactions between a regulated party and the regulating agency.<span style="mso-spacerun: yes;">&nbsp; </span>That’s one of the things <u>Buckman Co. v. Plaintiffs Legal Committee</u>, 531 U.S. 341 (2001), was about.<span style="mso-spacerun: yes;">&nbsp; </span>States have no authority over what an FDA-regulated manufacturer submits (or does not submit) to the FDA.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">Moreover, the theory of liability in <u>Cassel</u>, “that defendants had a duty to employ an alternative design .&nbsp;.&nbsp;. before FDA approval,” 2013 WL 4648449, at *5, is just the unsuccessful <u>Bartlett</u>stop-selling argument all over again using different words.<span style="mso-spacerun: yes;">&nbsp; </span>The Supreme stated in <u>Bartlett</u> that “our pre-emption cases presume that a manufacturer’s ability to stop selling does not turn impossibility into possibility.”<span style="mso-spacerun: yes;">&nbsp; </span><u>Mutual Pharmaceutical Co. v. Bartlett</u>, 133 S. Ct. 2466, 2477 n.3 (2013).<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">We reject this “stop-selling” rationale as incompatible with our pre-emption jurisprudence .&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>[A]n actor seeking to satisfy both his federal- and state-law obligations is not required to cease acting altogether in order to avoid liability. Indeed, if the option of ceasing to act defeated a claim of impossibility, impossibility pre-emption would be all but meaningless.&nbsp;.&nbsp;.&nbsp;.<span style="mso-spacerun: yes;">&nbsp; </span>In every instance in which the Court has found impossibility pre-emption, the direct conflict between federal- and state-law duties could easily have been avoided if the regulated actor had simply ceased acting.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;"><u>Id.</u> at 2477 (citations omitted).<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">What, then, at this point – or at the time of sale, when product liability traditionally judges defectiveness −<span style="mso-spacerun: yes;">&nbsp;</span>can/could the defendants do to avoid state-law liability under the novel theory of liability articulated in <u>Cassel</u>?<span style="mso-spacerun: yes;">&nbsp; </span>The only thing they can do is to stop selling their FDA-approved product.<span style="mso-spacerun: yes;">&nbsp; </span>They can’t take a time machine back to before FDA approval and somehow change what the FDA approved, so their only recourse to avoid liability is the very same stop selling alternative that the Supreme Court held was preempted in <u>Bartlett</u>.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">So it looks like the court was bamboozled in <u>Cassel</u>.<span style="mso-spacerun: yes;">&nbsp; </span>First, the theory that the plaintiffs purported to pursue doesn’t exist under any state’s law, since states have never sat in judgment on federal approvals, but rather on defects at the time of sale.<span style="mso-spacerun: yes;">&nbsp; </span>Second, even if such a theory could exist under state law, it’s preempted because it’s nothing more than old wine in a new bottle&nbsp;−<span style="mso-spacerun: yes;"> </span>the already-rejected demand that the defendant stop selling an FDA-approved product stated in a different way.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">And what of the final complaint in <u>Cassel</u>?<span style="mso-spacerun: yes;">&nbsp; </span>The end of the opinion states:<o:p></o:p></div><br /><div class="BlockTextWide" style="margin: 0in 0.5in 12pt;">Since defendants would find preemption wherever a manufacturer needs to ask for FDA approval before marketing, and since all new drugs require FDA approval before marketing, no drug manufacturer could ever be liable for a defectively designed product under defendants’ interpretation of the doctrine.<o:p></o:p></div><br /><div class="BodyTextUndent1" style="margin: 0in 0in 0pt;">2013 WL 4648449, at *5.<span style="mso-spacerun: yes;">&nbsp; </span>That’s 100% correct.<span style="mso-spacerun: yes;">&nbsp; </span>That is precisely what the Supreme Court held in <u>Levine</u>, when it decided to use congressional silence as an unprecedented statement of affirmative congressional purpose in order to eliminate the possibility of preemption under the more nuanced analysis of purposes and objectives preemption, and then disposed of impossiblity preemption under a bright-line rule that anything not requiring prior FDA approval can’t be impossible.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">As shown by <u>Mensing</u> and <u>Bartlett</u>, what’s sauce for the goose is sauce for the gander.<span style="mso-spacerun: yes;">&nbsp; </span>The converse is also true.<span style="mso-spacerun: yes;">&nbsp; </span>An FDA pre-approval requirement renders simultaneous compliance with an immediate state tort duty impossible.<span style="mso-spacerun: yes;">&nbsp; </span>All design changes to FDA-regulated products that could alter such products’ safety and effectiveness require FDA pre-approval and are therefore preempted under the test that originated in <u>Levine</u>.<span style="mso-spacerun: yes;">&nbsp; </span>Indeed, <u>Cassel</u> doesn’t – and couldn’t − deny this.<span style="mso-spacerun: yes;">&nbsp; </span>If it had, the plaintiffs wouldn’t have been running&nbsp;away full-tilt from traditional state “defect at sale”-based product liability law.<o:p></o:p></div><br /><div class="BodyText2Justified" style="margin: 0in 0in 0pt;">There’s really no way around this FDA-pre-approval requirement.<span style="mso-spacerun: yes;">&nbsp; </span>Something’s either impossible or it’s not, and the Supreme Court has said (three times) that pre-approval is, since the defendant loses its ability to take independent action.<span style="mso-spacerun: yes;">&nbsp; </span>Nuances are for “purposes and objectives” preemption, but <u>Levine</u> took that out of the mix.<span style="mso-spacerun: yes;">&nbsp; </span>As the novel “duty” asserted in <u>Cassel</u> demonstrates, any design-related claim that doesn’t involve a post-approval change is just some slightly more convoluted way of saying “stop selling” the FDA-approved product altogether.<span style="mso-spacerun: yes;">&nbsp; </span>Once a plaintiff takes the position that the design as submitted to the FDA was somehow “defective,” then the outcome is necessarily functionally indistinguishable from the “stop selling” theory disposed of in <u>Bartlett</u>.</div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:76:"http://druganddevicelaw.blogspot.com/2014/03/nice-try-but-no-brass-ring.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:27:"noreply@blogger.com (Bexis)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-19T16:24:17.231-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:23;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-7302166740774832651";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Tue, 18 Mar 2014 16:18:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:4:{i:0;a:5:{s:4:"data";s:10:"California";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:6:"Infuse";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:13:"Off-Label Use";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:99:"We’re in California for an Infuse Case, and Yada Yada Yada, The Court Rejects Rodriguez and Alton";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:36850:"<!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:DontVertAlignCellWithSp/>   <w:DontBreakConstrainedForcedTables/>   <w:DontVertAlignInTxbx/>   <w:Word11KerningPairs/>   <w:CachedColBalance/>  </w:Compatibility>  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="--"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]-->This post is from the non-Reed Smith side of the blog.<br /><!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:DontVertAlignCellWithSp/>   <w:DontBreakConstrainedForcedTables/>   <w:DontVertAlignInTxbx/>   <w:Word11KerningPairs/>   <w:CachedColBalance/>  </w:Compatibility>  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="--"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:DontVertAlignCellWithSp/>   <w:DontBreakConstrainedForcedTables/>   <w:DontVertAlignInTxbx/>   <w:Word11KerningPairs/>   <w:CachedColBalance/>  </w:Compatibility>  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="--"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267">  <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>  <w:LsdException Locked="false" Priority="0" Name="footer"/>  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" Priority="0" Name="Block Text"/>  <w:LsdException Locked="false" Priority="0" Name="Hyperlink"/>  <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-qformat:yes;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin:0in;  mso-para-margin-bottom:.0001pt;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:"Calibri","sans-serif";  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-fareast-font-family:"Times New Roman";  mso-fareast-theme-font:minor-fareast;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:"Times New Roman";  mso-bidi-theme-font:minor-bidi;} </style><![endif]--> <br /><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Have you ever told someone, “I’ll put it in the vault” or “not that there’s anything wrong with that”?<span style="mso-spacerun: yes;">&nbsp; </span>Or yelled “Serenity Now!” in a chaotic situation.<span style="mso-spacerun: yes;">&nbsp; </span>How about offered someone a “<a href="http://www.youtube.com/watch?v=KinXzRCjY4A" target="_blank">you are so good looking</a>” after a sneeze?<span style="mso-spacerun: yes;">&nbsp; </span>If not, you probably still know who we mean by Jerry, Elaine, George and Kramer.<span style="mso-spacerun: yes;">&nbsp; </span>But, if you did answer yes to anyone of those questions, you probably also know Newman, Frank and Estelle, Tim Whatley, Mr. Pitt, Puddy, Jackie Chiles, Crazy Joe Davola, and Uncle Leo with no further introduction.</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>It’s been off the air for 15 years, but <i style="mso-bidi-font-style: normal;">Seinfeld</i> left such an indelible mark on pop culture that certain phrases and quotes bring us right back to the mid-1990s:<span style="mso-spacerun: yes;">&nbsp; </span><a href="http://www.youtube.com/watch?v=YJyGJQx2Fgk" target="_blank">Soup Nazi</a>, The Human Fund, shrinkage, <a href="http://www.youtube.com/watch?v=lxGRE2wpjsY" target="_blank">stopping short</a>.<span style="mso-spacerun: yes;">&nbsp; </span>We all became much more familiar with the babka and the marble rye.<span style="mso-spacerun: yes;">&nbsp; </span>And, after seeing them on the show, we knew we had met one of these people in real life:<span style="mso-spacerun: yes;">&nbsp; </span>the close talker, the high talker, the low talker, the <a href="http://www.youtube.com/watch?v=6VGbY6sirHM#t=43" target="_blank">re-gifter</a>, and the <a href="http://www.youtube.com/watch?v=YWuSi00CcNk" target="_blank">double-dipper</a>.<span style="mso-spacerun: yes;">&nbsp; </span>Thanks to <i style="mso-bidi-font-style: normal;">Seinfeld</i> we know about <a href="http://www.youtube.com/watch?v=ythrdCsOFJU" target="_blank">anti-dentites</a>, that soup isn’t really a meal, and that “schmoopie” married George Stephanopoulis.<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>And when it comes to skimming over part of a story, nothing is as effective as “<a href="http://www.youtube.com/watch?v=O6kRqnfsBEc" target="_blank">yada yada yada.</a>”<span style="mso-spacerun: yes;">&nbsp; </span><span style="mso-spacerun: yes;"></span>Of all the famous Seinfeldisms, t</span><span lang="EN" style="mso-ansi-language: EN; mso-bidi-font-size: 12.0pt;">he Paley Center named “Yada Yada Yada” the No. 1 funniest phrase on “TV's 50 Funniest Phrases.”<span style="mso-spacerun: yes;">&nbsp; </span>So how did Seinfeld propel this rather ordinary saying that dates back to at least vaudevillian times into a pop culture phenomenon?<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span>Because t</span><span style="mso-bidi-font-size: 12.0pt;">he gag on <i style="mso-bidi-font-style: normal;">Seinfeld</i>was what was being yada yada’d.<span style="mso-spacerun: yes;">&nbsp; </span>To most people, the phrase was used to skip mundane, uninteresting or repetitive details in a story.<span style="mso-spacerun: yes;">&nbsp; </span>But George’s girlfriend used it to gloss over habits such as shoplifting and skipping out on checks.<span style="mso-spacerun: yes;">&nbsp; </span>Ah, the beauty of <i style="mso-bidi-font-style: normal;">Seinfeld.</i><span style="mso-spacerun: yes;">&nbsp; </span><span style="mso-spacerun: yes;">&nbsp;</span></span><span lang="EN" style="mso-ansi-language: EN; mso-bidi-font-size: 12.0pt;"></span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Well, we are doing some yada, yada’ing ourselves today in the context of discussing the latest InFuse decision – <i style="mso-bidi-font-style: normal;">Harris v. Medtronic, Inc.</i>, 2014 WL 866063 (Cal. Super. Feb. 27, 2014) (no pagination provided).<span style="mso-spacerun: yes;">&nbsp; </span>And, in our case we’ll come right out and tell you what we’re skipping – another discussion of <i style="mso-bidi-font-style: normal;">Coleman v. Medtronic, Inc.</i><span style="mso-spacerun: yes;">&nbsp; </span>You can read all our thoughts on that case <a href="http://druganddevicelaw.blogspot.com/2014/02/a-tale-of-two-decisions.html" target="_blank">here</a>.&nbsp;<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span>Taking a lesson from <i style="mso-bidi-font-style: normal;">Seinfeld</i> and George’s succinct girlfriend, we’re opting not to re-hash the many reasons we don’t like <i style="mso-bidi-font-style: normal;">Coleman</i>.<span style="mso-spacerun: yes;">&nbsp; </span>And, instead focus on some of the good we found in <i style="mso-bidi-font-style: normal;">Harris</i>; namely its rejection of our other two least favorite Infuse decisions --<i style="mso-bidi-font-style: normal;"> Ramirez v. Medtronic, Inc.</i>, 2013 WL 4446913 (D. Ariz. Aug. 21, 2013) and <span style="mso-spacerun: yes;">&nbsp;</span><i>Alton v. Medtronic, Inc</i>., 2013 WL 4786381 (D.Or. Sep. 6, 2013).<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i style="mso-bidi-font-style: normal;">Harris</i>, being a California trial court decision, is of course bound by that state’s appellate court decision in <i style="mso-bidi-font-style: normal;">Coleman</i>.<span style="mso-spacerun: yes;">&nbsp; </span>So, plaintiff Harris got to keep her negligence and strict liability claims premised on a failure to file adverse event reports and her negligence claim premised on off-label promotion, but not her strict liability off-label promotion claim.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span><span style="mso-spacerun: yes;"></span>Yada, yada, yada.</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The <i style="mso-bidi-font-style: normal;">Harris</i> court was faced with additional claims, however, not considered in<i style="mso-bidi-font-style: normal;"> Coleman</i>.<span style="mso-spacerun: yes;">&nbsp; </span>First up – design defect.<span style="mso-spacerun: yes;">&nbsp; </span>Here, the plaintiffs relied heavily on <i style="mso-bidi-font-style: normal;">Ramirez</i>, which the court noted is the only Infuse decision to allow a design defect claim to proceed as not preempted.<span style="mso-spacerun: yes;">&nbsp; </span>Recognizing it as the outlier it is, the <i style="mso-bidi-font-style: normal;">Harris</i> court rejected the underlying premise of <i style="mso-bidi-font-style: normal;">Ramirez</i> that when a device is used off-label it is “effectively a different device than the one for which a PMA had been secured” and therefore the FDA has not established requirements applicable to the specific device at issue (the first step in <i style="mso-bidi-font-style: normal;">Riegel</i> preemption).<span style="mso-spacerun: yes;">&nbsp; </span>Instead, the court ruled:</span></div><div class="MsoNormal"><br /></div><blockquote class="tr_bq"><div class="MsoBlockText"><span style="mso-bidi-font-size: 12.0pt;">Allowing Plaintiffs’ strict products liability design defect claim to proceed would permit a finding that a design defect rendered the Infuse device unreasonably dangerous even if Medtronic complied with all FDA regulations addressed to design. That would constitute imposition of requirements on the design of the device in addition to those mandated by the FDA through the PMA process. </span></div></blockquote><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;">The clear rejection of <i style="mso-bidi-font-style: normal;">Ramirez</i> in California is good news.</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Next – fraud.<span style="mso-spacerun: yes;">&nbsp; </span>Again the <i style="mso-bidi-font-style: normal;">Harris</i>court refused to follow <i style="mso-bidi-font-style: normal;">Ramirez</i>, opting instead to apply the analysis used in <i style="mso-bidi-font-style: normal;"><span style="mso-bidi-font-style: italic;">Caplinger v. Medtronic, Inc</span></i>., 921 F.Supp.2d 1206 (W.D. Okla. 2013) – discussed in our Infuse post <a href="http://druganddevicelaw.blogspot.com/2013/09/the-infuse-litigation-making-good-off.html" target="_blank">here</a>.&nbsp;<span style="mso-spacerun: yes;">&nbsp; </span>That’s more good news.</span></div><div class="MsoNormal"><br /></div><blockquote class="tr_bq"><div class="MsoBlockText"><span style="mso-bidi-font-size: 12.0pt;">To the extent Plaintiff's fraud claims are based on alleged misrepresentations and omissions in the actual warnings and labels accompanying the Infuse device, such claims are expressly preempted. <span style="mso-spacerun: yes;">&nbsp;</span>. . . To the extent Plaintiffs’ fraud claims are based on alleged misrepresentations and/or omissions regarding its practice of marketing off-label applications of the Infuse device, such as in reports to the FDA, such claims are impliedly preempted under <i style="mso-bidi-font-style: normal;">Buckman</i>, as such a claim is in substance a claim for violating the FDCA.</span></div></blockquote><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;">(citations omitted).<span style="mso-spacerun: yes;">&nbsp; </span>Even more good news, the court was unwilling to adopt the reasoning of <i>Alton</i>.<span style="mso-spacerun: yes;">&nbsp; </span>Part of the ruling in <i style="mso-bidi-font-style: normal;">Alton</i>was that plaintiff’s fraud claim escaped preemption because it fit in “the second category of parallel claims contemplated in <i>Lohr</i> and its progeny, as a claim premised on conduct that contravenes state-law duties of such generality as not to present any risk of interference with the federal medical-device regulatory scheme.”<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Alton</i>, 2013 WL 4786381 at *27.<span style="mso-spacerun: yes;">&nbsp; </span>The <i style="mso-bidi-font-style: normal;">Harris</i>court disagreed with this reading of <i style="mso-bidi-font-style: normal;">Lohr</i>:</span></div><div class="MsoNormal"><br /></div><blockquote class="tr_bq"><div class="MsoBlockText"><span style="mso-bidi-font-size: 12.0pt;">The court is unaware of any other decision in which <i style="mso-bidi-font-style: normal;">Lohr</i>has been interpreted as establishing two separate categories of parallel claims. . . .<span style="mso-spacerun: yes;">&nbsp; </span><i style="mso-bidi-font-style: normal;">Lohr</i> does state that U.S.C. section 360k does not preempt State or local requirements that are “equal to, or substantially identical to, requirements under the act.” <span style="mso-spacerun: yes;">&nbsp;</span>This language comes directly from 21 CFR sections 808.1(d)(2) and 808.5(b)(l)(i), both of which have to do with the procedures to be followed by States and localities in applying for an exemption from Federal preemption for a particular requirement. Section 360k itself says only that a requirement “which is different from, or in addition to, any requirement applicable under this chapter to the device, and which relates to the safety or effectiveness of the device or to any other matter included in a requirement applicable to the device under this chapter” is preempted. In fact, the <i style="mso-bidi-font-style: normal;">Lohr</i> court's discussion of the regulations was to illustrate that there were no State or local requirements at issue in that case that fell within the intended preemptive scope of section 360k(a). This portion of Lohr, however, cannot reasonably be read to mean that a requirement must be “substantially identical” in order to be “parallel.” Nor can the so-called “second category of parallel claims” articulated by the <i style="mso-bidi-font-style: normal;">Alton</i> court be reconciled with <i style="mso-bidi-font-style: normal;">Riegel</i>, which, while not expressly disapproving <i style="mso-bidi-font-style: normal;">Lohr</i>, clearly held that the concept of State or local “requirements” includes common law duties. <span style="mso-spacerun: yes;">&nbsp;</span>Accordingly, the court will not follow the trail blazed in <i style="mso-bidi-font-style: normal;">Alton</i>to decide whether Plaintiffs' fraud claims are “genuinely equivalent” to applicable federal requirements for purposes of the express preemption analysis.</span></div></blockquote><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;">(citations omitted).<span style="mso-spacerun: yes;">&nbsp; </span>That’s a mouthful, but we like it.<span style="mso-spacerun: yes;">&nbsp; </span></span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>But here is where we can get back to more yada yada’ing.<span style="mso-spacerun: yes;">&nbsp; </span>The court ultimately decides that “a state law fraud claim based on fraudulent statements made to promote off-label uses of a device are genuinely equivalent to a claim of misbranding under applicable federal law” and that therefore there is the possibility plaintiff could state a claim for fraud that is not preempted.<span style="mso-spacerun: yes;">&nbsp; </span>This is in line with the majority of Infuse decisions.<span style="mso-spacerun: yes;">&nbsp; </span>So, the last question is whether plaintiff pled this fraud claim with sufficient particularity to withstand a motion to dismiss.<span style="mso-spacerun: yes;">&nbsp; </span>The <i style="mso-bidi-font-style: normal;">Harris</i> court, somewhat hesitantly, said yes. Noting it was a “close call,” that the allegations of reliance “are far weaker,” and admonishing that success on the claim will require “proof of an actual link between [plaintiff and/or her surgeon] and the allegedly fraudulent promotional information and materials,” the court nevertheless ruled that for pleading purposes, plaintiff’s allegations were sufficient.</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal"><span style="mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Following <i style="mso-bidi-font-style: normal;">Coleman</i> we have to look for bright spots in California where we can, and this is one of them.<span style="mso-spacerun: yes;">&nbsp; </span>The detailed reasoning by the <i style="mso-bidi-font-style: normal;">Harris</i>court and its rejection of the Infuse outliers leaves us feeling somewhat satisfied. <span style="mso-spacerun: yes;">&nbsp;&nbsp;</span>We may not be celebrating a Fesitvus quite yet, but the decision is also no Urban Sombrero. <span style="mso-spacerun: yes;">&nbsp;</span><span style="mso-spacerun: yes;">&nbsp;</span></span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:88:"http://druganddevicelaw.blogspot.com/2014/03/were-in-california-for-infuse-case-and.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:36:"noreply@blogger.com (Michelle Yeary)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-04-10T15:03:26.536-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}i:24;a:6:{s:4:"data";s:0:"";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";s:5:"child";a:3:{s:0:"";a:7:{s:4:"guid";a:1:{i:0;a:5:{s:4:"data";s:59:"tag:blogger.com,1999:blog-36762711.post-6694154413162693972";s:7:"attribs";a:1:{s:0:"";a:1:{s:11:"isPermaLink";s:5:"false";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:7:"pubDate";a:1:{i:0;a:5:{s:4:"data";s:31:"Mon, 17 Mar 2014 18:04:00 +0000";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:8:"category";a:4:{i:0;a:5:{s:4:"data";s:12:"Class Action";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:1;a:5:{s:4:"data";s:8:"Missouri";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:2;a:5:{s:4:"data";s:8:"Pleading";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}i:3;a:5:{s:4:"data";s:10:"Preemption";s:7:"attribs";a:1:{s:0:"";a:1:{s:6:"domain";s:31:"http://www.blogger.com/atom/ns#";}}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:5:"title";a:1:{i:0;a:5:{s:4:"data";s:37:"Too Much Does Not a Class Action Make";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:11:"description";a:1:{i:0;a:5:{s:4:"data";s:25045:"<!--[if gte mso 9]><xml> <o:OfficeDocumentSettings>  <o:AllowPNG/> </o:OfficeDocumentSettings></xml><![endif]--><br /><!--[if gte mso 9]><xml> <w:WordDocument>  <w:View>Normal</w:View>  <w:Zoom>0</w:Zoom>  <w:TrackMoves/>  <w:TrackFormatting/>  <w:PunctuationKerning/>  <w:ValidateAgainstSchemas/>  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>  <w:DoNotPromoteQF/>  <w:LidThemeOther>EN-US</w:LidThemeOther>  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>  <w:Compatibility>   <w:BreakWrappedTables/>   <w:SnapToGridInCell/>   <w:WrapTextWithPunct/>   <w:UseAsianBreakRules/>   <w:DontGrowAutofit/>   <w:SplitPgBreakAndParaMark/>   <w:EnableOpenTypeKerning/>   <w:DontFlipMirrorIndents/>   <w:OverrideTableStyleHps/>  </w:Compatibility>  <m:mathPr>   <m:mathFont m:val="Cambria Math"/>   <m:brkBin m:val="before"/>   <m:brkBinSub m:val="&#45;-"/>   <m:smallFrac m:val="off"/>   <m:dispDef/>   <m:lMargin m:val="0"/>   <m:rMargin m:val="0"/>   <m:defJc m:val="centerGroup"/>   <m:wrapIndent m:val="1440"/>   <m:intLim m:val="subSup"/>   <m:naryLim m:val="undOvr"/>  </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267">  <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal"/>  <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>  <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title"/>  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>  <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>  <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong"/>  <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>  <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>  <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 1"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 1"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 1"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>  <w:LsdException Locked="false" Priority="34" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>  <w:LsdException Locked="false" Priority="29" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Quote"/>  <w:LsdException Locked="false" Priority="30" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 1"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 1"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 2"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 2"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 2"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 2"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 2"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 3"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 3"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 3"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 3"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 3"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 4"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 4"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 4"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 4"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 4"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 5"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 5"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 5"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 5"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 5"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>  <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading Accent 6"/>  <w:LsdException Locked="false" Priority="61" SemiHidden="false"    UnhideWhenUsed="false" Name="Light List Accent 6"/>  <w:LsdException Locked="false" Priority="62" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Grid Accent 6"/>  <w:LsdException Locked="false" Priority="63" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>  <w:LsdException Locked="false" Priority="64" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>  <w:LsdException Locked="false" Priority="65" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>  <w:LsdException Locked="false" Priority="66" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>  <w:LsdException Locked="false" Priority="67" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>  <w:LsdException Locked="false" Priority="68" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>  <w:LsdException Locked="false" Priority="69" SemiHidden="false"    UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>  <w:LsdException Locked="false" Priority="70" SemiHidden="false"    UnhideWhenUsed="false" Name="Dark List Accent 6"/>  <w:LsdException Locked="false" Priority="71" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>  <w:LsdException Locked="false" Priority="72" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful List Accent 6"/>  <w:LsdException Locked="false" Priority="73" SemiHidden="false"    UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>  <w:LsdException Locked="false" Priority="19" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>  <w:LsdException Locked="false" Priority="21" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>  <w:LsdException Locked="false" Priority="31" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>  <w:LsdException Locked="false" Priority="32" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>  <w:LsdException Locked="false" Priority="33" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */  table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin-top:0in;  mso-para-margin-right:0in;  mso-para-margin-bottom:10.0pt;  mso-para-margin-left:0in;  line-height:115%;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:"Calibri","sans-serif";  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:"Times New Roman";  mso-bidi-theme-font:minor-bidi;} </style><![endif]--> <br /><div class="MsoNormal">Maybe I can start a class action.<span style="mso-spacerun: yes;">&nbsp; </span>I mean, I find it annoying that convenience stores don’t carry cold 12-ounce soda cans anymore.<span style="mso-spacerun: yes;">&nbsp; </span>They don’t even carry the 16-oz bottles that existed years ago.<span style="mso-spacerun: yes;">&nbsp; </span>Nowadays, everything’s in a 20-ounce bottle.<span style="mso-spacerun: yes;">&nbsp; </span>But I don’t need 20 ounces of soda.<span style="mso-spacerun: yes;">&nbsp; </span>A twelve-ounce can is fine.<span style="mso-spacerun: yes;">&nbsp; </span>Heck, sometimes even an 8-ounce can is enough.<span style="mso-spacerun: yes;">&nbsp; </span>But at a convenience store, 8-ounce cans are kept next to the unicorn aisle.<span style="mso-spacerun: yes;">&nbsp; </span>Or try getting a 12-ounce cup of soda at a movie theater.<span style="mso-spacerun: yes;">&nbsp; </span>A half-filled “small” cup holds that much.<span style="mso-spacerun: yes;">&nbsp; </span>The cups should come with handles.<span style="mso-spacerun: yes;">&nbsp; </span>And how about the muffins we all now have in the morning?<span style="mso-spacerun: yes;">&nbsp; </span>At my local coffee/tea shop, they’re the size of Volkswagens.<span style="mso-spacerun: yes;">&nbsp; </span>They’re twice the size they were 5 years ago.<span style="mso-spacerun: yes;">&nbsp; </span>The muffin-top is bigger than the whole muffin used to be.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">Class action plaintiffs to the rescue.<span style="mso-spacerun: yes;">&nbsp; </span>Well, it’s not a soda or muffin class action.<span style="mso-spacerun: yes;">&nbsp; </span>It’s prescription eye drops.<span style="mso-spacerun: yes;">&nbsp; </span>But the idea is the same.<span style="mso-spacerun: yes;">&nbsp; </span>In <u>Carter v. Alcon Labs., Inc.</u>, 2014 U.S. Dist. LEXIS 32381 (E.D. Mo. Mar. 13, 2014), plaintiffs sought to certify a class under Missouri’s common law and Merchandising Practice Act because the smallest bottles of prescription eye drops contained more medication than the dosage for the recommended course of treatment.<span style="mso-spacerun: yes;">&nbsp; </span>For instance, the recommended seven-day course of treatment for Vigamox requires .8 mL, while the smallest bottle of Vigamox holds 3 mL of medication.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">So they filed a class action.&nbsp;</div><div class="MsoNormal"><br /></div><div class="MsoNormal">And they lost.<span style="mso-spacerun: yes;">&nbsp; </span>Fast.<span style="mso-spacerun: yes;">&nbsp; </span>It got only as far as a motion to dismiss.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">Why?<span style="mso-spacerun: yes;">&nbsp; </span>In short, the plaintiffs got the benefit of the bargain.<span style="mso-spacerun: yes;">&nbsp; </span>They got what they paid for.<span style="mso-spacerun: yes;">&nbsp; </span>They had no loss:<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal" style="margin-left: .5in;">Under the benefit-of-the-bargain test, which awards a prevailing party the difference between the value of the product as represented and the actual value of the product as received, Plaintiff has not suffered an ascertainable loss. <span style="mso-spacerun: yes;">&nbsp;</span>Plaintiff does not allege that the medication she purchased was anything other than represented or that it did not perform as intended.</div><div class="MsoNormal" style="margin-left: .5in;"><br /></div><div class="MsoNormal" style="margin-left: .5in;">The Court concludes that even without applying the benefit-of-the-bargain test for loss under the MMPA, Plaintiff has failed to state a claim. <span style="mso-spacerun: yes;">&nbsp;</span>Plaintiff's theory of her loss is the difference between what Defendants charge for the medication bottle available to consumers and the price they would charge for a bottle with less medication. <span style="mso-spacerun: yes;">&nbsp;</span>However, even if Defendants sold bottles with less medication, Plaintiff has not suggested there is anything to preclude them from charging what they now charge for the bottles currently available for purchase. Plaintiff has cited no authority from any jurisdiction suggesting that a drug manufacturer's choice of volume fill is an unfair practice, and this Court concludes that the Missouri Supreme Court would find that absent fraud or duress or price gauging, none of which were alleged here, no such cause of action exists under the MMPA.</div><div class="MsoNormal" style="margin-left: .5in;"><br /></div><div class="MsoNormal" style="margin-left: .5in;">Similarly, Plaintiff's claims for unjust enrichment and money had and received also fail. . . .&nbsp;</div><div class="MsoNormal" style="margin-left: .5in;"><br /></div><div class="MsoNormal"><u>Id.</u> at *11-12.</div><div class="MsoNormal"><br /></div><div class="MsoNormal">When medication is involved, this makes a whole lot of sense.<span style="mso-spacerun: yes;">&nbsp; </span>Certainly for a branded manufacturer, there’s nothing to suggest that a bottle with less medication would cost meaningfully less.<span style="mso-spacerun: yes;">&nbsp; </span>Even we lawyers know that the vast amount of the cost of a distributing medication comes from developing it.<span style="mso-spacerun: yes;">&nbsp; </span>Even generic manufacturers have significant costs other than the medication itself.<span style="mso-spacerun: yes;">&nbsp; </span>Frankly, there seems to be a whole lot of other things that would be wrong with this type of claim.<span style="mso-spacerun: yes;">&nbsp; </span>But the court got rid of it in the simplest way.<span style="mso-spacerun: yes;">&nbsp; </span>Plaintiffs got what they paid for.<span style="mso-spacerun: yes;">&nbsp;&nbsp;</span></div><div class="MsoNormal"><br /></div><div class="MsoNormal">There was also a preemption issue here.<span style="mso-spacerun: yes;">&nbsp; </span>The defense argued that it couldn’t relabel or redesign the bottles for these generic eye drops because it needed FDA approval to do that.<span style="mso-spacerun: yes;">&nbsp; </span>The defense lost this argument, but only because it hadn’t sufficiently established the need for prior FDA approval.<span style="mso-spacerun: yes;">&nbsp; </span>We suspect that, if another defendant in another class action makes such a showing, there will be preemption.</div><div class="MsoNormal"><br /></div><div class="MsoNormal">In any event, these “overfill” class actions seem to be going nowhere.<span style="mso-spacerun: yes;">&nbsp; </span>Oh, well.<span style="mso-spacerun: yes;">&nbsp; </span>It seems that the next time we’re reading one of these opinions, we’ll still be doing it while gulping a 20-ounce soda and hacking away at a huge peach-apple-crumb muffin.<span style="mso-spacerun: yes;">&nbsp; </span>Things could be worse.<span style="mso-spacerun: yes;">&nbsp; </span></div>";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:4:"link";a:1:{i:0;a:5:{s:4:"data";s:85:"http://druganddevicelaw.blogspot.com/2014/03/too-much-does-not-class-action-make.html";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:6:"author";a:1:{i:0;a:5:{s:4:"data";s:38:"noreply@blogger.com (John J. Sullivan)";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:27:"http://www.w3.org/2005/Atom";a:1:{s:7:"updated";a:1:{i:0;a:5:{s:4:"data";s:29:"2014-03-17T15:33:54.384-04:00";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}s:38:"http://purl.org/syndication/thread/1.0";a:1:{s:5:"total";a:1:{i:0;a:5:{s:4:"data";s:1:"0";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}}}s:39:"http://a9.com/-/spec/opensearchrss/1.0/";a:3:{s:12:"totalResults";a:1:{i:0;a:5:{s:4:"data";s:4:"2388";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:10:"startIndex";a:1:{i:0;a:5:{s:4:"data";s:1:"1";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}s:12:"itemsPerPage";a:1:{i:0;a:5:{s:4:"data";s:2:"25";s:7:"attribs";a:0:{}s:8:"xml_base";s:0:"";s:17:"xml_base_explicit";b:0;s:8:"xml_lang";s:0:"";}}}}}}}}}}}}s:4:"type";i:128;s:7:"headers";a:14:{s:16:"content-encoding";s:4:"gzip";s:4:"date";s:29:"Sun, 13 Apr 2014 13:59:50 GMT";s:12:"content-type";s:34:"application/rss+xml; charset=UTF-8";s:6:"server";s:15:"blogger-renderd";s:13:"cache-control";s:52:"public, must-revalidate, proxy-revalidate, max-age=1";s:4:"vary";s:15:"Accept-Encoding";s:7:"expires";s:29:"Sun, 13 Apr 2014 13:59:51 GMT";s:22:"x-content-type-options";s:7:"nosniff";s:16:"x-xss-protection";s:13:"1; mode=block";s:4:"etag";s:38:"W/b9391ac1-9957-413d-9bd5-2fddb097012f";s:13:"last-modified";s:29:"Fri, 11 Apr 2014 19:17:32 GMT";s:14:"content-length";s:6:"113378";s:15:"x-frame-options";s:10:"SAMEORIGIN";s:18:"alternate-protocol";s:7:"80:quic";}s:5:"build";s:14:"20090627192103";}